ticlopidine has been researched along with Recrudescence in 347 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In smokers, a double-dose clopidogrel regimen reduced major cardiovascular events and stent thrombosis after percutaneous coronary intervention, with no increase in major bleeding." | 9.24 | Double-Dose Versus Standard-Dose Clopidogrel According to Smoking Status Among Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. ( Bossard, M; Faxon, DP; Fox, KAA; Gao, P; Granger, CB; Jolly, SS; Mehta, SR; Montalescot, G; Natarajan, MK; Niemela, K; Steg, PG; Tanguay, JF; Widimsky, P; Yusuf, S, 2017) |
| "The aim of this study was to analyze the benefits and safety associated with the combination therapy of clopidogrel and aspirin among minor stroke or transient ischemic attack patients treated within 12 hours." | 9.22 | Treatment Effect of Clopidogrel Plus Aspirin Within 12 Hours of Acute Minor Stroke or Transient Ischemic Attack. ( Jing, J; Johnston, SC; Li, H; Li, Z; Liu, L; Meng, X; Pan, Y; Wang, C; Wang, D; Wang, X; Wang, Y; Xian, Y; Yang, X; Zhang, C; Zhao, X, 2016) |
| "The Elderly-ACS 2 study is a multicenter, randomized, parallel-group, open-label trial designed to demonstrate the superiority of a strategy of dual antiplatelet treatment using a reduced 5-mg daily dose of prasugrel over a standard strategy with a daily clopidogrel dose of 75mg in patients older than 74years with ACS (either ST- or non-ST-elevation myocardial infarction) undergoing early percutaneous revascularization." | 9.22 | A comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization: Design and rationale of the randomized Elderly-ACS 2 study. ( Bossi, I; Cacucci, M; Cavallini, C; Corrada, E; De Servi, S; Di Ascenzo, L; Ferrario, M; Ferri, LA; Gandolfo, N; Grosseto, D; Mariani, M; Moffa, N; Morici, N; Petronio, AS; Ravera, A; Savonitto, S; Sganzerla, P; Sibilio, G; Tondi, S; Tortorella, G; Toso, A, 2016) |
| "The role of the CYP2C19 genotype on clopidogrel efficacy has been studied widely, with data suggesting reduced clopidogrel efficacy in loss-of-function variant carriers taking clopidogrel after percutaneous coronary intervention; however, data are limited regarding the association between CYP2C19 genetic variants and outcomes in stroke patients." | 9.20 | CYP2C19 metabolizer status and clopidogrel efficacy in the Secondary Prevention of Small Subcortical Strokes (SPS3) study. ( Benavente, OR; Field, TS; Gong, Y; Horenstein, RB; Johnson, JA; Lewis, JP; McClure, LA; McDonough, CW; Mitchell, BD; Shuldiner, AR; Talbert, RL, 2015) |
| "The aim of this study was to assess the relationship between sex and clinical outcomes and treatment-related complications in patients with ST-elevation or non-ST-elevation acute coronary syndromes (ACS) randomized to treatment with ticagrelor or clopidogrel in the PLATelet inhibition and patient Outcomes (PLATO) trial." | 9.19 | The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial. ( Bach, RG; Becker, RC; Budaj, A; Heras, M; Himmelmann, A; Horrow, J; Husted, S; James, SK; Katus, HA; Lassila, R; Morais, J; Nicolau, JC; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, D, 2014) |
| "Among patients with recent lacunar strokes, the addition of clopidogrel to aspirin did not significantly reduce the risk of recurrent stroke and did significantly increase the risk of bleeding and death." | 9.16 | Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. ( Benavente, OR; Coffey, CS; Hart, RG; McClure, LA; Pearce, LA; Szychowski, JM, 2012) |
| "After an acute coronary syndrome, patients remain at risk of recurrent ischaemic events, despite contemporary treatment, including aspirin and clopidogrel." | 9.15 | Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. ( Budaj, A; Granger, CB; Khder, Y; Oldgren, J; Roberts, J; Siegbahn, A; Tijssen, JG; Van de Werf, F; Wallentin, L, 2011) |
| "Prasugrel is a novel thienopyridine that reduces new or recurrent myocardial infarctions (MIs) compared with clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention." | 9.14 | Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardi ( Antman, EM; Bonaca, MP; Bramucci, E; Braunwald, E; McCabe, CH; Morrow, DA; Murphy, SA; Nicolau, JC; Ruff, CT; Scirica, BM; White, HD; Wiviott, SD, 2009) |
| "The aim of this analysis was to evaluate whether routine pre-hospital administration of high-dose tirofiban in ST-segment elevation myocardial infarction (STEMI) decreases the incidence of early stent thrombosis after primary PCI." | 9.14 | Marked reduction of early stent thrombosis with pre-hospital initiation of high-dose Tirofiban in ST-segment elevation myocardial infarction. ( De Boer, MJ; Dill, T; Gosselink, AT; Hamm, C; Heestermans, AA; Hoorntje, JC; Koopmans, PC; Ten Berg, JM; Van 't Hof, AW; Van Houwelingen, G; Van Werkum, JW, 2009) |
| "We randomly assigned a total of 400 patients with ST-segment elevation myocardial infarction referred for primary percutaneous coronary intervention to treatment initiated before cardiac catheterization, with either heparin plus eptifibatide (201 patients) or heparin alone (199 patients), in addition to oral aspirin (160 mg) and high-dose clopidogrel (600 mg)." | 9.14 | Primary percutaneous coronary angioplasty with and without eptifibatide in ST-segment elevation myocardial infarction: a safety and efficacy study of integrilin-facilitated versus primary percutaneous coronary intervention in ST-segment elevation myocardi ( Froeschl, M; Glover, CA; Jadhav, S; Kass, M; Labinaz, M; Le May, MR; Marquis, JF; O'Brien, ER; So, DY; Thomas, A; Turek, M; Wells, GA, 2009) |
| "In the current era of early revascularization and routine use of dual antiplatelet therapy, the incremental benefit of warfarin to reduce the incidence of left ventricular thrombus (LVT) in patients with impaired left ventricular ejection fraction post anterior ST-elevation myocardial infarction (aSTEMI), remains uncertain." | 9.14 | Warfarin after anterior myocardial infarction in current era of dual antiplatelet therapy: a randomized feasibility trial. ( Ahmad, M; Eikelboom, JW; Natarajan, MK; Salehian, O; Schwalm, JD, 2010) |
| "This study sought to determine the efficacy of high-dose atorvastatin in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI)." | 9.14 | Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the STATIN STEMI trial. ( Cho, DK; Cho, JR; Cho, YH; Choi, D; Hong, MK; Jang, Y; Jeon, DW; Kim, BK; Kim, J; Kim, JS; Ko, YG; Lee, CJ; Lee, NH; Lee, SH; Oh, SJ; Yang, JY, 2010) |
| "All patients with acute ischemic stroke or transient ischemic attack within a 10 month period were administered 600 mg clopidogrel bolus if they were already taking aspirin regularly, or had aspirin allergy or intolerance." | 9.13 | Safety and tolerability of 600 mg clopidogrel bolus in patients with acute ischemic stroke: preliminary experience. ( Abdelmoula, MM; Divani, AA; Hussein, HM; Qureshi, AI; Suri, MF, 2008) |
| "Antiplatelet therapy with clopidogrel and acetylsalicylic acid (ASA) reduces major cardiovascular events in patients with ST and non-ST-segment-elevation acute coronary syndromes (ACS)." | 9.13 | Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. ( Bassand, JP; Chrolavicius, S; Diaz, R; Fox, KA; Granger, CB; Jolly, S; Mehta, SR; Rupprecht, HJ; Widimsky, P; Yusuf, S, 2008) |
| "To determine the prevalence of platelet nonresponsiveness to aspirin treatment for secondary stroke prophylaxis, the authors studied consecutive patients during a 29-month period." | 9.13 | Prevalence of platelet nonresponsiveness to aspirin in patients treated for secondary stroke prophylaxis and in patients with recurrent ischemic events. ( Bates, V; Forrest, A; Gengo, FM; Gengo, MF; Hourihane, M; Rainka, M; Robson, M, 2008) |
| "Sirolimus-eluting stents (SESs) recently proved to be superior to bare metal stents (BMSs) in decreasing the need for repeat revascularization in patients with ST-segment elevation myocardial infarction (STEMI) at 1 year." | 9.12 | Comparison of three-year clinical outcome of sirolimus- and paclitaxel-eluting stents versus bare metal stents in patients with ST-segment elevation myocardial infarction (from the RESEARCH and T-SEARCH Registries). ( Daemen, J; de Jaegere, PP; García-García, HM; Kukreja, N; Serruys, PW; Sianos, G; Tanimoto, S; van de Sande, M; van Domburg, RT, 2007) |
| "Fluctuations in urinary 11-DTB2 after cerebral infarction in blacks do not correlate with changes in aspirin doses, except perhaps when the dose changes by a factor of 4 or more." | 9.11 | Serial urinary 11-dehydrothromboxane B2, aspirin dose, and vascular events in blacks after recent cerebral infarction. ( Bang, NU; Bruno, A; Cohen, SN; Gorelick, PB; McConnell, JP; Tietjen, GE; Wallis, RA, 2004) |
| "To evaluate the impact of a clopidogrel therapy on the effectiveness of myocardial reperfusion in patients with ST-segment elevation acute myocardial infarction (AMI) undergoing routine infarct-related artery (IRA) stent implantation and receiving routine abciximab therapy." | 9.11 | A randomized trial comparing clopidogrel versus ticlopidine therapy in patients undergoing infarct artery stenting for acute myocardial infarction with abciximab as adjunctive therapy. ( Antoniucci, D; Memisha, G; Migliorini, A; Moschi, G; Parodi, G; Pupi, A; Sciagrà, R; Valenti, R, 2005) |
| "To determine the efficacy and safety of aspirin and ticlopidine to prevent recurrent stroke in black patients." | 9.10 | Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial. ( Gorelick, PB; Harris, Y; Hung, E; Kelly, M; Kittner, S; Leurgans, S; Richardson, D; Ruland, S, 2003) |
| "To compare the efficacy and safety of two antiplatelet regimens, ticlopidine alone (200 mg daily) and ticlopidine (100 mg daily) plus aspirin (81 mg daily), in patients with ischemic stroke from the Tokai district of Japan." | 9.10 | Ticlopidine alone versus ticlopidine plus aspirin for preventing recurrent stroke. ( Ito, E; Kuzuhara, S; Nakajima, M; Takahashi, A; Uchiyama, S; Yamamoto, H, 2003) |
| "The safety and tolerability of clopidogrel coadministration to patients with recent acute myocardial infarction (AMI) treated with recombinant tissue plasminogen activator (rt-PA) and heparin were assessed." | 9.09 | Clopidogrel-rt-PA-heparin combination in the treatment of acute myocardial infarction. ( Bassand, JP; Cariou, R; Grollier, G; Heyndrickx, GR; Kragten, J; Wolf, JE, 1999) |
| "We sought to compare the efficacy of aspirin and ticlopidine in survivors of acute myocardial infarction (AMI) treated with thrombolysis." | 9.09 | Ticlopidine versus aspirin after myocardial infarction (STAMI) trial. ( Cimminiello, C; Di Biase, M; Marubini, E; Pitzalis, MV; Rizzon, P; Scrutinio, D, 2001) |
| "The efficacy of combining antiplatelet agents with low doses of aspirin to prevent cardiac events in patients with myocardial infarction was examined." | 9.08 | Aspirin plus either dipyridamole or ticlopidine is effective in preventing recurrent myocardial infarction. Secondary Prevention Group. ( Hama, J; Ishikawa, K; Kanamasa, K; Katori, R; Kimura, A; Naito, T; Nakai, S; Ogawa, I; Oyaizu, M; Takenaka, T; Yamamoto, K; Yamamoto, T, 1997) |
| "Optimal antiplatelet therapy after an ischemic stroke or transient ischemic attack while on aspirin is uncertain." | 8.95 | Antiplatelet Regimen for Patients With Breakthrough Strokes While on Aspirin: A Systematic Review and Meta-Analysis. ( Hong, KS; Lee, M; Ovbiagele, B; Rao, NM; Saver, JL; Wu, YL, 2017) |
| "Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel for 90 days was recommended as the secondary prevention of minor ischaemic strokes or transient ischaemic attacks (TIAs) in 2014." | 8.93 | Dual antiplatelet therapy after stroke or transient ischaemic attack - how long to treat? The duration of aspirin plus clopidogrel in stroke or transient ischaemic attack: a systematic review and meta-analysis. ( Chang, T; Ge, F; Guo, R; Li, M; Lin, H; Liu, Y; Ruan, Z, 2016) |
| "Compared with monotherapy, short-term aspirin in combination with clopidogrel is more effective as secondary prevention of stroke or TIA without increasing the risk of hemorrhagic stroke and major bleeding events." | 8.91 | Aspirin plus clopidogrel as secondary prevention after stroke or transient ischemic attack: a systematic review and meta-analysis. ( Li, J; Li, Y; Shang, X; Wang, C; Yan, C; Zhang, L; Zhang, Q; Zheng, M, 2015) |
| "To present the systematic assessment on the efficacy and bleeding adverse events of dual-antiplatelet therapy with aspirin and clopidogrel versus aspirin-mono-antiplatelet therapy in patients with ischemic stroke or transient ischemic attack." | 8.91 | [Meta-analysis on the efficacy and adverse events of aspirin plus clopidogrel versus aspirin-monotherapy in patients with ischemic stroke or transient ischemic attack]. ( Gao, P; Hu, Y; Qian, J; Tang, X; Yang, C, 2015) |
| "Dual antiplatelet therapy with aspirin plus clopidogrel is not recommended for secondary stroke prevention because of lack of effectiveness and increased hemorrhagic risk." | 8.90 | Front-loading with clopidogrel plus aspirin followed by dual antiplatelet therapy in the prevention of early stroke recurrence. ( Censori, B, 2014) |
| " A total of 477 patients receiving double antiaggregation therapy with aspirin and clopidogrel, after suffering a first event, were followed for 1 year to record relapse, as a surrogate end point to measure their therapeutic response, as defined by presenting with an acute coronary event (unstable angina, ST-segment-elevation myocardial infarction, or non-ST-segment-elevation myocardial infarction), stent thrombosis/restenosis, or cardiac mortality." | 8.12 | Clinical and Pharmacological Parameters Determine Relapse During Clopidogrel Treatment of Acute Coronary Syndrome. ( Martínez-Quintana, E; Medina-Gil, JM; Rodríguez-González, F; Saavedra-Santana, P; Santana-Mateos, M; Tugores, A, 2022) |
| "In real-world practice settings, there is insufficient evidence on the efficacy of antiplatelet drugs, including clopidogrel, aspirin, and ticlopidine, in stroke prevention." | 7.96 | Efficacy of aspirin, clopidogrel, and ticlopidine in stroke prevention: A population-based case-cohort study in Taiwan. ( Hsu, YH; Ong, CT; Tsai, CF; Wong, YS, 2020) |
| "Clopidogrel HTPR does not seem to be a major contributor to recurrent ischemic events in Danish ischemic stroke patients." | 7.88 | Secondary Stroke Prophylaxis with Clopidogrel Produces Sufficient Antiplatelet Response. ( Jørgensen, NR; Rath, CL; Wienecke, T, 2018) |
| "Our findings indicate a favorable effect of clopidogrel at discharge compared with aspirin in preventing death, recurrent stroke, and CVD events in diabetic patients with a first-ever noncardioembolic AIS." | 7.85 | Aspirin Versus Clopidogrel for Type 2 Diabetic Patients with First-Ever Noncardioembolic Acute Ischemic Stroke: Ten-Year Survival Data from the Athens Stroke Outcome Project. ( Elisaf, M; Manios, E; Milionis, H; Ntaios, G; Papavasileiou, V; Spengos, K; Vemmos, K, 2017) |
| "We consecutively enrolled 375 patients with IS after they received clopidogrel therapy, and venous blood samples were subjected to genotyping allelic variants of genes modulating clopidogrel absorption (ATP binding cassette subfamily B1, ABCB1), metabolic activation (cytochrome P450[CYP] 3A and CYP2C19), and biologic activity (platelet membrane receptor [ P2Y12, P2Y1)], and glycoprotein IIIa [ GPIIIa]) and statistically analyzing their interactions with clopidogrel sensitivity (CS) and adverse events, risk of IS recurrence, myocardial infarction, and death during 6 months of follow-up." | 7.85 | Interaction of CYP2C19, P2Y12, and GPIIIa Variants Associates With Efficacy of Clopidogrel and Adverse Events on Patients With Ischemic Stroke. ( Cheng, W; Lin, J; Wang, C; Wang, Y; Yi, X; Zhou, Q, 2017) |
| "Active smokers with myocardial infarction were shown to have enhanced benefit with clopidogrel compared with aspirin." | 7.85 | Clopidogrel and ischemic stroke outcomes by smoking status: Smoker's paradox? ( Cao, Q; Dong, K; Feng, W; Hou, C; Huang, X; Ji, X; Ovbiagele, B; Song, H; Wang, M; Wang, Y; Zhang, Q, 2017) |
| "Research regarding clopidogrel resistance (CR) and ischemic stroke (IS) recurrence related to IS is scanty." | 7.83 | Clopidogrel Resistance Increases Rate of Recurrent Stroke and Other Vascular Events in Chinese Population. ( Cheng, W; Lin, J; Wang, C; Wu, L; Yi, X; Zhou, Q, 2016) |
| " We hypothesized that cytochrome P450 2C19 (CYP2C19) genotype influences the incidence of early recurrence on DWI in acute stroke patients treated with clopidogrel." | 7.81 | CYP2C19 genotype and early ischemic lesion recurrence in stroke patients treated with clopidogrel. ( Chun, S; Jeong, TD; Kang, DW; Kim, HJ; Kim, SM; Kwon, SU; Lee, W; Min, WK, 2015) |
| " We aimed to evaluate the effect of DAPT duration with clopidogrel and aspirin on the recurrence of ischaemic events and bleeding in a large, unselected ACS population." | 7.80 | Duration of dual antiplatelet treatment with clopidogrel and aspirin in patients with acute coronary syndrome. ( Hasvold, P; Held, C; James, S; Jensevik, K; Jernberg, T; Lagerqvist, B; Sundström, A; Varenhorst, C, 2014) |
| "To evaluate the effect of drug interaction between omeprazol and clopidogrel in hospital readmission of patients with acute coronary syndrome (ACS)." | 7.80 | [Effect of drug interaction between clopidogrel and omeprazole in hospital readmision of patients by a recurrent acute coronary syndrome: a case-control study]. ( Amariles, P; Angulo, NY; Betancourth, PM; Ceballos, M; Holguín, H, 2014) |
| "Although randomized clinical trials have compared clopidogrel with higher potency ADP receptor inhibitors (ADPris) among patients with myocardial infarction, little is known about the frequency and factors associated with switching between ADPris in clinical practice." | 7.80 | In-hospital switching between clopidogrel and prasugrel among patients with acute myocardial infarction treated with percutaneous coronary intervention: insights into contemporary practice from the national cardiovascular data registry. ( Alexander, KP; Bagai, A; Bhatt, DL; Cheema, AN; Curtis, JP; Granger, CB; Gurm, HS; McNamara, RL; Peterson, ED; Roe, MT; Saucedo, JF; Shah, B; Wang, TY; Wang, Y, 2014) |
| "The aim of the present study was to evaluate clopidogrel treatment after incident myocardial infarction (MI) in patients with and without chronic kidney disease (CKD)." | 7.80 | Benefit of clopidogrel therapy in patients with myocardial infarction and chronic kidney disease-a Danish nation-wide cohort study. ( Blicher, TM; Hommel, K; Kamper, AL; Kristensen, SL; Madsen, M; Olesen, JB; Torp-Pedersen, C, 2014) |
| "The benefit of extending clopidogrel treatment beyond the 12-month period recommended in current guidelines after myocardial infarction (MI) is debated." | 7.78 | Clopidogrel discontinuation after myocardial infarction and risk of thrombosis: a nationwide cohort study. ( Ahlehoff, O; Charlot, M; Gislason, GH; Hansen, ML; Hansen, PR; Køber, L; Lindhardsen, J; Madsen, JK; Nielsen, LH; Olsen, AM; Torp-Pedersen, C, 2012) |
| "The association between myocardial infarction (MI) and co-administration of proton pump inhibitors (PPIs) and clopidogrel remains controversial." | 7.77 | Risk of recurrent myocardial infarction with the concomitant use of clopidogrel and proton pump inhibitors. ( 't Jong, GW; Kuipers, EJ; Sturkenboom, MC; Valkhoff, VE; Van Soest, EM, 2011) |
| "Clopidogrel improves outcomes in patients with ST-segment elevation myocardial infarction (STEMI) and is recommended in the guidelines." | 7.76 | Cost-effectiveness analysis of short-term clopidogrel therapy for ST elevation myocardial infarction. ( Cannon, CP; Cohen, DJ; Gibler, KB; Huskamp, HA; Murphy, SA; Sabatine, MS, 2010) |
| "The purpose of this study was to determine the readmission rate for acute myocardial infarction (AMI) in patients discharged on clopidogrel and a proton-pump inhibitor (PPI) versus patients discharged on clopidogrel alone after experiencing an AMI and undergoing stent placement." | 7.76 | Recurrence of acute myocardial infarction in patients discharged on clopidogrel and a proton pump inhibitor after stent placement for acute myocardial infarction. ( Binkley, P; Donnally, MR; Evanchan, J; Mazzaferri, E, 2010) |
| "The combination of aspirin and clopidogrel is indicated after acute coronary events and possibly for a short period after TIA or minor ischemic stroke." | 7.76 | Low risk of rebound events after a short course of clopidogrel in acute TIA or minor stroke. ( Chandratheva, A; Geraghty, OC; Paul, NL; Rothwell, PM, 2010) |
| "To assess the prognosis of patients presenting with an acute coronary syndrome (ACS) despite chronic clopidogrel therapy (CCT)." | 7.75 | Prognosis of patients suffering an acute coronary syndrome while already under chronic clopidogrel therapy. ( Bonello, L; De Labriolle, A; Kent, KM; Lemesle, G; Pichard, AD; Roy, P; Satler, LF; Steinberg, DH; Suddath, WO; Torguson, R; Waksman, R, 2009) |
| "Combinations of aspirin, clopidogrel, and vitamin K antagonists are widely used in patients after myocardial infarction." | 7.75 | Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. ( Abildstrom, SZ; Andersson, C; Gislason, GH; Hansen, ML; Hansen, PR; Hvelplund, A; Jørgensen, C; Køber, L; Madsen, JK; Sørensen, R; Torp-Pedersen, C, 2009) |
| "The authors describe a case of a 74-year-old man with advanced coronary heart disease in whom pulmonary hemorrhagic complications during therapy with ticlopidine and subsequently with clopidogrel and amiodarone were observed." | 7.73 | [Recurrent hemoptysis following thienopyridines and amiodarone administration. therapeutic dilemma]. ( Cofta, S; Elikowski, W; Mańczak, J; Nowicki, A; Psuja, P, 2005) |
| "We investigated whether a combination of clopidogrel and glycoprotein (GP) IIb/IIIa inhibitors safely decreases hospital mortality, reinfarction, and major bleeding beyond either therapy alone in patients with non-ST-elevation myocardial infarction (NSTEMI)." | 7.73 | Effectiveness and safety of glycoprotein IIb/IIIa inhibitors and clopidogrel alone and in combination in non-ST-segment elevation myocardial infarction (from the National Registry of Myocardial Infarction-4). ( Bromberg-Marin, G; Canto, JG; Marin-Neto, JA; Parsons, LS; Rogers, WJ, 2006) |
| "During the period from January 2000 to May 2002, 70 patients who were prescribed clopidogrel (75 mg/day) for a previous history of non-aspirin-related peptic ulcer disease or a history of aspirin-related gastrointestinal complications (dyspepsia or peptic ulcer) were recruited." | 7.72 | High incidence of clopidogrel-associated gastrointestinal bleeding in patients with previous peptic ulcer disease. ( Chang, CM; Chen, WH; Kng, C; Lanas, AI; Ng, FH; Wong, BC; Wong, SY, 2003) |
| "The antiplatelet effect of clopidogrel was studied prospectively in 60 consecutive patients who underwent primary angioplasty (percutaneous coronary intervention [PCI]) with stenting for acute ST-segment-elevation myocardial infarction (STEMI) to determine whether variability in response to clopidogrel affects clinical outcomes." | 7.72 | Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. ( Beinart, R; Bienart, R; Goldenberg, I; Guetta, V; Hod, H; Matetzky, S; Novikov, I; Pres, H; Savion, N; Shechter, M; Shenkman, B; Varon, D, 2004) |
| "The thienopyridine derivatives, ticlopidine and clopidogrel, provide alternatives to aspirin for use in the prevention of recurrent ischemic events in the post-myocardial infarction patient." | 7.70 | Aspirin and newer orally active antiplatelet agents in the treatment of the post-myocardial infarction patient. ( Pepine, CJ, 1998) |
| "Ticlopidine is increasingly used in the secondary prophylaxis in patients with arterial occlusive diseases." | 7.70 | Ticlopidine induced prolonged leucopenia in a patient with immunocytoma and chronic hepatitis C. ( Ehringer, H; Minar, E; Parschalk, B; Redlich, K, 1999) |
| "The goal of this health economic analysis was to asses the cost-effectiveness of a fixed combination of aspirin plus extended-release dipyridamole (ASA/ER-DP) or clopidogrel compared with ASA monotherapy for prevention of recurrent ischemic stroke." | 7.70 | Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: a cost-effectiveness analysis. ( Gondek, K; Shah, H, 2000) |
| "The primary outcome is IS recurrence." | 6.80 | Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial. ( Hoshino, H; Kimura, K; Minematsu, K; Naritomi, H; Origasa, H; Toyoda, K; Uchiyama, S; Yamaguchi, T, 2015) |
| " The primary end point was major adverse cardiac events (death, MI, and ischemia-driven target vessel revascularization) at 12 months." | 6.74 | Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction. ( Cheong, SS; Cho, YH; Hong, MK; Hong, TJ; Jeong, MH; Kim, JJ; Kim, KS; Kim, YH; Lee, CW; Lee, JH; Lee, NH; Lee, SG; Lee, SH; Lim, DS; Park, DW; Park, SJ; Park, SW; Seong, IW; Seung, KB; Yang, JY; Yoon, J; Yun, SC, 2009) |
| "The primary end point was recurrence of ACS or death >30days after the index event." | 5.46 | Clopidogrel, prasugrel, or ticagrelor use and clinical outcome in patients with acute coronary syndrome: A nationwide long-term registry analysis from 2009 to 2014. ( Geroldinger, A; Heinze, G; Reichardt, B; Sheikh Rezaei, S; Wolzt, M, 2017) |
| "The major result events, included: (1) recurrence of ischemic stroke; (2) hemorrhagic transformation of ischemic stroke; (3) myocardial infarction; (4) the digestive hemorrhage." | 5.43 | [Retrospective cohort study for the impact on readmission of patients with ischemic stroke after treatment of aspirin plus clopidogrel or aspirin mono-therapy]. ( Gao, P; Hu, YH; Tang, X; Wei, CL; Yang, C; Zhang, YQ, 2016) |
| "Minor stroke and transient ischemic attack are common disorders with high rate of subsequent disabling stroke." | 5.43 | High-Sensitive C-Reactive Protein Predicts Recurrent Stroke and Poor Functional Outcome: Subanalysis of the Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events Trial. ( Li, J; Lin, J; Liu, L; Meng, X; Wang, A; Wang, C; Wang, Y; Zhao, X, 2016) |
| "In conclusion, in a dog coronary thrombosis model, ticagrelor blocks ADP-induced platelet activation and aggregation; prevents platelet-mediated thrombosis; prolongs reperfusion time and reduces re-occlusion and cyclic flow variation; and significantly decreases infarct size and rapidly restores myocardial tissue perfusion." | 5.36 | Adjunctive treatment with ticagrelor, but not clopidogrel, added to tPA enables sustained coronary artery recanalisation with recovery of myocardium perfusion in a canine coronary thrombosis model. ( Huang, Y; Khalil, M; Penn, MS; van Giezen, JJ; Wang, K; Wiktor, D; Zhou, X, 2010) |
| "Tirofiban was administered for 24 h and the IABP was withdrawn after 60 h." | 5.35 | Reversible clopidogrel resistance due to right ventricular myocardial infarction: risk factor of recurrent stent thrombosis? ( Braun-Dullaeus, RC; Hass, N; Ibrahim, K; Kolschmann, S; Strasser, RH, 2008) |
| " Our case report suggests that antithrombotic treatment by targeting of the activated platelets with a potent platelet inhibitor during the acute phase of type II HIT syndrome followed by long-term administration of oral anticoagulation may be an additional, safe and effective therapeutic alternative that merits to be systematically studied." | 5.33 | Recurrent arterial thromboses in a woman with heparin induced thrombocytopenia, successfully managed with iloprost followed by clopidogrel. An alternative therapeutic option for heparin induced thrombocytopenia type II syndrome. ( Alexandridou, S; Betsis, D; Blouhos, K; Megalopoulos, A; Tsachalis, T; Tsalis, K; Vasiliadis, K, 2006) |
| "In smokers, a double-dose clopidogrel regimen reduced major cardiovascular events and stent thrombosis after percutaneous coronary intervention, with no increase in major bleeding." | 5.24 | Double-Dose Versus Standard-Dose Clopidogrel According to Smoking Status Among Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. ( Bossard, M; Faxon, DP; Fox, KAA; Gao, P; Granger, CB; Jolly, SS; Mehta, SR; Montalescot, G; Natarajan, MK; Niemela, K; Steg, PG; Tanguay, JF; Widimsky, P; Yusuf, S, 2017) |
| "From January 2012 to 2016, long-termed thienopyridine users with a peptic ulcer history who did not have peptic ulcers at initial endoscopy were randomly assigned to receive either famotidine (40 mg, before bedtime) or placebo (before bedtime) for 6 months." | 5.24 | Histamine-2 Receptor Antagonist Cannot Prevent Recurrent Peptic Ulcers in Patients With Atherosclerotic Diseases Who Receive Platelet ADP Receptor Antagonist Monotherapy: A Randomized-Controlled, Double-Blind, and Double-Dummy Trial. ( Chen, WC; Cheng, JS; Hsu, PI; Kao, SS; Lai, KH; Liu, CP; Tsai, KW; Tsai, TJ; Tsay, FW; Wang, HM; Wu, DC, 2017) |
| "The aim of this study was to analyze the benefits and safety associated with the combination therapy of clopidogrel and aspirin among minor stroke or transient ischemic attack patients treated within 12 hours." | 5.22 | Treatment Effect of Clopidogrel Plus Aspirin Within 12 Hours of Acute Minor Stroke or Transient Ischemic Attack. ( Jing, J; Johnston, SC; Li, H; Li, Z; Liu, L; Meng, X; Pan, Y; Wang, C; Wang, D; Wang, X; Wang, Y; Xian, Y; Yang, X; Zhang, C; Zhao, X, 2016) |
| "Among patients with STEMI undergoing PPCI, ticagrelor reduces the incidence of MACCE and the composite end point of cardiovascular death, nonfatal MI, and stroke compared with clopidogrel." | 5.22 | Assessment of Ticagrelor Versus Clopidogrel Treatment in Patients With ST-elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. ( Jing, Q; Li, R; Liu, P; Liu, Y; Tang, X; Wang, Q; Zhang, P, 2016) |
| " In a previous study, we found that the number of MESs is associated with stroke recurrence and that clopidogrel plus aspirin more effectively reduce the number of MESs than does aspirin alone." | 5.22 | The curative effect comparison of two kinds of therapeutic regimens on decreasing the relative intensity of microembolic signal in CLAIR trial. ( Chen, C; Deng, QQ; Fu, JH; Huang, YN; Markus, H; Ratanakorn, D; Tang, J; Wong, KS; Zhao, H, 2016) |
| "The Elderly-ACS 2 study is a multicenter, randomized, parallel-group, open-label trial designed to demonstrate the superiority of a strategy of dual antiplatelet treatment using a reduced 5-mg daily dose of prasugrel over a standard strategy with a daily clopidogrel dose of 75mg in patients older than 74years with ACS (either ST- or non-ST-elevation myocardial infarction) undergoing early percutaneous revascularization." | 5.22 | A comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization: Design and rationale of the randomized Elderly-ACS 2 study. ( Bossi, I; Cacucci, M; Cavallini, C; Corrada, E; De Servi, S; Di Ascenzo, L; Ferrario, M; Ferri, LA; Gandolfo, N; Grosseto, D; Mariani, M; Moffa, N; Morici, N; Petronio, AS; Ravera, A; Savonitto, S; Sganzerla, P; Sibilio, G; Tondi, S; Tortorella, G; Toso, A, 2016) |
| "The Clopidogrel in High-Risk Patients with Acute Nondisabling Cerebrovascular Events trial randomized minor ischemic stroke or TIA patients to antiplatelet therapy of clopidogrel plus aspirin or aspirin alone." | 5.20 | Glycated albumin predicts the effect of dual and single antiplatelet therapy on recurrent stroke. ( Li, J; Lin, J; Liu, L; Wang, A; Wang, C; Wang, D; Wang, Y; Zhao, X, 2015) |
| "Between 2009 and 2012, 2286 patients invasively managed for ACS were enrolled in the multicentre Swiss ACS Bleeding Cohort, among whom 2148 patients received either prasugrel or clopidogrel according to current guidelines." | 5.20 | Safety profile of prasugrel and clopidogrel in patients with acute coronary syndromes in Switzerland. ( Auer, R; Carballo, D; Gencer, B; Heg, D; Jaguszewski, M; Jakob, P; Jüni, P; Klingenberg, R; Landmesser, U; Lüscher, TF; Mach, F; Maier, W; Matter, CM; Meier, B; Nanchen, D; Räber, L; Rodondi, N; Roffi, M; Stähli, BE; Stefanini, GG; Templin, C; Vogt, P; Windecker, S, 2015) |
| "The role of the CYP2C19 genotype on clopidogrel efficacy has been studied widely, with data suggesting reduced clopidogrel efficacy in loss-of-function variant carriers taking clopidogrel after percutaneous coronary intervention; however, data are limited regarding the association between CYP2C19 genetic variants and outcomes in stroke patients." | 5.20 | CYP2C19 metabolizer status and clopidogrel efficacy in the Secondary Prevention of Small Subcortical Strokes (SPS3) study. ( Benavente, OR; Field, TS; Gong, Y; Horenstein, RB; Johnson, JA; Lewis, JP; McClure, LA; McDonough, CW; Mitchell, BD; Shuldiner, AR; Talbert, RL, 2015) |
| "The aim of this study was to assess the relationship between sex and clinical outcomes and treatment-related complications in patients with ST-elevation or non-ST-elevation acute coronary syndromes (ACS) randomized to treatment with ticagrelor or clopidogrel in the PLATelet inhibition and patient Outcomes (PLATO) trial." | 5.19 | The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial. ( Bach, RG; Becker, RC; Budaj, A; Heras, M; Himmelmann, A; Horrow, J; Husted, S; James, SK; Katus, HA; Lassila, R; Morais, J; Nicolau, JC; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, D, 2014) |
| "Altogether 574 patients with acute (≤2 days) large-artery atherosclerosis stroke were randomly assigned to receive either combined clopidogrel and aspirin or aspirin alone." | 5.19 | A comparative study of dual versus monoantiplatelet therapy in patients with acute large-artery atherosclerosis stroke. ( Chi, W; Lin, J; Wang, C; Yi, X; Zhang, B, 2014) |
| "A subset of the TRITON-TIMI 38 study (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction 38), in which patients with acute coronary syndrome were randomized to treatment with aspirin and either clopidogrel or prasugrel, underwent isolated CABG (N = 346)." | 5.16 | Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis. ( Goodnough, LT; Lenarz, LA; Levy, JH; Poston, RS; Short, MA; Smith, PK; Weerakkody, GJ, 2012) |
| "Among patients with recent lacunar strokes, the addition of clopidogrel to aspirin did not significantly reduce the risk of recurrent stroke and did significantly increase the risk of bleeding and death." | 5.16 | Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. ( Benavente, OR; Coffey, CS; Hart, RG; McClure, LA; Pearce, LA; Szychowski, JM, 2012) |
| "After an acute coronary syndrome, patients remain at risk of recurrent ischaemic events, despite contemporary treatment, including aspirin and clopidogrel." | 5.15 | Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. ( Budaj, A; Granger, CB; Khder, Y; Oldgren, J; Roberts, J; Siegbahn, A; Tijssen, JG; Van de Werf, F; Wallentin, L, 2011) |
| "Prasugrel is a novel thienopyridine that reduces new or recurrent myocardial infarctions (MIs) compared with clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention." | 5.14 | Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardi ( Antman, EM; Bonaca, MP; Bramucci, E; Braunwald, E; McCabe, CH; Morrow, DA; Murphy, SA; Nicolau, JC; Ruff, CT; Scirica, BM; White, HD; Wiviott, SD, 2009) |
| "The aim of this analysis was to evaluate whether routine pre-hospital administration of high-dose tirofiban in ST-segment elevation myocardial infarction (STEMI) decreases the incidence of early stent thrombosis after primary PCI." | 5.14 | Marked reduction of early stent thrombosis with pre-hospital initiation of high-dose Tirofiban in ST-segment elevation myocardial infarction. ( De Boer, MJ; Dill, T; Gosselink, AT; Hamm, C; Heestermans, AA; Hoorntje, JC; Koopmans, PC; Ten Berg, JM; Van 't Hof, AW; Van Houwelingen, G; Van Werkum, JW, 2009) |
| "We randomly assigned a total of 400 patients with ST-segment elevation myocardial infarction referred for primary percutaneous coronary intervention to treatment initiated before cardiac catheterization, with either heparin plus eptifibatide (201 patients) or heparin alone (199 patients), in addition to oral aspirin (160 mg) and high-dose clopidogrel (600 mg)." | 5.14 | Primary percutaneous coronary angioplasty with and without eptifibatide in ST-segment elevation myocardial infarction: a safety and efficacy study of integrilin-facilitated versus primary percutaneous coronary intervention in ST-segment elevation myocardi ( Froeschl, M; Glover, CA; Jadhav, S; Kass, M; Labinaz, M; Le May, MR; Marquis, JF; O'Brien, ER; So, DY; Thomas, A; Turek, M; Wells, GA, 2009) |
| "In the current era of early revascularization and routine use of dual antiplatelet therapy, the incremental benefit of warfarin to reduce the incidence of left ventricular thrombus (LVT) in patients with impaired left ventricular ejection fraction post anterior ST-elevation myocardial infarction (aSTEMI), remains uncertain." | 5.14 | Warfarin after anterior myocardial infarction in current era of dual antiplatelet therapy: a randomized feasibility trial. ( Ahmad, M; Eikelboom, JW; Natarajan, MK; Salehian, O; Schwalm, JD, 2010) |
| "This study sought to determine the efficacy of high-dose atorvastatin in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI)." | 5.14 | Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the STATIN STEMI trial. ( Cho, DK; Cho, JR; Cho, YH; Choi, D; Hong, MK; Jang, Y; Jeon, DW; Kim, BK; Kim, J; Kim, JS; Ko, YG; Lee, CJ; Lee, NH; Lee, SH; Oh, SJ; Yang, JY, 2010) |
| "In the Bavarian Reperfusion Alternatives Evaluation (BRAVE)-3 study upstream administration of abciximab additional to 600 mg clopidogrel loading did not reduce the infarct size in patients with acute ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary interventions." | 5.14 | One-year clinical outcomes with abciximab in acute myocardial infarction: results of the BRAVE-3 randomized trial. ( Birkmeier, KA; Dirschinger, J; Dotzer, F; Huber, K; Kastrati, A; Mehilli, J; Moshage, W; Ndrepepa, G; Schömig, A; Schulz, S; Seyfarth, M, 2010) |
| "All patients with acute ischemic stroke or transient ischemic attack within a 10 month period were administered 600 mg clopidogrel bolus if they were already taking aspirin regularly, or had aspirin allergy or intolerance." | 5.13 | Safety and tolerability of 600 mg clopidogrel bolus in patients with acute ischemic stroke: preliminary experience. ( Abdelmoula, MM; Divani, AA; Hussein, HM; Qureshi, AI; Suri, MF, 2008) |
| "Antiplatelet therapy with clopidogrel and acetylsalicylic acid (ASA) reduces major cardiovascular events in patients with ST and non-ST-segment-elevation acute coronary syndromes (ACS)." | 5.13 | Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. ( Bassand, JP; Chrolavicius, S; Diaz, R; Fox, KA; Granger, CB; Jolly, S; Mehta, SR; Rupprecht, HJ; Widimsky, P; Yusuf, S, 2008) |
| "To determine the prevalence of platelet nonresponsiveness to aspirin treatment for secondary stroke prophylaxis, the authors studied consecutive patients during a 29-month period." | 5.13 | Prevalence of platelet nonresponsiveness to aspirin in patients treated for secondary stroke prophylaxis and in patients with recurrent ischemic events. ( Bates, V; Forrest, A; Gengo, FM; Gengo, MF; Hourihane, M; Rainka, M; Robson, M, 2008) |
| "Sirolimus-eluting stents (SESs) recently proved to be superior to bare metal stents (BMSs) in decreasing the need for repeat revascularization in patients with ST-segment elevation myocardial infarction (STEMI) at 1 year." | 5.12 | Comparison of three-year clinical outcome of sirolimus- and paclitaxel-eluting stents versus bare metal stents in patients with ST-segment elevation myocardial infarction (from the RESEARCH and T-SEARCH Registries). ( Daemen, J; de Jaegere, PP; García-García, HM; Kukreja, N; Serruys, PW; Sianos, G; Tanimoto, S; van de Sande, M; van Domburg, RT, 2007) |
| "Fluctuations in urinary 11-DTB2 after cerebral infarction in blacks do not correlate with changes in aspirin doses, except perhaps when the dose changes by a factor of 4 or more." | 5.11 | Serial urinary 11-dehydrothromboxane B2, aspirin dose, and vascular events in blacks after recent cerebral infarction. ( Bang, NU; Bruno, A; Cohen, SN; Gorelick, PB; McConnell, JP; Tietjen, GE; Wallis, RA, 2004) |
| "We studied 18 558 patients with ischemic stroke, myocardial infarction, or peripheral arterial disease who participated in the trial of Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE), a study that compared the occurrence of ischemic stroke, myocardial infarction, or vascular death under randomized treatment with aspirin or clopidogrel." | 5.11 | Leukocyte count as an independent predictor of recurrent ischemic events. ( Boddy, AW; Brandt, T; Buggle, F; Dukovic, DA; Grau, AJ; Hacke, W; Lichy, C, 2004) |
| "Although full platelet inhibition with aspirin and thienopyridines before coronary stenting has significantly reduced the risk of acute stent thrombosis, peri-procedural myonecrosis still occurs frequently and is associated with increased death rate." | 5.11 | Does pre-treatment with aspirin and loading dose clopidogrel obviate the need for glycoprotein IIb/IIIa antagonists during elective coronary stenting? A focus on peri-procedural myonecrosis. ( Bosmans, JM; Claeys, MJ; Michiels, JJ; Van Der Goten, P; Van der Planken, MG; Vertessen, F; Vrints, CJ; Wuyts, FL, 2005) |
| "To evaluate the impact of a clopidogrel therapy on the effectiveness of myocardial reperfusion in patients with ST-segment elevation acute myocardial infarction (AMI) undergoing routine infarct-related artery (IRA) stent implantation and receiving routine abciximab therapy." | 5.11 | A randomized trial comparing clopidogrel versus ticlopidine therapy in patients undergoing infarct artery stenting for acute myocardial infarction with abciximab as adjunctive therapy. ( Antoniucci, D; Memisha, G; Migliorini, A; Moschi, G; Parodi, G; Pupi, A; Sciagrà, R; Valenti, R, 2005) |
| "To determine the efficacy and safety of aspirin and ticlopidine to prevent recurrent stroke in black patients." | 5.10 | Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial. ( Gorelick, PB; Harris, Y; Hung, E; Kelly, M; Kittner, S; Leurgans, S; Richardson, D; Ruland, S, 2003) |
| "To compare the efficacy and safety of two antiplatelet regimens, ticlopidine alone (200 mg daily) and ticlopidine (100 mg daily) plus aspirin (81 mg daily), in patients with ischemic stroke from the Tokai district of Japan." | 5.10 | Ticlopidine alone versus ticlopidine plus aspirin for preventing recurrent stroke. ( Ito, E; Kuzuhara, S; Nakajima, M; Takahashi, A; Uchiyama, S; Yamamoto, H, 2003) |
| "The safety and tolerability of clopidogrel coadministration to patients with recent acute myocardial infarction (AMI) treated with recombinant tissue plasminogen activator (rt-PA) and heparin were assessed." | 5.09 | Clopidogrel-rt-PA-heparin combination in the treatment of acute myocardial infarction. ( Bassand, JP; Cariou, R; Grollier, G; Heyndrickx, GR; Kragten, J; Wolf, JE, 1999) |
| "We sought to compare the efficacy of aspirin and ticlopidine in survivors of acute myocardial infarction (AMI) treated with thrombolysis." | 5.09 | Ticlopidine versus aspirin after myocardial infarction (STAMI) trial. ( Cimminiello, C; Di Biase, M; Marubini, E; Pitzalis, MV; Rizzon, P; Scrutinio, D, 2001) |
| "One hundred twenty-three patients with successful stenting after acute myocardial infarction were randomized to receive aspirin plus ticlopidine (n = 61) or intense anticoagulant therapy (n = 62)." | 5.08 | Coronary stent placement in patients with acute myocardial infarction: comparison of clinical and angiographic outcome after randomization to antiplatelet or anticoagulant therapy. ( Alt, E; Blasini, R; Dirschinger, J; Hadamitzky, M; Hausleiter, J; Kastrati, A; Neumann, FJ; Schmitt, C; Schömig, A; Schühlen, H; Walter, H; Zitzmann-Roth, EM, 1997) |
| "The efficacy of combining antiplatelet agents with low doses of aspirin to prevent cardiac events in patients with myocardial infarction was examined." | 5.08 | Aspirin plus either dipyridamole or ticlopidine is effective in preventing recurrent myocardial infarction. Secondary Prevention Group. ( Hama, J; Ishikawa, K; Kanamasa, K; Katori, R; Kimura, A; Naito, T; Nakai, S; Ogawa, I; Oyaizu, M; Takenaka, T; Yamamoto, K; Yamamoto, T, 1997) |
| "The Canadian American Ticlopidine Study (CATS) is a randomised, double-blind, placebo-controlled trial to assess the effect of ticlopidine (250 mg twice daily) in reducing the rate of subsequent occurrence of stroke, myocardial infarction, or vascular death in patients who have had a recent thromboembolic stroke." | 5.06 | The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. ( Blakely, JA; Easton, JD; Ellis, DJ; Gent, M; Hachinski, VC; Harbison, JW; Panak, E; Roberts, RS; Sicurella, J; Turpie, AG, 1989) |
| "Optimal antiplatelet therapy after an ischemic stroke or transient ischemic attack while on aspirin is uncertain." | 4.95 | Antiplatelet Regimen for Patients With Breakthrough Strokes While on Aspirin: A Systematic Review and Meta-Analysis. ( Hong, KS; Lee, M; Ovbiagele, B; Rao, NM; Saver, JL; Wu, YL, 2017) |
| "Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel for 90 days was recommended as the secondary prevention of minor ischaemic strokes or transient ischaemic attacks (TIAs) in 2014." | 4.93 | Dual antiplatelet therapy after stroke or transient ischaemic attack - how long to treat? The duration of aspirin plus clopidogrel in stroke or transient ischaemic attack: a systematic review and meta-analysis. ( Chang, T; Ge, F; Guo, R; Li, M; Lin, H; Liu, Y; Ruan, Z, 2016) |
| "Compared with monotherapy, short-term aspirin in combination with clopidogrel is more effective as secondary prevention of stroke or TIA without increasing the risk of hemorrhagic stroke and major bleeding events." | 4.91 | Aspirin plus clopidogrel as secondary prevention after stroke or transient ischemic attack: a systematic review and meta-analysis. ( Li, J; Li, Y; Shang, X; Wang, C; Yan, C; Zhang, L; Zhang, Q; Zheng, M, 2015) |
| "To present the systematic assessment on the efficacy and bleeding adverse events of dual-antiplatelet therapy with aspirin and clopidogrel versus aspirin-mono-antiplatelet therapy in patients with ischemic stroke or transient ischemic attack." | 4.91 | [Meta-analysis on the efficacy and adverse events of aspirin plus clopidogrel versus aspirin-monotherapy in patients with ischemic stroke or transient ischemic attack]. ( Gao, P; Hu, Y; Qian, J; Tang, X; Yang, C, 2015) |
| "Dual antiplatelet therapy with aspirin plus clopidogrel is not recommended for secondary stroke prevention because of lack of effectiveness and increased hemorrhagic risk." | 4.90 | Front-loading with clopidogrel plus aspirin followed by dual antiplatelet therapy in the prevention of early stroke recurrence. ( Censori, B, 2014) |
| " In comparison with mono antiplatelet therapy, dual therapy (aspirin+dipyridamole and aspirin+clopidogrel) significantly reduced stroke recurrence, dual 58 (3." | 4.88 | Dual or mono antiplatelet therapy for patients with acute ischemic stroke or transient ischemic attack: systematic review and meta-analysis of randomized controlled trials. ( Algra, A; Bath, MW; Bath, PM; Chen, C; Dengler, R; Diener, HC; Geeganage, CM; Markus, HS; Topol, EJ, 2012) |
| "We performed this meta-analysis to update the clinical evidences on the relation between clopidogrel non-responsiveness and clinical outcomes in patients with coronary artery disease (CAD) who underwent percutaneous coronary intervention." | 4.86 | Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated meta-analysis. ( Abbate, R; Gensini, GF; Giusti, B; Gori, AM; Marcucci, R; Sofi, F, 2010) |
| " Pooled data from trials comparing antithrombotic treatment with placebo show that warfarin reduces the risk of stroke by 62% and that aspirin alone reduces the risk by 22%." | 4.82 | [Preventing cerebrovascular accidents during atrial fibrillation]. ( Boccara, F; Cohen, A; Ederhy, S; Hammoudi, N; Janower, S; Meuleman, C, 2005) |
| " In the CAPRIE (Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events) Trial, clopidogrel (clopidogrel bisulphate) was superior to acetylsalicylic acid (ASA) in reducing the combined risk of ischaemic stroke (IS), myocardial infarction (MI) or vascular death in patients with symptomatic atherosclerosis." | 4.81 | From CURE to MATCH: ADP receptor antagonists as the treatment of choice for high-risk atherothrombotic patients. ( Hacke, W, 2002) |
| " The gastrointestinal bleeding risk was significantly lower with ticlopidine and clopidogrel, which were both somewhat more effective than aspirin in the prevention of vascular events." | 4.80 | Bleeding complications in secondary stroke prevention by antiplatelet therapy: a benefit-risk analysis. ( Boysen, G, 1999) |
| "At the acute phase of cerebral infarction, two recent large studies found that the use of aspirin reduces both mortality and the risk of the recurrence of stroke." | 4.80 | [Aspirin and cerebral ischemic accidents]. ( Bousser, MG; Crassard, I; Niclot, P, 2000) |
| "English-language articles published after 1977 and indexed in MEDLINE under the following Medical Subject Heading terms: anticoagulants, aspirin, dipyridamole, ticlopidine, or sulfinpyrazone, combined with cerebrovascular disorders." | 4.79 | Medical treatment for stroke prevention. ( Barnett, HJ; Feussner, JR; Matchar, DB; McCrory, DC, 1994) |
| " A total of 477 patients receiving double antiaggregation therapy with aspirin and clopidogrel, after suffering a first event, were followed for 1 year to record relapse, as a surrogate end point to measure their therapeutic response, as defined by presenting with an acute coronary event (unstable angina, ST-segment-elevation myocardial infarction, or non-ST-segment-elevation myocardial infarction), stent thrombosis/restenosis, or cardiac mortality." | 4.12 | Clinical and Pharmacological Parameters Determine Relapse During Clopidogrel Treatment of Acute Coronary Syndrome. ( Martínez-Quintana, E; Medina-Gil, JM; Rodríguez-González, F; Saavedra-Santana, P; Santana-Mateos, M; Tugores, A, 2022) |
| "We pooled individual patient data from 6 randomized clinical trials (CAPRIE [Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events], ESPS-2 [European Stroke Prevention Study-2], MATCH [Management of Atherothrombosis With Clopidogrel in High-Risk Patients], CHARISMA [Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance], ESPRIT [European/Australasian Stroke Prevention in Reversible Ischemia Trial], and PRoFESS [Prevention Regimen for Effectively Avoiding Second Strokes]) investigating antiplatelet therapy in the subacute or chronic phase after noncardioembolic transient ischemic attack or stroke." | 4.02 | Balancing Benefits and Risks of Long-Term Antiplatelet Therapy in Noncardioembolic Transient Ischemic Attack or Stroke. ( Algra, A; Bath, PM; Csiba, L; Diener, HC; Greving, JP; Hacke, W; Hilkens, NA; Kappelle, LJ; Koudstaal, PJ; Leys, D; Mas, JL; Sacco, RL, 2021) |
| "In real-world practice settings, there is insufficient evidence on the efficacy of antiplatelet drugs, including clopidogrel, aspirin, and ticlopidine, in stroke prevention." | 3.96 | Efficacy of aspirin, clopidogrel, and ticlopidine in stroke prevention: A population-based case-cohort study in Taiwan. ( Hsu, YH; Ong, CT; Tsai, CF; Wong, YS, 2020) |
| "A total of 168 patients with coronary heart disease who underwent PCI operation and received clopidogrel treatment were enrolled." | 3.88 | CYP2C19 and ABCB1 genetic polymorphisms correlate with the recurrence of ischemic cardiovascular adverse events after clopidogrel treatment. ( Fang, W; Gan, Q; Han, W; Hou, X; Liu, Y, 2018) |
| "Clopidogrel HTPR does not seem to be a major contributor to recurrent ischemic events in Danish ischemic stroke patients." | 3.88 | Secondary Stroke Prophylaxis with Clopidogrel Produces Sufficient Antiplatelet Response. ( Jørgensen, NR; Rath, CL; Wienecke, T, 2018) |
| "From January 2014 to September 2014, a single center continuously enrolled patients with minor ischemic stroke or high-risk TIA and gave them antiplatelet therapy consisting of aspirin with clopidogrel." | 3.85 | The association between high on-treatment platelet reactivity and early recurrence of ischemic events after minor stroke or TIA. ( Cao, Y; Dong, K; Liu, L; Rao, Z; Wang, A; Wang, F; Wang, Y; Zhao, X; Zheng, H, 2017) |
| "Our findings indicate a favorable effect of clopidogrel at discharge compared with aspirin in preventing death, recurrent stroke, and CVD events in diabetic patients with a first-ever noncardioembolic AIS." | 3.85 | Aspirin Versus Clopidogrel for Type 2 Diabetic Patients with First-Ever Noncardioembolic Acute Ischemic Stroke: Ten-Year Survival Data from the Athens Stroke Outcome Project. ( Elisaf, M; Manios, E; Milionis, H; Ntaios, G; Papavasileiou, V; Spengos, K; Vemmos, K, 2017) |
| "We consecutively enrolled 375 patients with IS after they received clopidogrel therapy, and venous blood samples were subjected to genotyping allelic variants of genes modulating clopidogrel absorption (ATP binding cassette subfamily B1, ABCB1), metabolic activation (cytochrome P450[CYP] 3A and CYP2C19), and biologic activity (platelet membrane receptor [ P2Y12, P2Y1)], and glycoprotein IIIa [ GPIIIa]) and statistically analyzing their interactions with clopidogrel sensitivity (CS) and adverse events, risk of IS recurrence, myocardial infarction, and death during 6 months of follow-up." | 3.85 | Interaction of CYP2C19, P2Y12, and GPIIIa Variants Associates With Efficacy of Clopidogrel and Adverse Events on Patients With Ischemic Stroke. ( Cheng, W; Lin, J; Wang, C; Wang, Y; Yi, X; Zhou, Q, 2017) |
| "Acute coronary syndrome patients infected with HIV (n = 80) were matched to ACS patients without HIV (n = 160) on age, sex, diabetes, and DAPT (aspirin 100%, clopidogrel 68%, prasugrel 31%, ticagrelor 1%)." | 3.85 | Platelet reactivity in human immunodeficiency virus infected patients on dual antiplatelet therapy for an acute coronary syndrome: the EVERE2ST-HIV study. ( Boccara, F; Boyd, A; Brugier, D; Cohen, A; Collet, JP; Curjol, A; Galier, S; Hauguel-Moreau, M; Hulot, JS; Kerneis, M; Montalescot, G; Salem, JE; Silvain, J, 2017) |
| "Active smokers with myocardial infarction were shown to have enhanced benefit with clopidogrel compared with aspirin." | 3.85 | Clopidogrel and ischemic stroke outcomes by smoking status: Smoker's paradox? ( Cao, Q; Dong, K; Feng, W; Hou, C; Huang, X; Ji, X; Ovbiagele, B; Song, H; Wang, M; Wang, Y; Zhang, Q, 2017) |
| "Research regarding clopidogrel resistance (CR) and ischemic stroke (IS) recurrence related to IS is scanty." | 3.83 | Clopidogrel Resistance Increases Rate of Recurrent Stroke and Other Vascular Events in Chinese Population. ( Cheng, W; Lin, J; Wang, C; Wu, L; Yi, X; Zhou, Q, 2016) |
| "From a cohort of 1900 patients with ischemic stroke, we selected 42 patients treated with clopidogrel, including 21 with a recurrent vascular event and 21 without vascular recurrence during the first year of follow-up." | 3.83 | TRAF3 Epigenetic Regulation Is Associated With Vascular Recurrence in Patients With Ischemic Stroke. ( Carrera, C; Cullell, N; Fernandez-Cadenas, I; Fontana, P; Gallego-Fabrega, C; Krupinski, J; Martí-Fàbregas, J; Montaner, J; Muiño, E; Pera, J; Pezzini, A; Reny, JL; Segura, T; Serrano-Heras, G; Slowik, A, 2016) |
| "Proton pump inhibitors (PPIs) reduce gastrointestinal bleeding events but may alter clopidogrel metabolism." | 3.83 | Impact of Proton Pump Inhibitor Use on the Comparative Effectiveness and Safety of Prasugrel Versus Clopidogrel: Insights From the Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acu ( Baker, BA; Cohen, DJ; Effron, MB; Faries, DE; Jackson, LR; Ju, C; McCoy, LA; Messenger, JC; Peterson, ED; Wang, TY; Zettler, M, 2016) |
| " We hypothesized that cytochrome P450 2C19 (CYP2C19) genotype influences the incidence of early recurrence on DWI in acute stroke patients treated with clopidogrel." | 3.81 | CYP2C19 genotype and early ischemic lesion recurrence in stroke patients treated with clopidogrel. ( Chun, S; Jeong, TD; Kang, DW; Kim, HJ; Kim, SM; Kwon, SU; Lee, W; Min, WK, 2015) |
| "We conducted a nested case-control study of Ontarians aged 66 years and older treated with clopidogrel between September 1 2003 and March 31 2013 following acute myocardial infarction." | 3.81 | A population-based study of the drug interaction between clopidogrel and angiotensin converting enzyme inhibitors. ( Cressman, AM; Fernandes, KA; Gomes, T; Juurlink, DN; Macdonald, EM; Mamdani, MM; Paterson, JM, 2015) |
| "In patients with ischemic stroke of non-cardioembolic origin, acetylsalicylic acid, clopidogrel, or a combination of acetylsalicylic acid and dipyridamole are recommended for the prevention of a recurrent stroke." | 3.81 | Comparison of antiplatelet regimens in secondary stroke prevention: a nationwide cohort study. ( Carlson, N; Christiansen, CB; Gerds, TA; Gislason, G; Jørgensen, ME; Kristensen, SL; Numé, AK; Olesen, JB; Pallisgaard, J; Torp-Pedersen, C, 2015) |
| "To assess the association of genetic polymorphisms of CYP2C19*2,*3,*17 with the recurrence risk of ischemic stroke during clopidogrel prevention in ethnic Han Chinese from Fujian Province." | 3.81 | [Association of CYP2C19 gene polymorphisms with long-term recurrent risk of ischemic stroke among ethnic Han Chinese from Fujian]. ( Fang, L; Huang, H; Lin, M; Wang, N; Yang, Z; Zhao, Y, 2015) |
| "A retrospective review of all patients with stroke and transient ischemic attack (TIA) tested for the clopidogrel CYP2C19 genotype was performed, with a collection of data including race/ethnicity, CYP2C19 status, and the presence of recurrent vascular events." | 3.80 | Reduced clopidogrel metabolism in a multiethnic population: prevalence and rates of recurrent cerebrovascular events. ( Barazangi, N; Chen, C; Jaramillo, V; Rose, J; Spokoyny, I; Tong, D; Wong, C, 2014) |
| " We aimed to evaluate the effect of DAPT duration with clopidogrel and aspirin on the recurrence of ischaemic events and bleeding in a large, unselected ACS population." | 3.80 | Duration of dual antiplatelet treatment with clopidogrel and aspirin in patients with acute coronary syndrome. ( Hasvold, P; Held, C; James, S; Jensevik, K; Jernberg, T; Lagerqvist, B; Sundström, A; Varenhorst, C, 2014) |
| "To evaluate the effect of drug interaction between omeprazol and clopidogrel in hospital readmission of patients with acute coronary syndrome (ACS)." | 3.80 | [Effect of drug interaction between clopidogrel and omeprazole in hospital readmision of patients by a recurrent acute coronary syndrome: a case-control study]. ( Amariles, P; Angulo, NY; Betancourth, PM; Ceballos, M; Holguín, H, 2014) |
| "We estimated the effectiveness and safety of antiplatelet drugs (aspirin and clopidogrel) for the prevention of recurrent ischemic stroke in end-stage renal disease patients undergoing dialysis during long-term follow-up after first-time ischemic stroke." | 3.80 | Effectiveness and safety of antiplatelet in stroke patients with end-stage renal disease undergoing dialysis. ( Chen, CY; Huang, YB; Lai, WT; Lee, CT; Lee, KT, 2014) |
| "Although randomized clinical trials have compared clopidogrel with higher potency ADP receptor inhibitors (ADPris) among patients with myocardial infarction, little is known about the frequency and factors associated with switching between ADPris in clinical practice." | 3.80 | In-hospital switching between clopidogrel and prasugrel among patients with acute myocardial infarction treated with percutaneous coronary intervention: insights into contemporary practice from the national cardiovascular data registry. ( Alexander, KP; Bagai, A; Bhatt, DL; Cheema, AN; Curtis, JP; Granger, CB; Gurm, HS; McNamara, RL; Peterson, ED; Roe, MT; Saucedo, JF; Shah, B; Wang, TY; Wang, Y, 2014) |
| "The aim of the present study was to evaluate clopidogrel treatment after incident myocardial infarction (MI) in patients with and without chronic kidney disease (CKD)." | 3.80 | Benefit of clopidogrel therapy in patients with myocardial infarction and chronic kidney disease-a Danish nation-wide cohort study. ( Blicher, TM; Hommel, K; Kamper, AL; Kristensen, SL; Madsen, M; Olesen, JB; Torp-Pedersen, C, 2014) |
| " Whether the bolus dose alone is sufficient for ST-elevation myocardial infarction patients receiving a high loading dose of clopidogrel is unknown." | 3.79 | Abciximab bolus with optional infusion in intervention for ST-elevation myocardial infarction. ( Berglund, U; Janzon, M; Nilsson, L, 2013) |
| "The benefit of extending clopidogrel treatment beyond the 12-month period recommended in current guidelines after myocardial infarction (MI) is debated." | 3.78 | Clopidogrel discontinuation after myocardial infarction and risk of thrombosis: a nationwide cohort study. ( Ahlehoff, O; Charlot, M; Gislason, GH; Hansen, ML; Hansen, PR; Køber, L; Lindhardsen, J; Madsen, JK; Nielsen, LH; Olsen, AM; Torp-Pedersen, C, 2012) |
| "We conducted a population-based nested case-control study among patients aged 66 years or older who commenced clopidogrel between April 1, 2002 and December 31, 2009, following hospital discharge for acute myocardial infarction (AMI)." | 3.78 | Antidepressant use, serotonin transporter affinity, and reinfarction among patients receiving clopidogrel: a population-based study. ( Alshaikh, M; Fnais, N; Gomes, T; Juurlink, D; Mamdani, M; Yao, Z, 2012) |
| "The association between myocardial infarction (MI) and co-administration of proton pump inhibitors (PPIs) and clopidogrel remains controversial." | 3.77 | Risk of recurrent myocardial infarction with the concomitant use of clopidogrel and proton pump inhibitors. ( 't Jong, GW; Kuipers, EJ; Sturkenboom, MC; Valkhoff, VE; Van Soest, EM, 2011) |
| "We conducted a retrospective cohort study to assess CV outcomes of 9753 patients taking dual antiplatelet therapy of aspirin plus clopidogrel with or without a PPI after hospitalization for acute coronary syndrome (ACS)." | 3.77 | Relationship between cardiovascular outcomes and proton pump inhibitor use in patients receiving dual antiplatelet therapy after acute coronary syndrome. ( Chen, PF; Hsiao, FY; Huang, WF; Mullins, CD; Tsai, YW; Wen, YW, 2011) |
| "Administrative claims from a large, geographically diverse US health plan were used to evaluate acetylsalicylic acid / extended-release dipyridamole (ASA/ERDP) treated and clopidogrel treated patients from November 1, 2002 - December 31, 2005 who had an ischemic stroke requiring hospitalization." | 3.76 | Impact of persistence with antiplatelet therapy on recurrent ischemic stroke and predictors of nonpersistence among ischemic stroke survivors. ( Burke, JP; Henk, H; Sander, S; Shah, H; Zarotsky, V, 2010) |
| "Clopidogrel improves outcomes in patients with ST-segment elevation myocardial infarction (STEMI) and is recommended in the guidelines." | 3.76 | Cost-effectiveness analysis of short-term clopidogrel therapy for ST elevation myocardial infarction. ( Cannon, CP; Cohen, DJ; Gibler, KB; Huskamp, HA; Murphy, SA; Sabatine, MS, 2010) |
| "The purpose of this study was to determine the readmission rate for acute myocardial infarction (AMI) in patients discharged on clopidogrel and a proton-pump inhibitor (PPI) versus patients discharged on clopidogrel alone after experiencing an AMI and undergoing stent placement." | 3.76 | Recurrence of acute myocardial infarction in patients discharged on clopidogrel and a proton pump inhibitor after stent placement for acute myocardial infarction. ( Binkley, P; Donnally, MR; Evanchan, J; Mazzaferri, E, 2010) |
| "The combination of aspirin and clopidogrel is indicated after acute coronary events and possibly for a short period after TIA or minor ischemic stroke." | 3.76 | Low risk of rebound events after a short course of clopidogrel in acute TIA or minor stroke. ( Chandratheva, A; Geraghty, OC; Paul, NL; Rothwell, PM, 2010) |
| "To examine the risk for adverse cardiovascular outcomes related to concomitant use of PPIs and clopidogrel compared with that of PPIs alone in adults hospitalized for myocardial infarction." | 3.76 | Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study. ( Abildstrøm, SZ; Ahlehoff, O; Charlot, M; Gislason, G; Hansen, PR; Jørgensen, CH; Køber, L; Madsen, JK; Norgaard, ML; Sørensen, R; Torp-Pedersen, C, 2010) |
| "Among 13 636 patients prescribed clopidogrel following acute myocardial infarction, we identified 734 cases readmitted with myocardial infarction and 2057 controls." | 3.75 | A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. ( Austin, PC; Gomes, T; Henry, DA; Juurlink, DN; Ko, DT; Kopp, A; Mamdani, MM; Szmitko, PE; Tu, JV, 2009) |
| "To assess the prognosis of patients presenting with an acute coronary syndrome (ACS) despite chronic clopidogrel therapy (CCT)." | 3.75 | Prognosis of patients suffering an acute coronary syndrome while already under chronic clopidogrel therapy. ( Bonello, L; De Labriolle, A; Kent, KM; Lemesle, G; Pichard, AD; Roy, P; Satler, LF; Steinberg, DH; Suddath, WO; Torguson, R; Waksman, R, 2009) |
| "(1) For patients with acute coronary syndromes who have undergone percutaneous angioplasty and stenting, the best-assessed treatment for preventing relapses is a combination of aspirin and clopidogrel; (2) Prasugrel, an antiplatelet drug belonging the same chemical class as clopidogrel, is authorized in the EU for use in this indication; (3) Clinical evaluation is based on a randomized double-blind trial comparing prasugrel + aspirin versus clopidogrel + aspirin in 13 608 patients with acute coronary syndromes, half of whom were treated for at least 15 months." | 3.75 | Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel. ( , 2009) |
| "Combinations of aspirin, clopidogrel, and vitamin K antagonists are widely used in patients after myocardial infarction." | 3.75 | Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. ( Abildstrom, SZ; Andersson, C; Gislason, GH; Hansen, ML; Hansen, PR; Hvelplund, A; Jørgensen, C; Køber, L; Madsen, JK; Sørensen, R; Torp-Pedersen, C, 2009) |
| "The rate of clopidogrel use within 30 days after hospital discharge following myocardial infarction increased from 35% in the prior-authorization period to 88% in the limited-use period." | 3.74 | Cardiovascular outcomes after a change in prescription policy for clopidogrel. ( Behlouli, H; Cox, J; Demers, V; Jackevicius, CA; Johansen, H; Kalavrouziotis, D; Melo, M; Newman, A; Pilote, L; Rinfret, S; Tu, JV, 2008) |
| "Aspirin resistance is a well-documented laboratory finding, but the effects of clinical aspirin (ASA) failure on patients with acute coronary syndrome (ACS) have been debated." | 3.74 | Dual antiplatelet agent failure: a new syndrome or clinical nonentity? ( Armstrong, DF; Barnes, GD; Eagle, KA; Froehlich, JB; Gurm, HS; Kline-Rogers, E; Li, J; Vedre, A, 2007) |
| "In acute ischemic stroke and transient ischemic attack (TIA), aspirin is recommended to all patients (except immediately following thrombolysis)." | 3.74 | [Antithrombotic therapy in ischemic stroke and transient ischemic attack]. ( Husted, SE; Overgaard, K; Poulsen, TS, 2007) |
| "A literature search was conducted using EMBASE (1980-January 2008), PubMed (1966-January 2008), Google, and a manual search of the reference lists using the search terms gastrointestinal bleed, gastrointestinal hemorrhage, peptic ulcer hemorrhage, ASA, aspirin, Plavix, clopidogrel, and PPI." | 3.74 | Single antiplatelet therapy for patients with previous gastrointestinal bleeds. ( Ackman, ML; Gellatly, RM, 2008) |
| "The case is reported of a patient presenting with recurrent acute myocardial infarction due to stent thrombosis resulting from possible clopidogrel resistance caused by interaction between clopidogrel and anti-tuberculosis drugs." | 3.74 | Drug interaction with anti-mycobacterial treatment as a cause of clopidogrel resistance. ( Smith, D; Srinivasan, M, 2008) |
| " The cost-effectiveness of longer combination therapy depends critically on the balance of thrombotic event rates, durable efficacy, and the increased bleeding rate in patients taking clopidogrel." | 3.73 | A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone. ( Heidenreich, PA; Schleinitz, MD, 2005) |
| "Thrombotic events still occur in aspirin-treated patients with coronary artery disease." | 3.73 | Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance. ( Barnard, MR; Fox, ML; Frelinger, AL; Furman, MI; Li, Y; Linden, MD; Michelson, AD, 2006) |
| "The authors describe a case of a 74-year-old man with advanced coronary heart disease in whom pulmonary hemorrhagic complications during therapy with ticlopidine and subsequently with clopidogrel and amiodarone were observed." | 3.73 | [Recurrent hemoptysis following thienopyridines and amiodarone administration. therapeutic dilemma]. ( Cofta, S; Elikowski, W; Mańczak, J; Nowicki, A; Psuja, P, 2005) |
| "We investigated whether a combination of clopidogrel and glycoprotein (GP) IIb/IIIa inhibitors safely decreases hospital mortality, reinfarction, and major bleeding beyond either therapy alone in patients with non-ST-elevation myocardial infarction (NSTEMI)." | 3.73 | Effectiveness and safety of glycoprotein IIb/IIIa inhibitors and clopidogrel alone and in combination in non-ST-segment elevation myocardial infarction (from the National Registry of Myocardial Infarction-4). ( Bromberg-Marin, G; Canto, JG; Marin-Neto, JA; Parsons, LS; Rogers, WJ, 2006) |
| "Aspirin is the drug of choice in most patients with acute stroke, if thrombolysis is contraindicated." | 3.72 | [Anticoagulation and antiaggregation in neurological patients]. ( Arnold, M; Mattle, HP; Nedeltchev, K, 2003) |
| "During the period from January 2000 to May 2002, 70 patients who were prescribed clopidogrel (75 mg/day) for a previous history of non-aspirin-related peptic ulcer disease or a history of aspirin-related gastrointestinal complications (dyspepsia or peptic ulcer) were recruited." | 3.72 | High incidence of clopidogrel-associated gastrointestinal bleeding in patients with previous peptic ulcer disease. ( Chang, CM; Chen, WH; Kng, C; Lanas, AI; Ng, FH; Wong, BC; Wong, SY, 2003) |
| "The antiplatelet effect of clopidogrel was studied prospectively in 60 consecutive patients who underwent primary angioplasty (percutaneous coronary intervention [PCI]) with stenting for acute ST-segment-elevation myocardial infarction (STEMI) to determine whether variability in response to clopidogrel affects clinical outcomes." | 3.72 | Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. ( Beinart, R; Bienart, R; Goldenberg, I; Guetta, V; Hod, H; Matetzky, S; Novikov, I; Pres, H; Savion, N; Shechter, M; Shenkman, B; Varon, D, 2004) |
| "The possible additive antiplatelet effects of aspirin and clopidogrel have been explored in the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) and Management of Atherothrombosis with Clopidogrel in High Risk Patients (MATCH) studies." | 3.72 | Long-term combination therapy with aspirin and clopidogrel. ( Cheung, BM; Cheung, G; Kumana, CR; Lauder, IJ, 2004) |
| "The thienopyridine derivatives, ticlopidine and clopidogrel, provide alternatives to aspirin for use in the prevention of recurrent ischemic events in the post-myocardial infarction patient." | 3.70 | Aspirin and newer orally active antiplatelet agents in the treatment of the post-myocardial infarction patient. ( Pepine, CJ, 1998) |
| "Ticlopidine is increasingly used in the secondary prophylaxis in patients with arterial occlusive diseases." | 3.70 | Ticlopidine induced prolonged leucopenia in a patient with immunocytoma and chronic hepatitis C. ( Ehringer, H; Minar, E; Parschalk, B; Redlich, K, 1999) |
| "Ischemic event rates were estimated for 12,931 aspirin users drawn from the Saskatchewan Health population between 1990 and 1995 who had an index diagnosis of myocardial infarction, ischemic stroke, or peripheral arterial disease." | 3.70 | Generalizing the results of clinical trials to actual practice: the example of clopidogrel therapy for the prevention of vascular events. CAPRA (CAPRIE Actual Practice Rates Analysis) Study Group. Clopidogrel versus Aspirin in Patients at Risk of Ischaemi ( Caro, JJ; Migliaccio-Walle, K, 1999) |
| "The goal of this health economic analysis was to asses the cost-effectiveness of a fixed combination of aspirin plus extended-release dipyridamole (ASA/ER-DP) or clopidogrel compared with ASA monotherapy for prevention of recurrent ischemic stroke." | 3.70 | Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: a cost-effectiveness analysis. ( Gondek, K; Shah, H, 2000) |
| "Compared with aspirin alone, use of the new antiplatelet regimens, including aspirin combined with dipyridamole and clopidogrel bisulfate, has been found to further reduce the risk of stroke and other vascular events in patients who have experienced stroke or transient ischemic attack." | 3.70 | Cost-effectiveness of new antiplatelet regimens used as secondary prevention of stroke or transient ischemic attack. ( Bounameaux, H; Gaspoz, JM; Sarasin, FP, 2000) |
| "A 63-year-old woman was referred to our division because of massive hemoptysis (200 ml) after administration of ticlopidine, an anti-thrombotic drug, for prevention of recurrent brain infarction." | 3.68 | [A case of hemoptysis due to administration of an anti-thrombotic drug]. ( Hashiguchi, K; Kawane, H; Soejima, R; Umeki, S; Wakunami, M; Yagi, S, 1990) |
| "Patients with lacunar stroke and CMBs likely harbor a more advanced form of cerebral small vessel disease in need of efficacious therapeutic strategies." | 2.84 | Microbleeds in the Secondary Prevention of Small Subcortical Strokes Trial: Stroke, mortality, and treatment interactions. ( Anderson, DC; Bazan, C; Benavente, OR; Catanese, L; Hart, RG; Kase, CS; Marti-Fabregas, J; McClure, LA; Pearce, LA; Sharma, M; Shoamanesh, A, 2017) |
| " Secondary outcomes include target lesion revascularization, major bleeding, ipsilateral major amputation, all-cause mortality, and all adverse events that take place in those six months." | 2.84 | SAFE (Sarpogrelate Anplone in Femoro-popliteal artery intervention Efficacy) study: study protocol for a randomized controlled trial. ( Ahn, S; Cho, MJ; Cho, S; Ha, J; Kim, SY; Lee, J; Min, SI; Min, SK, 2017) |
| "The primary outcome is IS recurrence." | 2.80 | Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial. ( Hoshino, H; Kimura, K; Minematsu, K; Naritomi, H; Origasa, H; Toyoda, K; Uchiyama, S; Yamaguchi, T, 2015) |
| "Among 1244 patients with lacunar stroke (mean age, 63." | 2.79 | C-reactive protein as a prognostic marker after lacunar stroke: levels of inflammatory markers in the treatment of stroke study. ( Benavente, OR; Coffey, CS; Del Brutto, OH; Elkind, MS; Luna, JM; McClure, LA; Meyer, BC; Pettigrew, LC; Pretell, EJ; Roldan, A; Tapia, J; White, C; Zhang, Y, 2014) |
| "We sought to compare the effects of clopidogrel combined with warfarin with clopidogrel alone in the prevention of restenosis after endovascular treatment (EVT) of the femoropopliteal artery." | 2.78 | A prospective randomized controlled clinical trial on clopidogrel combined with warfarin versus clopidogrel alone in the prevention of restenosis after endovascular treatment of the femoropopliteal artery. ( Feng, Y; Guo, M; Li, H; Liang, G; Luo, X; Zhang, C; Zhang, F, 2013) |
| " The primary end point was major adverse cardiac events (death, MI, and ischemia-driven target vessel revascularization) at 12 months." | 2.74 | Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction. ( Cheong, SS; Cho, YH; Hong, MK; Hong, TJ; Jeong, MH; Kim, JJ; Kim, KS; Kim, YH; Lee, CW; Lee, JH; Lee, NH; Lee, SG; Lee, SH; Lim, DS; Park, DW; Park, SJ; Park, SW; Seong, IW; Seung, KB; Yang, JY; Yoon, J; Yun, SC, 2009) |
| "Cilostazol is an antiplatelet agent that increases the intracellular concentration of cyclic adenosine monophosphate by inhibiting phosphodiesterase III; it has been shown to reduce neointimal hyperplasia in animal balloon injury models." | 2.70 | Effects of cilostazol on late lumen loss and repeat revascularization after Palmaz-Schatz coronary stent implantation. ( Ayabe, S; Hara, K; Ikari, Y; Kozuma, K; Kuroda, Y; Morino, Y; Tamura, T; Tanabe, K; Yamasaki, M, 2001) |
| "Cilostazol is a potent antiplatelet agent with less serious side effects." | 2.69 | Comparison of cilostazol versus ticlopidine therapy after stent implantation. ( Hong, MK; Kim, HS; Kim, JJ; Lee, CW; Lee, HJ; Park, HK; Park, SJ; Park, SW, 1999) |
| "Cilostazol is a potent antiplatelet agent with antiproliferative properties." | 2.69 | Effects of cilostazol on angiographic restenosis after coronary stent placement. ( Hong, MK; Kim, HS; Kim, JJ; Lee, CW; Lee, NH; Nah, DY; Park, SJ; Park, SW, 2000) |
| "Ticlopidine has not been formally compared with aspirin in patients with a completed stroke." | 2.67 | Ticlopidine versus aspirin for the prevention of recurrent stroke. Analysis of patients with minor stroke from the Ticlopidine Aspirin Stroke Study. ( Harbison, JW, 1992) |
| " The combination of clopidogrel and aspirin is not recommended for long-term use (more than two to three years) because of increased bleeding risk." | 2.55 | Recurrent Ischemic Stroke: Strategies for Prevention. ( Garcellano, M; Oza, R; Rundell, K, 2017) |
| " Proton pump inhibitors cause few adverse effects with short-term use; however, long-term use has been scrutinized for appropriateness, drug-drug interactions, and the potential for adverse effects (e." | 2.48 | Reducing adverse effects of proton pump inhibitors. ( Ament, PW; Dicola, DB; James, ME, 2012) |
| "Bleeding is potentially the most significant antiplatelet-associated side effect." | 2.47 | Review and management of side effects associated with antiplatelet therapy for prevention of recurrent cerebrovascular events. ( Guthrie, R, 2011) |
| " If both Clopidogrel and PPI need to be prescribed, a split dosage regimen of PPI in the morning and clopidogrel in the evening can be recommended." | 2.46 | [Dilemma between gastroprotection and cardiovascular prevention]. ( Kandulski, A; Malfertheiner, P; Venerito, M, 2010) |
| "Atherothrombosis is a progressive and generalized pathologic process that affects the vascular system." | 2.44 | Antiplatelet therapy for atherothrombotic disease: an update for the primary care physician. ( Brown, MT; Kikano, GE, 2007) |
| "The short-term risk of stroke after transient ischemic attack (TIA) is about 10% to 20% in the first 3 months, with much of the risk front-loaded in the first week." | 2.43 | Stroke prevention. MATCHing therapy to the patient with TIA. ( Buchan, AM; Demchuk, AM; Hill, MD; Weir, NU, 2005) |
| "About 80% of strokes have ischemic origin." | 2.43 | [Current concepts of the antiplatelet and anticoagulant treatment in the prevention of stroke]. ( Szapáry, L, 2005) |
| "The diagnosis of carotid stenosis is made after occurrence of a cerebral ischemic event or during an angiologic examination, mainly using Doppler/Duplex-sonography." | 2.42 | [Carotid stenosis: diagnosis, patient selection, therapy]. ( Barth, A, 2003) |
| "In a cohort receiving PED, a 600-mg loading dose of clopidogrel should be safe and efficacious in those off the standard protocol or showing <30% platelet inhibition before treatment." | 1.46 | Safety and Efficacy of a 600-mg Loading Dose of Clopidogrel 24 Hours Before Pipeline Embolization Device Treatment. ( Atallah, E; Bekelis, K; Chalouhi, N; Hasan, D; Jabbour, P; Rosenwasser, RH; Saad, H; Smith, M; Tjoumakaris, S; Zarzour, H, 2017) |
| "Given the high risk of stroke recurrence, antiplatelets followed by anticoagulation for secondary prevention were initiated." | 1.46 | Isolated left ventricular non-compaction (LVNC) and recurrent strokes: to anticoagulate or not to anticoagulate, that is the question. ( Abubakar, H; Hassan, AAI; Ibrahim, W; Subahi, A, 2017) |
| "The primary end point was recurrence of ACS or death >30days after the index event." | 1.46 | Clopidogrel, prasugrel, or ticagrelor use and clinical outcome in patients with acute coronary syndrome: A nationwide long-term registry analysis from 2009 to 2014. ( Geroldinger, A; Heinze, G; Reichardt, B; Sheikh Rezaei, S; Wolzt, M, 2017) |
| "The early recurrence of neurological symptoms (NR) after urgent aggressive best medical therapy (BMT) in symptomatic carotid stenosis is not well documented." | 1.43 | Risk of early recurrent stroke in symptomatic carotid stenosis after best medical therapy and before endarterectomy. ( Ellemann, K; Gottschalksen, B; Owen-Falkenberg, A; Shahidi, S, 2016) |
| "Six cases (6." | 1.43 | Complication of Stenting in Intracranial Arterial Stenosis. ( Liu, L; Zhang, F, 2016) |
| "The major result events, included: (1) recurrence of ischemic stroke; (2) hemorrhagic transformation of ischemic stroke; (3) myocardial infarction; (4) the digestive hemorrhage." | 1.43 | [Retrospective cohort study for the impact on readmission of patients with ischemic stroke after treatment of aspirin plus clopidogrel or aspirin mono-therapy]. ( Gao, P; Hu, YH; Tang, X; Wei, CL; Yang, C; Zhang, YQ, 2016) |
| "Minor stroke and transient ischemic attack are common disorders with high rate of subsequent disabling stroke." | 1.43 | High-Sensitive C-Reactive Protein Predicts Recurrent Stroke and Poor Functional Outcome: Subanalysis of the Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events Trial. ( Li, J; Lin, J; Liu, L; Meng, X; Wang, A; Wang, C; Wang, Y; Zhao, X, 2016) |
| "Recurrent epistaxis is a rare presentation of internal carotid artery C4/C5 segment pseudo-aneurysm rupture." | 1.40 | Endovascular treatment of internal carotid artery pseudo-aneurysm presenting with epistaxis. A case report. ( Bazina, A; Hucika, Z; Mišmaš, A; Pavliša, G; Poljaković, Z, 2014) |
| "Intrahepatic hemorrhage is a very rare complication of warfarin, and our patient experienced intrahepatic and subgaleal hemorrhage although she did not have any risk factors for bleeding or instability of the international normalized ratio control." | 1.39 | Simultaneous intrahepatic and subgaleal hemorrhage in antiphospholipid syndrome following anticoagulation therapy. ( Baek, YH; Cho, DS; Chung, WT; Han, SY; Kang, SH; Lee, SW; Park, IC, 2013) |
| "Atorvastatin 80 mg was found to be independent predictor of survival, and major amputation was found to be independent predictor of mortality." | 1.39 | Long-term results of plaque excision combined with aggressive pharmacotherapy in high-risk patients with advanced peripheral artery disease (SAVE a LEG registry). ( Buszman, PE; Buszman, PP; Kiesz, RS; Konkolewska, MD; Martin, JL; Radvany, MG; Szymanski, R; Wiernek, BK; Wiernek, SL, 2013) |
| "Within a regional STEMI system of care, half-dose fibrinolysis combined with immediate transfer for PCI may be a safe and effective option for STEMI patients with expected delays due to long-distance transfer." | 1.38 | Safety and efficacy of a pharmaco-invasive reperfusion strategy in rural ST-elevation myocardial infarction patients with expected delays due to long-distance transfers. ( Dirks, TG; Duval, S; Garberich, RF; Harris, JL; Henry, TD; Larson, DM; Madison, JD; Sharkey, SW; Stokman, PJ; Westin, RK, 2012) |
| "Cardiogenic shock was present in 12 (11%) patients and in-hospital mortality was 6." | 1.38 | The HEART study: a real-world experience using the CID Chrono Carbostent in primary and rescue PCI. ( Buffon, A; Burzotta, F; Crea, F; De Caterina, AR; Leone, AM; Mazzari, MA; Mongiardo, R; Niccoli, G; Porto, I; Rebuzzi, AG; Sgueglia, GA; Trani, C, 2012) |
| "An acute spontaneous spinal epidural hematoma (SSEH) is a rare spinal pathology." | 1.37 | Relapsed spontaneous spinal epidural hematoma associated with aspirin and clopidogrel. ( Cho, YR; Hong, BY; Kim, HS; Kim, HW; Ko, YJ; Lee, JI; Lim, SH, 2011) |
| "The primary outcome was first recurrence of stroke of any type and the secondary outcome was a composite of stroke, myocardial infarction, or death from vascular causes." | 1.37 | Level of systolic blood pressure within the normal range and risk of recurrent stroke. ( Bath, PM; Cotton, D; Diener, HC; Donnan, GA; Martin, RH; Ovbiagele, B; Vinisko, R; Yusuf, S, 2011) |
| "In conclusion, in a dog coronary thrombosis model, ticagrelor blocks ADP-induced platelet activation and aggregation; prevents platelet-mediated thrombosis; prolongs reperfusion time and reduces re-occlusion and cyclic flow variation; and significantly decreases infarct size and rapidly restores myocardial tissue perfusion." | 1.36 | Adjunctive treatment with ticagrelor, but not clopidogrel, added to tPA enables sustained coronary artery recanalisation with recovery of myocardium perfusion in a canine coronary thrombosis model. ( Huang, Y; Khalil, M; Penn, MS; van Giezen, JJ; Wang, K; Wiktor, D; Zhou, X, 2010) |
| "Tirofiban was administered for 24 h and the IABP was withdrawn after 60 h." | 1.35 | Reversible clopidogrel resistance due to right ventricular myocardial infarction: risk factor of recurrent stent thrombosis? ( Braun-Dullaeus, RC; Hass, N; Ibrahim, K; Kolschmann, S; Strasser, RH, 2008) |
| "Acute myocardial infarction is a rare condition in young athletes." | 1.35 | Recurrent myocardial infarction in a young football player with antithrombin III deficiency. ( Bosevski, M; Kalpak, O; Maksimovic, J; Pejkov, H; Peovska, I, 2008) |
| " The ExTRACT-TIMI 25 trial employed a novel dosing regimen for enoxaparin adjusted for age and renal function, which was designed to minimize bleeding risk while maintaining the beneficial effects of enoxaparin." | 1.35 | ExTRACT-TIMI 25 in perspective: key lessons regarding enoxaparin as an adjunct to fibrinolytic therapy. ( Giugliano, RP; Thomas, D, 2009) |
| "He was diagnosed as idiopathic cerebral infarction." | 1.35 | [Recurrent idiopathic cerebral infarction in a 5-year-old boy, with emphasis on the importance of platelet aggregation analysis for appropriate selection of anti-platelet drugs]. ( Ikegami, M; Matsuda, S; Miyashita, Y; Obara, S; Shimizu, M; Sugiyama, N; Takagi, S; Takizawa, S; Yokoyama, J, 2009) |
| "A 70-year-old male patient with 90% stenosis of the right carotid artery and total occlusion of the left carotid artery underwent right carotid stenting." | 1.34 | Carotid artery in-stent restenosis in a patient with contralateral total occlusion, resolved with drug-eluting stenting. ( Iancu, A; Lazar, A, 2007) |
| "Patients with transient ischemic attack (TIA) or ischemic stroke carry a risk of recurrent stroke of between 5% and 20% per year." | 1.33 | Secondary stroke prevention with antiplatelet drugs: have we reached the ceiling? ( Diener, HC, 2006) |
| "Symptom recurrence (angina and congestive heart failure), adverse cardiac events (myocardial infarction, coronary reintervention, and sudden cardiac death), and overall mortality were prospectively recorded." | 1.33 | Postoperative clopidogrel improves mid-term outcome after off-pump coronary artery bypass graft surgery: a prospective study. ( Aytac, A; Cui, H; Gurbuz, AT; Vuran, AC; Zia, AA, 2006) |
| " Our case report suggests that antithrombotic treatment by targeting of the activated platelets with a potent platelet inhibitor during the acute phase of type II HIT syndrome followed by long-term administration of oral anticoagulation may be an additional, safe and effective therapeutic alternative that merits to be systematically studied." | 1.33 | Recurrent arterial thromboses in a woman with heparin induced thrombocytopenia, successfully managed with iloprost followed by clopidogrel. An alternative therapeutic option for heparin induced thrombocytopenia type II syndrome. ( Alexandridou, S; Betsis, D; Blouhos, K; Megalopoulos, A; Tsachalis, T; Tsalis, K; Vasiliadis, K, 2006) |
| "Although saddle embolism is a relatively rare event, orthopaedic surgeons should be aware of this condition." | 1.33 | Saddle embolism after corrective femoral osteotomy: a case report. ( Hoshino, Y; Kariya, Y; Konishi, H; Noguchi, K; Ohashi, Y; Sekiya, H, 2006) |
| "Poststroke recurrence rate was low (7." | 1.32 | Ischaemic stroke in young people: a prospective and long-term follow-up study. ( Carerj, S; Di Perri, R; Epifanio, A; Gallitto, G; Gangemi, S; Granata, A; La Spina, P; Leggiadro, N; Manganaro, A; Musolino, R; Tripodi, F, 2003) |
| " We present several illustrative cases in which platelet monitoring with the Rapid Platelet Function Assay (RPFA, Accumetrics) was used to guide dosing of a glycoprotein (GP) IIb/IIIa inhibitor for coronary and peripheral intervention among patients at increased bleeding risk." | 1.31 | Clinical application of procedural platelet monitoring during percutaneous coronary intervention among patients at increased bleeding risk. ( Chew, DP; Moliterno, DJ; Mukherjee, D; Raymond, RE; Robbins, M; Yadav, JS, 2001) |
| "Fibrin monomers were threefold positive and D-dimer concentration was increased to 4 mg/l (elevated clotting activation)." | 1.28 | [Recurrent thromboembolism due to increased acetylsalicylic acid-resistant platelet aggregation]. ( Himmelreich, G; Riess, H, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (2.02) | 18.7374 |
| 1990's | 52 (14.99) | 18.2507 |
| 2000's | 132 (38.04) | 29.6817 |
| 2010's | 152 (43.80) | 24.3611 |
| 2020's | 4 (1.15) | 2.80 |
| Authors | Studies |
|---|---|
| Santana-Mateos, M | 1 |
| Medina-Gil, JM | 2 |
| Saavedra-Santana, P | 1 |
| Martínez-Quintana, E | 2 |
| Rodríguez-González, F | 2 |
| Tugores, A | 2 |
| Hankey, GJ | 2 |
| Wong, YS | 1 |
| Tsai, CF | 1 |
| Hsu, YH | 1 |
| Ong, CT | 1 |
| Hilkens, NA | 1 |
| Algra, A | 3 |
| Diener, HC | 6 |
| Bath, PM | 4 |
| Csiba, L | 1 |
| Hacke, W | 3 |
| Kappelle, LJ | 1 |
| Koudstaal, PJ | 2 |
| Leys, D | 2 |
| Mas, JL | 1 |
| Sacco, RL | 1 |
| Greving, JP | 1 |
| Rao, Z | 2 |
| Zheng, H | 2 |
| Wang, F | 2 |
| Wang, A | 6 |
| Liu, L | 8 |
| Dong, K | 3 |
| Zhao, X | 7 |
| Wang, Y | 17 |
| Cao, Y | 2 |
| Pareek, M | 1 |
| Bhatt, DL | 6 |
| Ten Berg, JM | 4 |
| Kristensen, SD | 1 |
| Grove, EL | 1 |
| Shavadia, J | 1 |
| Welsh, R | 1 |
| Gershlick, A | 1 |
| Zheng, Y | 2 |
| Huber, K | 3 |
| Halvorsen, S | 2 |
| Steg, PG | 3 |
| Van de Werf, F | 3 |
| Armstrong, PW | 3 |
| Kern, A | 1 |
| Gil, RJ | 1 |
| Bojko, K | 1 |
| Sienkiewicz, E | 1 |
| Januszko-Giergielewicz, B | 1 |
| Górny, J | 1 |
| Bil, J | 1 |
| Shoamanesh, A | 1 |
| Pearce, LA | 4 |
| Bazan, C | 2 |
| Catanese, L | 1 |
| McClure, LA | 5 |
| Sharma, M | 1 |
| Marti-Fabregas, J | 3 |
| Anderson, DC | 2 |
| Kase, CS | 1 |
| Hart, RG | 4 |
| Benavente, OR | 7 |
| Lee, M | 2 |
| Saver, JL | 2 |
| Hong, KS | 1 |
| Rao, NM | 2 |
| Wu, YL | 2 |
| Ovbiagele, B | 4 |
| Ramotowski, B | 1 |
| Żuk, A | 1 |
| Budaj, A | 4 |
| Atallah, E | 1 |
| Saad, H | 1 |
| Bekelis, K | 1 |
| Chalouhi, N | 1 |
| Tjoumakaris, S | 1 |
| Hasan, D | 1 |
| Zarzour, H | 1 |
| Smith, M | 1 |
| Rosenwasser, RH | 1 |
| Jabbour, P | 1 |
| Milionis, H | 1 |
| Ntaios, G | 1 |
| Papavasileiou, V | 1 |
| Spengos, K | 1 |
| Manios, E | 1 |
| Elisaf, M | 1 |
| Vemmos, K | 1 |
| Zhang, J | 3 |
| Sun, H | 1 |
| Ming, T | 1 |
| Liu, X | 2 |
| Cong, Y | 1 |
| Li, F | 1 |
| Li, Z | 2 |
| Ahn, S | 1 |
| Lee, J | 1 |
| Min, SK | 1 |
| Ha, J | 1 |
| Min, SI | 1 |
| Kim, SY | 1 |
| Cho, MJ | 1 |
| Cho, S | 1 |
| Subahi, A | 1 |
| Hassan, AAI | 1 |
| Abubakar, H | 1 |
| Ibrahim, W | 1 |
| Oza, R | 1 |
| Rundell, K | 1 |
| Garcellano, M | 1 |
| Bossard, M | 1 |
| Granger, CB | 4 |
| Tanguay, JF | 1 |
| Montalescot, G | 2 |
| Faxon, DP | 1 |
| Jolly, SS | 1 |
| Widimsky, P | 2 |
| Niemela, K | 1 |
| Natarajan, MK | 2 |
| Gao, P | 3 |
| Fox, KAA | 1 |
| Yusuf, S | 4 |
| Mehta, SR | 3 |
| Kim, JB | 1 |
| Choi, BG | 1 |
| Rha, SW | 1 |
| Seo, HS | 1 |
| Choi, SY | 1 |
| Byun, JK | 1 |
| Na, JO | 1 |
| Choi, CU | 1 |
| Kim, EJ | 1 |
| Park, CG | 1 |
| Oh, DJ | 1 |
| Woodhouse, LJ | 1 |
| Appleton, JP | 1 |
| Beridze, M | 1 |
| Christensen, H | 1 |
| Dineen, RA | 1 |
| Duley, L | 1 |
| England, TJ | 1 |
| Flaherty, K | 1 |
| Havard, D | 1 |
| Heptinstall, S | 1 |
| James, M | 1 |
| Krishnan, K | 1 |
| Markus, HS | 2 |
| Montgomery, AA | 1 |
| Pocock, SJ | 1 |
| Randall, M | 1 |
| Ranta, A | 1 |
| Robinson, TG | 1 |
| Scutt, P | 1 |
| Venables, GS | 2 |
| Sprigg, N | 1 |
| Hou, X | 1 |
| Han, W | 1 |
| Gan, Q | 1 |
| Liu, Y | 3 |
| Fang, W | 1 |
| Belcaro, G | 2 |
| Dugall, M | 2 |
| Hu, S | 2 |
| Feragalli, B | 2 |
| Cotellese, R | 2 |
| Ledda, A | 1 |
| Corsi, M | 1 |
| Ricci, A | 1 |
| Ippolito, E | 1 |
| Errichi, BM | 1 |
| Cornelli, U | 1 |
| Cesarone, MR | 2 |
| Hosoi, M | 2 |
| Rath, CL | 1 |
| Jørgensen, NR | 1 |
| Wienecke, T | 1 |
| Bradford, HD | 1 |
| Gizzi, C | 1 |
| Rodriguez, P | 1 |
| Ringelstein, A | 1 |
| Schlamann, M | 1 |
| Goericke, SL | 1 |
| Mönninghoff, C | 1 |
| Sandalcioglu, IE | 1 |
| El Hindy, N | 1 |
| Forsting, M | 1 |
| Wanke, I | 1 |
| Gershlick, AH | 1 |
| Goldstein, P | 1 |
| Wilcox, R | 1 |
| Danays, T | 1 |
| Lambert, Y | 1 |
| Sulimov, V | 1 |
| Rosell Ortiz, F | 1 |
| Ostojic, M | 1 |
| Welsh, RC | 1 |
| Carvalho, AC | 1 |
| Nanas, J | 1 |
| Arntz, HR | 1 |
| Grajek, S | 1 |
| Fresco, C | 1 |
| Bluhmki, E | 1 |
| Regelin, A | 1 |
| Vandenberghe, K | 1 |
| Bogaerts, K | 1 |
| Li, H | 3 |
| Zhang, F | 2 |
| Liang, G | 1 |
| Luo, X | 1 |
| Zhang, C | 2 |
| Feng, Y | 1 |
| Guo, M | 1 |
| Berglund, U | 1 |
| Nilsson, L | 1 |
| Janzon, M | 1 |
| Spokoyny, I | 1 |
| Barazangi, N | 1 |
| Jaramillo, V | 1 |
| Rose, J | 1 |
| Chen, C | 3 |
| Wong, C | 1 |
| Tong, D | 1 |
| Strobl, FF | 1 |
| Brechtel, K | 1 |
| Schmehl, J | 1 |
| Zeller, T | 2 |
| Reiser, MF | 1 |
| Claussen, CD | 1 |
| Tepe, G | 1 |
| Varenhorst, C | 1 |
| Jensevik, K | 1 |
| Jernberg, T | 1 |
| Sundström, A | 1 |
| Hasvold, P | 1 |
| Held, C | 1 |
| Lagerqvist, B | 1 |
| James, S | 1 |
| Park, IC | 1 |
| Baek, YH | 1 |
| Han, SY | 1 |
| Lee, SW | 2 |
| Chung, WT | 1 |
| Kang, SH | 1 |
| Cho, DS | 1 |
| Pergolini, A | 1 |
| Pino, PG | 1 |
| Zampi, G | 1 |
| Polizzi, V | 1 |
| Musumeci, F | 1 |
| Gremmel, T | 1 |
| Koppensteiner, R | 1 |
| Ay, C | 1 |
| Panzer, S | 1 |
| Pumar, JM | 1 |
| Banguero, A | 1 |
| Arias-Rivas, S | 1 |
| Blanco, M | 2 |
| Rodríguez-Yáñez, M | 1 |
| Sucasas, P | 1 |
| Castiñeira-Mourenza, JA | 1 |
| Vázquez-Herrero, F | 1 |
| Tai, WA | 1 |
| Albers, GW | 1 |
| Garay-Sánchez, P | 1 |
| Limiñana, JM | 1 |
| Saavedra, P | 1 |
| Elkind, MS | 1 |
| Luna, JM | 1 |
| Zhang, Y | 2 |
| Coffey, CS | 2 |
| Roldan, A | 1 |
| Del Brutto, OH | 1 |
| Pretell, EJ | 1 |
| Pettigrew, LC | 1 |
| Meyer, BC | 1 |
| Tapia, J | 2 |
| White, C | 1 |
| Amariles, P | 1 |
| Holguín, H | 1 |
| Angulo, NY | 1 |
| Betancourth, PM | 1 |
| Ceballos, M | 1 |
| Chen, CY | 1 |
| Lee, KT | 1 |
| Lee, CT | 1 |
| Lai, WT | 1 |
| Huang, YB | 1 |
| Husted, S | 1 |
| James, SK | 1 |
| Bach, RG | 1 |
| Becker, RC | 1 |
| Heras, M | 1 |
| Himmelmann, A | 1 |
| Horrow, J | 1 |
| Katus, HA | 1 |
| Lassila, R | 1 |
| Morais, J | 2 |
| Nicolau, JC | 2 |
| Storey, RF | 2 |
| Wojdyla, D | 1 |
| Wallentin, L | 2 |
| Yi, X | 4 |
| Lin, J | 7 |
| Wang, C | 10 |
| Zhang, B | 1 |
| Chi, W | 1 |
| Vranckx, P | 2 |
| Leonardi, S | 1 |
| Tebaldi, M | 2 |
| Biscaglia, S | 2 |
| Parrinello, G | 1 |
| Rao, SV | 1 |
| Mehran, R | 1 |
| Valgimigli, M | 2 |
| Lai, YS | 1 |
| Yang, LT | 1 |
| Kao Yang, YH | 1 |
| Liu, PY | 1 |
| Censori, B | 1 |
| Postma, S | 1 |
| Dambrink, JH | 1 |
| Ottervanger, JP | 1 |
| Gosselink, AT | 2 |
| Koopmans, PC | 2 |
| Suryapranata, H | 1 |
| van 't Hof, AW | 2 |
| Bakal, JA | 1 |
| Roe, MT | 3 |
| Ohman, EM | 2 |
| Goodman, SG | 2 |
| Fox, KA | 3 |
| Westerhout, CM | 1 |
| Hochman, JS | 1 |
| Lokhnygina, Y | 1 |
| Brown, EB | 1 |
| Bagai, A | 1 |
| Wang, TY | 4 |
| Curtis, JP | 1 |
| Gurm, HS | 2 |
| Shah, B | 1 |
| Cheema, AN | 1 |
| Peterson, ED | 5 |
| Saucedo, JF | 1 |
| McNamara, RL | 1 |
| Alexander, KP | 1 |
| Blicher, TM | 1 |
| Hommel, K | 1 |
| Kristensen, SL | 2 |
| Torp-Pedersen, C | 5 |
| Madsen, M | 1 |
| Kamper, AL | 1 |
| Olesen, JB | 2 |
| Orban, M | 2 |
| Mayer, K | 2 |
| Morath, T | 1 |
| Bernlochner, I | 2 |
| Hadamitzky, M | 4 |
| Braun, S | 1 |
| Schulz, S | 3 |
| Hoppmann, P | 1 |
| Hausleiter, J | 4 |
| Tiroch, K | 1 |
| Mehilli, J | 4 |
| Schunkert, H | 1 |
| Massberg, S | 1 |
| Laugwitz, KL | 3 |
| Sibbing, D | 3 |
| Kastrati, A | 8 |
| Sun, W | 1 |
| Li, Y | 3 |
| Li, J | 7 |
| Zhang, Z | 1 |
| Zhu, W | 1 |
| Liu, W | 1 |
| Cai, Q | 1 |
| Wang, X | 3 |
| Cao, L | 1 |
| Bai, W | 1 |
| Fan, X | 1 |
| Ma, M | 1 |
| Guo, R | 2 |
| Xu, G | 1 |
| Lee, HC | 1 |
| Lee, JD | 1 |
| Chang, KC | 1 |
| Wu, CY | 1 |
| Lee, TH | 1 |
| Wang, HH | 1 |
| Toyoda, K | 1 |
| Uchiyama, S | 2 |
| Hoshino, H | 1 |
| Kimura, K | 1 |
| Origasa, H | 1 |
| Naritomi, H | 1 |
| Minematsu, K | 1 |
| Yamaguchi, T | 1 |
| Bazina, A | 1 |
| Mišmaš, A | 1 |
| Hucika, Z | 1 |
| Pavliša, G | 1 |
| Poljaković, Z | 1 |
| Jeong, TD | 1 |
| Kim, SM | 1 |
| Kim, HJ | 1 |
| Lee, W | 1 |
| Kwon, SU | 1 |
| Min, WK | 1 |
| Kang, DW | 1 |
| Chun, S | 1 |
| Zhang, Q | 2 |
| Zheng, M | 1 |
| Zhang, L | 3 |
| Shang, X | 1 |
| Yan, C | 1 |
| Sun, B | 1 |
| Dong, M | 1 |
| Yang, L | 1 |
| Wu, C | 1 |
| Zhu, L | 1 |
| Cong, YL | 1 |
| Wang, D | 3 |
| Klingenberg, R | 1 |
| Heg, D | 1 |
| Räber, L | 1 |
| Carballo, D | 1 |
| Nanchen, D | 1 |
| Gencer, B | 1 |
| Auer, R | 1 |
| Jaguszewski, M | 1 |
| Stähli, BE | 1 |
| Jakob, P | 1 |
| Templin, C | 2 |
| Stefanini, GG | 1 |
| Meier, B | 2 |
| Vogt, P | 1 |
| Roffi, M | 1 |
| Maier, W | 1 |
| Landmesser, U | 1 |
| Rodondi, N | 1 |
| Mach, F | 1 |
| Windecker, S | 2 |
| Jüni, P | 1 |
| Lüscher, TF | 1 |
| Matter, CM | 1 |
| Sueta, D | 1 |
| Hokimoto, S | 1 |
| Enomoto, K | 1 |
| Ono, T | 1 |
| Tabata, T | 1 |
| Kajiwara, I | 1 |
| Kaikita, K | 1 |
| Saruwatari, J | 1 |
| Oniki, K | 1 |
| Nakagawa, K | 1 |
| Ogawa, H | 1 |
| Field, TS | 4 |
| Asinger, RW | 1 |
| Smyth, NG | 1 |
| De, SK | 1 |
| Yang, J | 1 |
| Peng, L | 1 |
| Li, X | 1 |
| Liu, J | 1 |
| Xu, Q | 1 |
| Lu, C | 1 |
| Chen, Y | 1 |
| Yin, T | 1 |
| Cressman, AM | 1 |
| Macdonald, EM | 1 |
| Fernandes, KA | 1 |
| Gomes, T | 3 |
| Paterson, JM | 1 |
| Mamdani, MM | 2 |
| Juurlink, DN | 2 |
| McDonough, CW | 1 |
| Mitchell, BD | 1 |
| Gong, Y | 1 |
| Horenstein, RB | 1 |
| Lewis, JP | 1 |
| Talbert, RL | 1 |
| Johnson, JA | 1 |
| Shuldiner, AR | 1 |
| Wei, YQ | 1 |
| Wang, DG | 1 |
| Yang, H | 1 |
| Cao, H | 1 |
| Batchelder, A | 1 |
| Hunter, J | 1 |
| Cairns, V | 1 |
| Sandford, R | 1 |
| Munshi, A | 1 |
| Naylor, AR | 1 |
| Wong, KS | 2 |
| Leng, X | 1 |
| Pu, Y | 1 |
| Jing, J | 3 |
| Zou, X | 1 |
| Pan, Y | 3 |
| Meng, X | 4 |
| Soo, Y | 1 |
| Johnston, SC | 2 |
| Li-Sha, G | 1 |
| Peng, C | 1 |
| Yue-Chun, L | 1 |
| Kim, YS | 1 |
| Lee, SR | 1 |
| Christiansen, CB | 1 |
| Pallisgaard, J | 1 |
| Gerds, TA | 1 |
| Jørgensen, ME | 1 |
| Numé, AK | 1 |
| Carlson, N | 1 |
| Gislason, G | 2 |
| Odden, MC | 1 |
| Sawaya, BP | 1 |
| White, CL | 1 |
| Peralta, CA | 1 |
| Pergola, PE | 1 |
| Fang, L | 1 |
| Zhao, Y | 1 |
| Wang, N | 1 |
| Yang, Z | 1 |
| Huang, H | 1 |
| Lin, M | 1 |
| Lee, JY | 1 |
| Moon, IT | 1 |
| Lee, HY | 1 |
| Lee, HL | 1 |
| Han, DS | 1 |
| Park, TK | 1 |
| Song, YB | 1 |
| Ahn, J | 1 |
| Carriere, KC | 1 |
| Hahn, JY | 1 |
| Yang, JH | 1 |
| Choi, SH | 1 |
| Choi, JH | 1 |
| Lee, SH | 3 |
| Gwon, HC | 1 |
| Shahidi, S | 1 |
| Owen-Falkenberg, A | 1 |
| Gottschalksen, B | 1 |
| Ellemann, K | 1 |
| Han, SW | 1 |
| Kim, YJ | 1 |
| Ahn, SH | 1 |
| Seo, WK | 1 |
| Yu, S | 1 |
| Oh, SH | 1 |
| Kim, YN | 1 |
| Lee, KY | 1 |
| Murphy, SJ | 1 |
| Coughlan, CA | 1 |
| Tobin, O | 1 |
| Kinsella, J | 1 |
| Lonergan, R | 1 |
| Gutkin, M | 1 |
| McCabe, DJ | 1 |
| Yang, C | 2 |
| Qian, J | 1 |
| Tang, X | 3 |
| Hu, Y | 1 |
| Parker, WA | 1 |
| Zhou, Q | 3 |
| Wu, L | 1 |
| Cheng, W | 3 |
| Wilson, LK | 1 |
| Arauz, A | 1 |
| Dake, MD | 1 |
| Ansel, GM | 1 |
| Jaff, MR | 1 |
| Ohki, T | 1 |
| Saxon, RR | 1 |
| Smouse, HB | 1 |
| Machan, LS | 1 |
| Snyder, SA | 1 |
| O'Leary, EE | 1 |
| Ragheb, AO | 1 |
| Yang, X | 2 |
| Xian, Y | 1 |
| Li, R | 1 |
| Jing, Q | 1 |
| Wang, Q | 1 |
| Liu, P | 1 |
| Zhang, P | 1 |
| Ge, F | 1 |
| Lin, H | 1 |
| Li, M | 1 |
| Ruan, Z | 1 |
| Chang, T | 1 |
| Gallego-Fabrega, C | 1 |
| Carrera, C | 1 |
| Reny, JL | 2 |
| Fontana, P | 2 |
| Slowik, A | 1 |
| Pera, J | 1 |
| Pezzini, A | 1 |
| Serrano-Heras, G | 1 |
| Segura, T | 1 |
| Muiño, E | 1 |
| Cullell, N | 1 |
| Montaner, J | 1 |
| Krupinski, J | 1 |
| Fernandez-Cadenas, I | 1 |
| Ayub, A | 1 |
| Parkash, O | 1 |
| Naeem, B | 1 |
| Murtaza, D | 1 |
| Khan, AH | 1 |
| Jafri, W | 1 |
| Hamid, S | 1 |
| Jaitner, J | 1 |
| Fries, V | 1 |
| Dommasch, M | 1 |
| Ott, I | 1 |
| Langwieser, N | 1 |
| Fusaro, M | 1 |
| Ibrahim, T | 1 |
| Holzgreve, H | 1 |
| Doll, JA | 1 |
| Choudhry, NK | 1 |
| Cannon, CP | 3 |
| Cohen, DJ | 4 |
| Fonarow, GC | 1 |
| Henry, TD | 2 |
| Bhandary, DD | 1 |
| Khan, N | 1 |
| Davidson-Ray, LD | 1 |
| Anstrom, K | 1 |
| Zhang, YQ | 1 |
| Wei, CL | 1 |
| Hu, YH | 1 |
| Deng, QQ | 1 |
| Tang, J | 1 |
| Markus, H | 1 |
| Huang, YN | 1 |
| Zhao, H | 1 |
| Ratanakorn, D | 1 |
| Fu, JH | 1 |
| Chi, L | 1 |
| He, Y | 1 |
| Fosbøl, EL | 1 |
| Ju, C | 2 |
| Anstrom, KJ | 1 |
| Zettler, ME | 1 |
| Messenger, JC | 2 |
| Waksman, R | 5 |
| Effron, MB | 2 |
| Baker, BA | 2 |
| Jackson, LR | 1 |
| McCoy, LA | 1 |
| Zettler, M | 1 |
| Faries, DE | 1 |
| Ferri, LA | 1 |
| Morici, N | 1 |
| Grosseto, D | 1 |
| Tortorella, G | 1 |
| Bossi, I | 1 |
| Sganzerla, P | 1 |
| Cacucci, M | 1 |
| Sibilio, G | 1 |
| Tondi, S | 1 |
| Toso, A | 1 |
| Ferrario, M | 1 |
| Gandolfo, N | 1 |
| Ravera, A | 1 |
| Mariani, M | 1 |
| Corrada, E | 1 |
| Di Ascenzo, L | 1 |
| Petronio, AS | 2 |
| Cavallini, C | 1 |
| Moffa, N | 1 |
| De Servi, S | 1 |
| Savonitto, S | 1 |
| Hsu, PI | 1 |
| Wu, DC | 1 |
| Tsay, FW | 1 |
| Cheng, JS | 1 |
| Liu, CP | 1 |
| Lai, KH | 1 |
| Chen, WC | 1 |
| Wang, HM | 1 |
| Tsai, TJ | 1 |
| Tsai, KW | 1 |
| Kao, SS | 1 |
| Hauguel-Moreau, M | 1 |
| Boccara, F | 2 |
| Boyd, A | 1 |
| Salem, JE | 1 |
| Brugier, D | 1 |
| Curjol, A | 1 |
| Hulot, JS | 1 |
| Kerneis, M | 1 |
| Galier, S | 1 |
| Cohen, A | 2 |
| Collet, JP | 1 |
| Silvain, J | 1 |
| Song, H | 1 |
| Hou, C | 1 |
| Cao, Q | 1 |
| Huang, X | 1 |
| Feng, W | 1 |
| Wang, M | 1 |
| Ji, X | 1 |
| Sun, Y | 1 |
| Li, C | 1 |
| Hu, D | 1 |
| Zhang, X | 1 |
| Yu, T | 1 |
| Tao, M | 1 |
| Wang, DW | 1 |
| Shen, X | 1 |
| Sheikh Rezaei, S | 1 |
| Geroldinger, A | 1 |
| Heinze, G | 1 |
| Reichardt, B | 1 |
| Wolzt, M | 1 |
| Li, XG | 1 |
| Ma, N | 1 |
| Sun, SS | 1 |
| Xu, Z | 1 |
| Li, W | 1 |
| Wang, YJ | 1 |
| Miao, ZR | 1 |
| Zhao, ZG | 1 |
| Lin, Y | 1 |
| Ou, L | 1 |
| Chen, W | 1 |
| Diener, C | 1 |
| Ibrahim, K | 1 |
| Hass, N | 1 |
| Kolschmann, S | 1 |
| Strasser, RH | 1 |
| Braun-Dullaeus, RC | 1 |
| Neumann, FJ | 3 |
| Byrne, RA | 2 |
| Iijima, R | 1 |
| Büttner, HJ | 1 |
| Khattab, AA | 1 |
| Blankenship, JC | 1 |
| Pache, J | 2 |
| Minners, J | 1 |
| Seyfarth, M | 3 |
| Graf, I | 1 |
| Skelding, KA | 1 |
| Dirschinger, J | 5 |
| Richardt, G | 1 |
| Berger, PB | 1 |
| Schömig, A | 8 |
| Peovska, I | 1 |
| Maksimovic, J | 1 |
| Kalpak, O | 1 |
| Pejkov, H | 1 |
| Bosevski, M | 1 |
| Suri, MF | 1 |
| Hussein, HM | 1 |
| Abdelmoula, MM | 1 |
| Divani, AA | 1 |
| Qureshi, AI | 1 |
| Thomas, D | 1 |
| Giugliano, RP | 1 |
| Jackevicius, CA | 1 |
| Tu, JV | 2 |
| Demers, V | 1 |
| Melo, M | 1 |
| Cox, J | 1 |
| Rinfret, S | 1 |
| Kalavrouziotis, D | 1 |
| Johansen, H | 1 |
| Behlouli, H | 1 |
| Newman, A | 1 |
| Pilote, L | 1 |
| Bassand, JP | 2 |
| Chrolavicius, S | 1 |
| Diaz, R | 1 |
| Jolly, S | 1 |
| Rupprecht, HJ | 1 |
| Angiolillo, DJ | 1 |
| Suryadevara, S | 1 |
| Capranzano, P | 1 |
| Zenni, MZ | 1 |
| Guzman, LA | 1 |
| Bass, TA | 3 |
| Sugiyama, N | 1 |
| Matsuda, S | 1 |
| Shimizu, M | 1 |
| Obara, S | 1 |
| Ikegami, M | 1 |
| Yokoyama, J | 1 |
| Miyashita, Y | 1 |
| Takizawa, S | 1 |
| Takagi, S | 1 |
| Ko, DT | 1 |
| Szmitko, PE | 1 |
| Austin, PC | 1 |
| Henry, DA | 1 |
| Kopp, A | 1 |
| Bonello, L | 1 |
| De Labriolle, A | 1 |
| Lemesle, G | 2 |
| Steinberg, DH | 1 |
| Roy, P | 1 |
| Torguson, R | 1 |
| Suddath, WO | 1 |
| Satler, LF | 3 |
| Kent, KM | 4 |
| Pichard, AD | 3 |
| Brackbill, ML | 1 |
| Kidd, RS | 1 |
| Abdoo, AD | 1 |
| Warner, JG | 1 |
| Harralson, AF | 1 |
| Morrow, DA | 1 |
| Wiviott, SD | 2 |
| White, HD | 1 |
| Bramucci, E | 1 |
| Murphy, SA | 3 |
| Bonaca, MP | 1 |
| Ruff, CT | 1 |
| Scirica, BM | 1 |
| McCabe, CH | 1 |
| Antman, EM | 1 |
| Braunwald, E | 1 |
| Beccia, M | 1 |
| Ceschin, V | 1 |
| Bozzao, A | 1 |
| Romano, A | 1 |
| Biraschi, F | 1 |
| Fantozzi, LM | 1 |
| Rasura, M | 1 |
| Sadler, GJ | 1 |
| Poullis, AP | 1 |
| Beales, IL | 1 |
| Yamasaki, H | 1 |
| Matsubara, S | 2 |
| Sasaki, I | 1 |
| Nagahiro, S | 1 |
| Heestermans, AA | 2 |
| Van Werkum, JW | 2 |
| Hamm, C | 1 |
| Dill, T | 1 |
| De Boer, MJ | 1 |
| Van Houwelingen, G | 1 |
| Hoorntje, JC | 1 |
| Lee, CW | 3 |
| Park, DW | 1 |
| Kim, YH | 1 |
| Hong, MK | 5 |
| Kim, JJ | 3 |
| Park, SW | 3 |
| Yun, SC | 1 |
| Seong, IW | 1 |
| Lee, JH | 1 |
| Lee, NH | 3 |
| Cho, YH | 2 |
| Cheong, SS | 1 |
| Lim, DS | 1 |
| Yang, JY | 2 |
| Lee, SG | 1 |
| Kim, KS | 1 |
| Yoon, J | 1 |
| Jeong, MH | 2 |
| Seung, KB | 1 |
| Hong, TJ | 1 |
| Park, SJ | 3 |
| Sharma, RK | 1 |
| Reddy, HK | 1 |
| Singh, VN | 1 |
| Sharma, R | 1 |
| Voelker, DJ | 1 |
| Bhatt, G | 1 |
| Sørensen, R | 2 |
| Hansen, ML | 2 |
| Abildstrom, SZ | 1 |
| Hvelplund, A | 1 |
| Andersson, C | 1 |
| Jørgensen, C | 1 |
| Madsen, JK | 3 |
| Hansen, PR | 3 |
| Køber, L | 3 |
| Gislason, GH | 2 |
| Juhász, M | 1 |
| Herszényi, L | 1 |
| Tulassay, Z | 1 |
| Le May, MR | 1 |
| Wells, GA | 1 |
| Glover, CA | 1 |
| So, DY | 1 |
| Froeschl, M | 1 |
| Marquis, JF | 1 |
| O'Brien, ER | 1 |
| Turek, M | 1 |
| Thomas, A | 1 |
| Kass, M | 1 |
| Jadhav, S | 1 |
| Labinaz, M | 1 |
| Randall, MS | 1 |
| McKevitt, FM | 1 |
| Kumar, S | 1 |
| Cleveland, TJ | 1 |
| Endean, K | 1 |
| Gaines, PA | 1 |
| Sofi, F | 2 |
| Marcucci, R | 2 |
| Gori, AM | 2 |
| Giusti, B | 2 |
| Abbate, R | 2 |
| Gensini, GF | 2 |
| Schwalm, JD | 1 |
| Ahmad, M | 1 |
| Salehian, O | 1 |
| Eikelboom, JW | 1 |
| Burke, JP | 1 |
| Sander, S | 1 |
| Shah, H | 2 |
| Zarotsky, V | 1 |
| Henk, H | 1 |
| Gibler, KB | 1 |
| Huskamp, HA | 1 |
| Sabatine, MS | 2 |
| Evanchan, J | 1 |
| Donnally, MR | 1 |
| Binkley, P | 1 |
| Mazzaferri, E | 1 |
| Kim, JS | 1 |
| Kim, J | 1 |
| Choi, D | 1 |
| Lee, CJ | 1 |
| Ko, YG | 1 |
| Kim, BK | 1 |
| Oh, SJ | 1 |
| Jeon, DW | 1 |
| Cho, JR | 1 |
| Cho, DK | 1 |
| Jang, Y | 2 |
| Piatek, L | 1 |
| Piatek, K | 1 |
| Polewczyk, A | 1 |
| Sielski, J | 1 |
| Janion, M | 1 |
| Geraghty, OC | 1 |
| Paul, NL | 1 |
| Chandratheva, A | 1 |
| Rothwell, PM | 2 |
| Birkmeier, KA | 1 |
| Ndrepepa, G | 1 |
| Moshage, W | 1 |
| Dotzer, F | 1 |
| Karabay, CY | 1 |
| Can, MM | 1 |
| Tanboğa, IH | 1 |
| Ahmet, G | 1 |
| Bitigen, A | 1 |
| Serebruany, V | 1 |
| Wang, K | 1 |
| Zhou, X | 1 |
| Huang, Y | 1 |
| Khalil, M | 1 |
| Wiktor, D | 1 |
| van Giezen, JJ | 1 |
| Penn, MS | 1 |
| Tiroch, KA | 1 |
| Koch, W | 1 |
| Roosen-Runge, T | 1 |
| Charlot, M | 2 |
| Ahlehoff, O | 2 |
| Norgaard, ML | 1 |
| Jørgensen, CH | 1 |
| Abildstrøm, SZ | 1 |
| Venerito, M | 1 |
| Kandulski, A | 1 |
| Malfertheiner, P | 1 |
| Valkhoff, VE | 1 |
| 't Jong, GW | 1 |
| Van Soest, EM | 1 |
| Kuipers, EJ | 1 |
| Sturkenboom, MC | 1 |
| Park, KH | 1 |
| Lee, MG | 1 |
| Ko, JS | 1 |
| Sim, DS | 1 |
| Yoon, NS | 1 |
| Yoon, HJ | 1 |
| Hong, YJ | 1 |
| Kim, KH | 1 |
| Park, HW | 1 |
| Kim, JH | 1 |
| Ahn, Y | 1 |
| Cho, JG | 1 |
| Park, JC | 1 |
| Kang, JC | 1 |
| Barison, A | 1 |
| de Carlo, M | 1 |
| Bellini, F | 1 |
| Capozza, PF | 1 |
| Lunardini, A | 1 |
| Lim, SH | 1 |
| Hong, BY | 1 |
| Cho, YR | 1 |
| Kim, HS | 4 |
| Lee, JI | 1 |
| Kim, HW | 1 |
| Ko, YJ | 1 |
| Farina, A | 1 |
| Spinazzola, A | 1 |
| Abbiati, G | 1 |
| Arpini, MT | 1 |
| Bergamaschi, L | 1 |
| Riva, A | 1 |
| Berticelli, P | 1 |
| Guthrie, R | 1 |
| Oldgren, J | 1 |
| Khder, Y | 1 |
| Roberts, J | 1 |
| Siegbahn, A | 1 |
| Tijssen, JG | 1 |
| Vidal-Jordana, A | 1 |
| Barroeta-Espar, I | 1 |
| Sáinz Pelayo, MP | 1 |
| Mateo, J | 1 |
| Delgado-Mederos, R | 1 |
| Mono, ML | 1 |
| Geister, L | 1 |
| Galimanis, A | 1 |
| Jung, S | 1 |
| Praz, F | 1 |
| Arnold, M | 2 |
| Fischer, U | 1 |
| Wolff, S | 1 |
| Findling, O | 1 |
| Wahl, A | 1 |
| Mattle, HP | 2 |
| Nedeltchev, K | 2 |
| Hsiao, FY | 1 |
| Mullins, CD | 1 |
| Wen, YW | 1 |
| Huang, WF | 1 |
| Chen, PF | 1 |
| Tsai, YW | 1 |
| Cuisset, T | 2 |
| Quilici, J | 2 |
| Grosdidier, C | 1 |
| Fourcade, L | 1 |
| Gaborit, B | 1 |
| Pankert, M | 1 |
| Molines, L | 1 |
| Morange, PE | 2 |
| Bonnet, JL | 2 |
| Alessi, MC | 2 |
| Larson, DM | 1 |
| Duval, S | 1 |
| Sharkey, SW | 1 |
| Garberich, RF | 1 |
| Madison, JD | 1 |
| Stokman, PJ | 1 |
| Dirks, TG | 1 |
| Westin, RK | 1 |
| Harris, JL | 1 |
| Leone, AM | 1 |
| Sgueglia, GA | 1 |
| Porto, I | 1 |
| Niccoli, G | 1 |
| Burzotta, F | 1 |
| Trani, C | 1 |
| De Caterina, AR | 1 |
| Buffon, A | 1 |
| Mazzari, MA | 1 |
| Mongiardo, R | 1 |
| Rebuzzi, AG | 1 |
| Crea, F | 1 |
| Delhaye, C | 1 |
| Martin, RH | 1 |
| Cotton, D | 1 |
| Vinisko, R | 1 |
| Donnan, GA | 1 |
| Geeganage, CM | 1 |
| Topol, EJ | 3 |
| Dengler, R | 1 |
| Bath, MW | 1 |
| Combescure, C | 1 |
| Daali, Y | 1 |
| Smith, PK | 1 |
| Goodnough, LT | 1 |
| Levy, JH | 1 |
| Poston, RS | 1 |
| Short, MA | 1 |
| Weerakkody, GJ | 1 |
| Lenarz, LA | 1 |
| Nielsen, LH | 1 |
| Lindhardsen, J | 1 |
| Olsen, AM | 1 |
| Szychowski, JM | 1 |
| Ament, PW | 1 |
| Dicola, DB | 1 |
| James, ME | 1 |
| Fang, YB | 1 |
| Li, Q | 1 |
| Yang, PF | 1 |
| Huang, QH | 1 |
| Zhao, WY | 1 |
| Xu, Y | 1 |
| Hong, B | 1 |
| Liu, JM | 1 |
| Fnais, N | 1 |
| Alshaikh, M | 1 |
| Yao, Z | 1 |
| Juurlink, D | 1 |
| Mamdani, M | 1 |
| Campo, G | 1 |
| Burrows, AM | 1 |
| Zipfel, G | 1 |
| Lanzino, G | 1 |
| Kiesz, RS | 1 |
| Wiernek, SL | 1 |
| Wiernek, BK | 1 |
| Radvany, MG | 1 |
| Buszman, PP | 1 |
| Szymanski, R | 1 |
| Konkolewska, MD | 1 |
| Martin, JL | 1 |
| Buszman, PE | 1 |
| Mulukutla, SR | 1 |
| Marroquin, OC | 1 |
| Vlachos, HA | 1 |
| Selzer, F | 1 |
| Toma, C | 1 |
| Kip, KE | 1 |
| Abbott, JD | 1 |
| Holper, E | 1 |
| Lee, JS | 1 |
| Khandhar, S | 1 |
| Kutcher, M | 1 |
| Kelsey, S | 1 |
| Smith, C | 1 |
| Faxon, D | 1 |
| Williams, DO | 1 |
| Li, L | 1 |
| Han, JL | 1 |
| Li, HY | 1 |
| Qiao, R | 1 |
| Yu, HY | 1 |
| Zeng, H | 1 |
| Gao, W | 1 |
| Shatin, D | 1 |
| Schech, SD | 1 |
| Brinker, A | 1 |
| Turpie, AG | 2 |
| Hiller, E | 1 |
| Kübler, W | 1 |
| Fitchett, D | 1 |
| Gupta, M | 1 |
| Langer, A | 1 |
| Musolino, R | 1 |
| La Spina, P | 1 |
| Granata, A | 1 |
| Gallitto, G | 1 |
| Leggiadro, N | 1 |
| Carerj, S | 1 |
| Manganaro, A | 1 |
| Tripodi, F | 1 |
| Epifanio, A | 1 |
| Gangemi, S | 1 |
| Di Perri, R | 1 |
| Aslam, MS | 1 |
| Balasubramanian, J | 1 |
| Greenspahn, BR | 1 |
| Yang, CW | 1 |
| Chen, YC | 1 |
| Dunn, P | 1 |
| Chang, MY | 1 |
| Fang, JT | 1 |
| Huang, CC | 1 |
| Gerschutz, GP | 1 |
| Cha, DH | 1 |
| Malik, IA | 1 |
| Cheneau, E | 1 |
| Ajani, AE | 1 |
| Leborgne, L | 1 |
| Wolfram, R | 1 |
| Porrazzo, M | 1 |
| Pinnow, E | 1 |
| Lindsay, J | 1 |
| Gorelick, PB | 3 |
| Richardson, D | 1 |
| Kelly, M | 1 |
| Ruland, S | 1 |
| Hung, E | 1 |
| Harris, Y | 1 |
| Kittner, S | 1 |
| Leurgans, S | 1 |
| Ng, FH | 1 |
| Wong, SY | 1 |
| Chang, CM | 1 |
| Chen, WH | 1 |
| Kng, C | 1 |
| Lanas, AI | 1 |
| Wong, BC | 1 |
| Ito, E | 2 |
| Takahashi, A | 1 |
| Yamamoto, H | 1 |
| Kuzuhara, S | 1 |
| Nakajima, M | 1 |
| Barth, A | 1 |
| Werner, GS | 1 |
| Emig, U | 1 |
| Mutschke, O | 1 |
| Schwarz, G | 1 |
| Bahrmann, P | 1 |
| Figulla, HR | 1 |
| Zakarija, A | 1 |
| Bandarenko, N | 1 |
| Pandey, DK | 1 |
| Auerbach, A | 1 |
| Raisch, DW | 1 |
| Kim, B | 1 |
| Kwaan, HC | 1 |
| McKoy, JM | 1 |
| Schmitt, BP | 1 |
| Davidson, CJ | 2 |
| Yarnold, PR | 1 |
| Bennett, CL | 2 |
| Bruno, A | 2 |
| McConnell, JP | 1 |
| Cohen, SN | 1 |
| Tietjen, GE | 1 |
| Wallis, RA | 1 |
| Bang, NU | 1 |
| Grau, AJ | 1 |
| Boddy, AW | 1 |
| Dukovic, DA | 1 |
| Buggle, F | 1 |
| Lichy, C | 1 |
| Brandt, T | 1 |
| Santa-Cruz, RA | 1 |
| Steinhubl, SR | 1 |
| Matetzky, S | 1 |
| Shenkman, B | 1 |
| Guetta, V | 1 |
| Shechter, M | 1 |
| Beinart, R | 1 |
| Bienart, R | 1 |
| Goldenberg, I | 1 |
| Novikov, I | 1 |
| Pres, H | 1 |
| Savion, N | 1 |
| Varon, D | 1 |
| Hod, H | 1 |
| Wienbergen, H | 1 |
| Gitt, AK | 1 |
| Schiele, R | 1 |
| Juenger, C | 1 |
| Heer, T | 1 |
| Vogel, C | 1 |
| Gottwik, M | 1 |
| Senges, J | 1 |
| SoRelle, R | 1 |
| Locker, C | 1 |
| Mohr, R | 1 |
| Lev-Ran, O | 1 |
| Uretzky, G | 1 |
| Frimerman, A | 1 |
| Shaham, Y | 1 |
| Shapira, I | 1 |
| Bogousslavsky, J | 1 |
| Hirsh, J | 1 |
| Claeys, MJ | 1 |
| Van der Planken, MG | 1 |
| Bosmans, JM | 1 |
| Michiels, JJ | 1 |
| Vertessen, F | 1 |
| Van Der Goten, P | 1 |
| Wuyts, FL | 1 |
| Vrints, CJ | 1 |
| von Mach, MA | 1 |
| Eich, A | 1 |
| Weilemann, LS | 1 |
| Münzel, T | 1 |
| Weir, NU | 1 |
| Demchuk, AM | 1 |
| Buchan, AM | 1 |
| Hill, MD | 1 |
| Kumana, CR | 1 |
| Cheung, G | 1 |
| Lauder, IJ | 1 |
| Cheung, BM | 1 |
| Schleinitz, MD | 1 |
| Heidenreich, PA | 1 |
| Sick, PB | 1 |
| Brosteanu, O | 1 |
| Ulrich, M | 1 |
| Thiele, H | 1 |
| Niebauer, J | 1 |
| Busch, I | 1 |
| Schuler, G | 1 |
| Parodi, G | 1 |
| Sciagrà, R | 1 |
| Migliorini, A | 1 |
| Memisha, G | 1 |
| Moschi, G | 1 |
| Valenti, R | 1 |
| Pupi, A | 1 |
| Antoniucci, D | 1 |
| Lee, E | 1 |
| Mavrikakis, I | 1 |
| Paul, B | 1 |
| Liu, C | 1 |
| Jamieson, DG | 1 |
| Parekh, A | 1 |
| Ezekowitz, MD | 1 |
| Ederhy, S | 1 |
| Meuleman, C | 1 |
| Hammoudi, N | 1 |
| Janower, S | 1 |
| Szapáry, L | 2 |
| Lewis, BS | 1 |
| Halon, DA | 1 |
| Zhao, F | 1 |
| Peters, RJ | 1 |
| Keltai, M | 1 |
| Brogan, GX | 1 |
| Mulgund, J | 1 |
| Gibler, WB | 1 |
| Pollack, CV | 1 |
| Farkouh, ME | 1 |
| Glowczynska, R | 1 |
| Malek, LA | 1 |
| Spiewak, M | 2 |
| Filipiak, KJ | 2 |
| Grabowski, M | 2 |
| Kisiel, B | 1 |
| Kochman, J | 1 |
| Kostrzewa, G | 1 |
| Ploski, R | 1 |
| Opolski, G | 2 |
| Gurbuz, AT | 1 |
| Zia, AA | 1 |
| Vuran, AC | 1 |
| Cui, H | 1 |
| Aytac, A | 1 |
| Megalopoulos, A | 1 |
| Vasiliadis, K | 1 |
| Tsachalis, T | 1 |
| Tsalis, K | 1 |
| Blouhos, K | 1 |
| Alexandridou, S | 1 |
| Betsis, D | 1 |
| Vats, HS | 1 |
| Hocking, WG | 1 |
| Rezkalla, SH | 1 |
| Schaefer, A | 1 |
| Stumme, B | 1 |
| Drexler, H | 1 |
| von Depka, M | 1 |
| Casella, G | 1 |
| Greco, C | 1 |
| Perugini, E | 1 |
| Pallotti, MG | 1 |
| Pavesi, PC | 1 |
| Di Pasquale, G | 1 |
| Frelinger, AL | 1 |
| Furman, MI | 1 |
| Linden, MD | 1 |
| Fox, ML | 1 |
| Barnard, MR | 1 |
| Michelson, AD | 1 |
| Elikowski, W | 1 |
| Cofta, S | 1 |
| Nowicki, A | 1 |
| Mańczak, J | 1 |
| Psuja, P | 1 |
| Stiefelhagen, P | 1 |
| Plokker, HW | 1 |
| Onizuka, M | 1 |
| Kazekawa, K | 1 |
| Nagata, S | 1 |
| Tsutsumi, M | 1 |
| Aikawa, H | 1 |
| Tomokiyo, M | 1 |
| Iko, M | 1 |
| Kodama, T | 1 |
| Nii, K | 1 |
| Tanaka, A | 1 |
| Sekiya, H | 1 |
| Noguchi, K | 1 |
| Ohashi, Y | 1 |
| Kariya, Y | 1 |
| Hoshino, Y | 1 |
| Konishi, H | 1 |
| Gibson, CM | 1 |
| Ly, HQ | 1 |
| Ciaglo, LN | 1 |
| Southard, MC | 1 |
| Stein, EB | 1 |
| Buros, JL | 1 |
| Cordonnier, C | 1 |
| Fuchs, I | 1 |
| Frossard, M | 1 |
| Spiel, A | 1 |
| Riedmüller, E | 1 |
| Laggner, AN | 1 |
| Jilma, B | 1 |
| Frere, C | 1 |
| Nait-Saidi, L | 1 |
| Carvajal, J | 1 |
| Lehmann, A | 1 |
| Lambert, M | 1 |
| Bromberg-Marin, G | 1 |
| Marin-Neto, JA | 1 |
| Parsons, LS | 1 |
| Canto, JG | 1 |
| Rogers, WJ | 1 |
| Johansen, M | 1 |
| Sharifkazemi, MB | 1 |
| Zamirian, M | 1 |
| Aslani, A | 1 |
| O'Donoghue, M | 1 |
| Bliden, KP | 1 |
| DiChiara, J | 1 |
| Tantry, US | 1 |
| Bassi, AK | 1 |
| Chaganti, SK | 1 |
| Gurbel, PA | 1 |
| Małek, ŁA | 1 |
| Szpotańska, M | 1 |
| Rosiak, M | 1 |
| Główczyńska, R | 1 |
| Imiela, T | 1 |
| Huczek, Z | 1 |
| Liao, JK | 1 |
| Daemen, J | 1 |
| Tanimoto, S | 1 |
| García-García, HM | 1 |
| Kukreja, N | 1 |
| van de Sande, M | 1 |
| Sianos, G | 1 |
| de Jaegere, PP | 1 |
| van Domburg, RT | 1 |
| Serruys, PW | 1 |
| Tohgi, H | 2 |
| Lapostolle, F | 1 |
| Catineau, J | 1 |
| Lapandry, C | 1 |
| Adnet, F | 1 |
| Kikano, GE | 1 |
| Brown, MT | 1 |
| Iancu, A | 1 |
| Lazar, A | 1 |
| Luxembourg, B | 1 |
| Mani, H | 1 |
| Toennes, SW | 1 |
| Strubel, G | 1 |
| Klaeffling, C | 1 |
| Daemgen-von Brevern, G | 1 |
| Geisen, C | 1 |
| Lindhoff-Last, E | 1 |
| Barnes, GD | 1 |
| Kline-Rogers, E | 1 |
| Vedre, A | 1 |
| Armstrong, DF | 1 |
| Froehlich, JB | 1 |
| Eagle, KA | 1 |
| Overgaard, K | 1 |
| Poulsen, TS | 1 |
| Husted, SE | 1 |
| Fehér, G | 1 |
| Bagoly, E | 1 |
| Kövér, F | 1 |
| Koltai, K | 1 |
| Hantó, K | 1 |
| Pozsgai, E | 1 |
| Komoly, S | 1 |
| Dóczi, T | 1 |
| Tóth, K | 1 |
| Kaya, MG | 1 |
| Durakoglugil, E | 1 |
| Yalcin, R | 1 |
| Gengo, FM | 1 |
| Rainka, M | 1 |
| Robson, M | 1 |
| Gengo, MF | 1 |
| Forrest, A | 1 |
| Hourihane, M | 1 |
| Bates, V | 1 |
| Morel, O | 1 |
| Bernhard, N | 1 |
| Desprez, D | 1 |
| Grunebaum, L | 1 |
| Freyssinet, JM | 1 |
| Toti, F | 1 |
| Bareiss, P | 1 |
| Lev, EI | 1 |
| Kornowski, R | 2 |
| Vaknin-Assa, H | 1 |
| Brosh, D | 1 |
| Fuchs, S | 1 |
| Battler, A | 1 |
| Assali, A | 1 |
| Nagarakanti, R | 1 |
| Sodhi, S | 1 |
| Lee, R | 1 |
| Ezekowitz, M | 1 |
| Gellatly, RM | 1 |
| Ackman, ML | 1 |
| Srinivasan, M | 1 |
| Smith, D | 1 |
| Offerhaus, L | 1 |
| Herce Muñoz, M | 1 |
| Sancho Rieger, J | 1 |
| López-Trigo Picho, J | 1 |
| Matchar, DB | 1 |
| McCrory, DC | 1 |
| Barnett, HJ | 1 |
| Feussner, JR | 1 |
| Chiba, K | 1 |
| Takahashi, H | 1 |
| Tamura, K | 1 |
| Sasaki, K | 1 |
| Suzuki, H | 1 |
| Yao, SK | 2 |
| Ober, JC | 2 |
| Ferguson, JJ | 2 |
| Maffrand, JP | 2 |
| Anderson, HV | 2 |
| Buja, LM | 2 |
| Willerson, JT | 2 |
| Weiller, C | 1 |
| Kitazume, H | 1 |
| Ageishi, Y | 1 |
| Iwama, T | 1 |
| Kubo, I | 1 |
| Suzuki, A | 1 |
| Eeckhout, E | 1 |
| Kappenberger, L | 1 |
| Goy, JL | 1 |
| Lo, CY | 1 |
| Cheng, IK | 1 |
| Tso, WK | 1 |
| Mak, KO | 1 |
| Saito, S | 1 |
| Hosokawa, FG | 1 |
| Kim, K | 1 |
| Tanaka, S | 1 |
| Miyake, S | 1 |
| Walter, H | 3 |
| Schühlen, H | 4 |
| Zitzmann-Roth, EM | 1 |
| Blasini, R | 1 |
| Schmitt, C | 1 |
| Alt, E | 1 |
| Gusev, EI | 1 |
| Skvortsova, VI | 1 |
| Kolesnikova, TI | 1 |
| Kabanov, AA | 1 |
| Iasamanova, AN | 1 |
| Gregorini, L | 1 |
| Marco, J | 1 |
| Baim, DS | 1 |
| Carrozza, JP | 1 |
| Ishikawa, K | 1 |
| Kanamasa, K | 1 |
| Hama, J | 1 |
| Ogawa, I | 1 |
| Takenaka, T | 1 |
| Naito, T | 1 |
| Yamamoto, T | 1 |
| Nakai, S | 1 |
| Oyaizu, M | 1 |
| Kimura, A | 1 |
| Yamamoto, K | 1 |
| Katori, R | 1 |
| Barragan, P | 1 |
| Pietri, P | 1 |
| Villain, P | 1 |
| Silvestri, M | 1 |
| Roquebert, PO | 1 |
| Ulm, K | 2 |
| Moussa, I | 1 |
| Di Mario, C | 1 |
| Moses, J | 1 |
| Reimers, B | 1 |
| Di Francesco, L | 1 |
| Martini, G | 1 |
| Tobis, J | 1 |
| Colombo, A | 2 |
| Zitzmann-Roth, E | 1 |
| Elezi, S | 1 |
| Anzuini, A | 2 |
| Rosanio, S | 2 |
| Legrand, V | 2 |
| Tocchi, M | 2 |
| Coppi, R | 2 |
| Marazzi, G | 1 |
| Vicedomini, G | 1 |
| Pagnotta, P | 1 |
| Montorfano, M | 1 |
| Bonnier, H | 2 |
| Sheiban, I | 2 |
| Kulbertus, HE | 2 |
| Chierchia, SL | 2 |
| Feldman, TE | 1 |
| Stone, GW | 1 |
| Stoupel, E | 1 |
| van Gijn, J | 1 |
| Elsner, M | 1 |
| Peifer, A | 1 |
| Drexler, M | 1 |
| Wenzel, C | 1 |
| Hebbeker, C | 1 |
| Kasper, W | 1 |
| Oemrawsingh, PV | 2 |
| Tuinenburg, JC | 1 |
| Schalij, MJ | 2 |
| Jukema, JW | 1 |
| Reiber, JH | 1 |
| Bruschke, AV | 2 |
| Pizzulli, L | 1 |
| Lüderitz, B | 1 |
| Udayachalerm, W | 1 |
| van der Wall, EE | 1 |
| Martínez Elbal, L | 1 |
| López Mínguez, JR | 1 |
| Alonso, M | 1 |
| Calvo, I | 1 |
| Insa, L | 1 |
| Lezaun, R | 1 |
| Colman, T | 1 |
| Esplugas, E | 1 |
| Vázquez, N | 1 |
| Picó, F | 1 |
| Amaro, A | 1 |
| Pepine, CJ | 1 |
| Dippel, DW | 1 |
| Saucedo, J | 1 |
| Greenberg, A | 1 |
| Leon, MB | 1 |
| Morice, MC | 1 |
| Lincoff, AM | 2 |
| Califf, RM | 1 |
| Moliterno, DJ | 2 |
| Ellis, SG | 1 |
| Ducas, J | 1 |
| Kramer, JH | 1 |
| Kleiman, NS | 1 |
| Cohen, EA | 1 |
| Booth, JE | 1 |
| Sapp, SK | 1 |
| Cabot, CF | 1 |
| Cariou, R | 1 |
| Grollier, G | 1 |
| Kragten, J | 1 |
| Wolf, JE | 1 |
| Heyndrickx, GR | 1 |
| Boysen, G | 1 |
| Lee, HJ | 1 |
| Park, HK | 1 |
| Jauhar, R | 1 |
| Bergman, G | 1 |
| Savino, S | 1 |
| Deutsch, E | 1 |
| Shaknovich, A | 1 |
| Parikh, M | 1 |
| Sanborn, TA | 1 |
| Holm, J | 1 |
| Hillarp, A | 1 |
| Erhardt, L | 1 |
| Berntorp, E | 1 |
| Yoon, Y | 1 |
| Shim, WH | 1 |
| Lee, DH | 1 |
| Pyun, WB | 1 |
| Kim, IJ | 1 |
| Cho, SY | 1 |
| Redlich, K | 1 |
| Parschalk, B | 1 |
| Ehringer, H | 1 |
| Minar, E | 1 |
| Robbins, MA | 1 |
| Marso, SP | 1 |
| Wolski, K | 1 |
| Peterson, J | 1 |
| Brener, S | 1 |
| Caro, JJ | 1 |
| Migliaccio-Walle, K | 1 |
| Crassard, I | 1 |
| Niclot, P | 1 |
| Bousser, MG | 1 |
| Van Langenhove, G | 1 |
| Vermeersch, P | 1 |
| Serrano, P | 1 |
| Kutryk, MJ | 1 |
| Stockman, D | 1 |
| Convens, C | 1 |
| Van den Branden, F | 1 |
| Vanagt, E | 1 |
| Albertal, M | 1 |
| Van den Heuvel, P | 1 |
| Connors, JM | 1 |
| Carwile, JM | 1 |
| Moake, JL | 1 |
| Bell, WR | 1 |
| Tarantolo, SR | 1 |
| McCarthy, LJ | 1 |
| Sarode, R | 1 |
| Hatfield, AJ | 1 |
| Feldman, MD | 1 |
| Tsai, HM | 1 |
| Witkowski, A | 1 |
| Ruzyłło, W | 1 |
| Gil, R | 1 |
| Górecka, B | 1 |
| Purzycki, Z | 1 |
| Kośmider, M | 1 |
| Poloński, L | 1 |
| Lekston, A | 1 |
| Gasior, M | 1 |
| Zmudka, K | 1 |
| Pieniazek, P | 1 |
| Buszman, P | 1 |
| Drzewiecki, J | 1 |
| Ciećwierz, D | 1 |
| Sadowski, Z | 1 |
| Gondek, K | 1 |
| Nah, DY | 1 |
| Sarasin, FP | 1 |
| Gaspoz, JM | 1 |
| Bounameaux, H | 1 |
| Kozuma, K | 1 |
| Hara, K | 2 |
| Yamasaki, M | 1 |
| Morino, Y | 2 |
| Ayabe, S | 1 |
| Kuroda, Y | 2 |
| Tanabe, K | 1 |
| Ikari, Y | 2 |
| Tamura, T | 1 |
| Gawaz, M | 1 |
| Müller, I | 1 |
| Rüdiger, S | 1 |
| Pogatsa-Murray, G | 1 |
| Wolf, B | 1 |
| Naber, CK | 1 |
| Kaiser, CA | 1 |
| Rahman, YA | 1 |
| Haude, M | 1 |
| Erbel, R | 1 |
| Baumgart, D | 1 |
| Scrutinio, D | 1 |
| Cimminiello, C | 1 |
| Marubini, E | 1 |
| Pitzalis, MV | 1 |
| Di Biase, M | 1 |
| Rizzon, P | 1 |
| Nakajima, H | 1 |
| Kollum, M | 1 |
| Bhargava, B | 1 |
| Mintz, GS | 2 |
| Kolodgie, FD | 1 |
| Virmani, R | 1 |
| Tanabe, Y | 1 |
| Nakagawa, I | 1 |
| Suzuki, K | 1 |
| Mukherjee, D | 1 |
| Chew, DP | 1 |
| Robbins, M | 1 |
| Yadav, JS | 1 |
| Raymond, RE | 1 |
| Liistro, F | 1 |
| Vaidyanathan, S | 1 |
| Soni, BM | 1 |
| Singh, G | 1 |
| Hughes, PL | 1 |
| Mansour, P | 1 |
| Goertler, M | 1 |
| Blaser, T | 1 |
| Krueger, S | 1 |
| Hofmann, K | 1 |
| Baeumer, M | 1 |
| Wallesch, CW | 1 |
| Limpijankit, T | 1 |
| Honda, Y | 1 |
| Lansky, AJ | 1 |
| Bonneau, HN | 1 |
| Yock, PG | 1 |
| Fitzgerald, PJ | 1 |
| Harbison, JW | 2 |
| Hattori, A | 1 |
| Haynes, RB | 1 |
| Sandler, RS | 1 |
| Larson, EB | 1 |
| Pater, JL | 1 |
| Yatsu, FM | 1 |
| Lowenthal, A | 1 |
| Hershey, LA | 1 |
| Himmelreich, G | 1 |
| Riess, H | 1 |
| Wakunami, M | 1 |
| Umeki, S | 1 |
| Hashiguchi, K | 1 |
| Yagi, S | 1 |
| Kawane, H | 1 |
| Soejima, R | 1 |
| Cox, JL | 1 |
| Gotlieb, AI | 1 |
| Gent, M | 1 |
| Blakely, JA | 1 |
| Easton, JD | 1 |
| Ellis, DJ | 1 |
| Hachinski, VC | 1 |
| Panak, E | 1 |
| Roberts, RS | 1 |
| Sicurella, J | 1 |
| Manopulo, R | 1 |
| Sturani, A | 1 |
| Insarda, P | 1 |
| Zorzon, M | 1 |
| Monti, F | 1 |
| Del Pio Luogo, T | 1 |
| Cazzato, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| STREAM (Strategic Reperfusion Early After Myocardial Infarction). Comparison of the Efficacy and Safety of a Strategy of Early Fibrinolytic Treatment With Tenecteplase and Additional Antiplatelet and Antithrombin Therapy Followed by Catheterisation Within[NCT00623623] | Phase 3 | 1,899 participants (Actual) | Interventional | 2008-03-01 | Completed | ||
| Low-dose Aspirin Therapy in Patients With Non-Cardioembolic Ischemic Stroke and Microbleeds[NCT04504864] | Phase 4 | 400 participants (Anticipated) | Interventional | 2020-10-01 | Recruiting | ||
| SAFE (Sarpogrelate Anplone in Femoro-popliteal Artery Intervention Efficacy) Study : a Randomized Controlled Trial[NCT02959606] | Phase 4 | 272 participants (Anticipated) | Interventional | 2016-12-31 | Recruiting | ||
| Randomized, Multinational, Double-blind Study, Comparing a High Loading Dose Regimen of Clopidogrel Versus Standard Dose in Patients With Unstable Angina or Myocardial Infarction Managed With an Early Invasive Strategy.[NCT00335452] | Phase 3 | 25,086 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| STrategic Reperfusion in Elderly Patients Early After Myocardial Infarction[NCT02777580] | Phase 4 | 609 participants (Actual) | Interventional | 2017-08-01 | Active, not recruiting | ||
| Dapagliflozin Effects on Mayor Adverse Cardiovascular Events in Patients With Acute Myocardial Infarction (DAPA-AMI). Randomized Clinical Trial[NCT04717986] | 188 participants (Actual) | Interventional | 2021-01-26 | Completed | |||
| Reperfusion Strategies in ST Elevation Myocardial Infarction Network - Sao Paulo Registry.[NCT02090712] | 3,000 participants (Anticipated) | Observational [Patient Registry] | 2010-01-31 | Enrolling by invitation | |||
| Follow-up Management of Peripheral Arterial Intervention With Clopidogrel MIRROR-Study[NCT00163267] | Phase 2/Phase 3 | 80 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| A Retrospective Epidemiological Study to Investigate Outcome and Mortality With Longterm Antithrombotic Therapy in Acute Coronary Syndrome Patients[NCT01623700] | 78,000 participants (Actual) | Observational | 2006-01-31 | Active, not recruiting | |||
| Secondary Prevention of Small Subcortical Strokes (SPS3) Trial[NCT00059306] | Phase 3 | 3,020 participants (Actual) | Interventional | 2003-02-28 | Completed | ||
| A Randomised, Double-blind, Parallel Group, Phase 3, Efficacy and Safety Study of Ticagrelor Compared With Clopidogrel for Prevention of Vascular Events in Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS) [PLATO- a Study of PLATelet Inh[NCT00391872] | Phase 3 | 18,624 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects With Unstable Angina/Non-ST-Elevation Myocardial Infarction Who Are Medically Managed[NCT00699998] | Phase 3 | 9,326 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| Cilostazol Stroke Prevention Study for Antiplatelet Combination[NCT01995370] | Phase 4 | 1,884 participants (Actual) | Interventional | 2013-12-13 | Completed | ||
| Study of the Efficacy and Safety of Cilostazol in the Prevention of Ischemic Vascular Events in Diabetic Patients With Symptomatic Peripheral Artery Disease.[NCT02983214] | Phase 4 | 826 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| Comparison of Biolimus Eluted From an Erodable Stent Coating With Bare-Metal Stents in Acute ST-Elevation Myocardial Infarction and In Vivo 3-Vessel Assessment of Time-Related Changes of Culprit and Non-Culprit Lesions by IVUS/OCT in AMI[NCT00962416] | Phase 4 | 1,161 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| Inflammation and Acute Coronary Syndromes (ACS) - Novel Strategies for Prevention and Clinical Management[NCT01000701] | 4,000 participants (Anticipated) | Observational | 2009-10-31 | Recruiting | |||
| Randomized,Double-blind Trial Comparing the Effects of a 3-month Clopidogrel Regimen,Combined With ASA During the First 21days,Versus ASA Alone for the Acute Treatment of TIA or Minor Stroke[NCT00979589] | Phase 3 | 5,100 participants (Actual) | Interventional | 2009-12-31 | Completed | ||
| Carotid Stenosis Management During COVID-19 Era - Best Medical Intervention Alone (CASCOM Pilot Study): A Prospective Observational Study[NCT04947046] | 120 participants (Anticipated) | Observational | 2020-03-11 | Recruiting | |||
| Comparison of Triflusal and Clopidogrel Effect in Secondary Prevention of Stroke Based on the Cytochrome P450 2C19 Genotyping[NCT01174693] | Phase 4 | 795 participants (Actual) | Interventional | 2010-03-31 | Completed | ||
| A Multicenter, Randomized, Controlled, Superiority Clinical Trial to Evaluate the Safety and Efficacy of Drug-eluting Peripheral Arterial Stent System（G-stream） in the Treatment of the Above-the-knee Femoropopliteal Artery Stenosis or Occlusion[NCT05780359] | 280 participants (Anticipated) | Interventional | 2022-05-27 | Recruiting | |||
| Evaluation of the Zilver PTX Drug-Eluting Stent in the Above-the-Knee Femoropopliteal Artery[NCT00120406] | 474 participants (Actual) | Interventional | 2005-03-31 | Completed | |||
| The TRANSLATE-ACS Study: Treatment With ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome[NCT01088503] | 12,227 participants (Actual) | Observational | 2010-03-31 | Completed | |||
| Phase IV: A Comparison of Reduced-dose Prasugrel and Clopidogrel in Elderly Patients With Acute Coronary Syndrome Undergoing Early Percutaneous Coronary Intervention (PCI)[NCT01777503] | Phase 4 | 2,000 participants (Anticipated) | Interventional | 2012-11-30 | Recruiting | ||
| Follow up of Ticagrelor Treatment Patterns in Chinese Acute Coronary Syndromes Patients- A Database Retrospective Study[NCT04861363] | 20,000 participants (Anticipated) | Observational | 2019-06-19 | Enrolling by invitation | |||
| The Optimal Regimen of Medical Treatment in Endovascular Therapy in Ischemic Cerebrovascular Disease Based on Clopidogrel Resistance[NCT01925872] | 2,000 participants (Anticipated) | Observational | 2013-05-31 | Enrolling by invitation | |||
| Prospective, Randomized, Double-Blind, Active-Controlled, Multicenter Trial of Bivalirudin and Un-fractionated Heparin in Patients Undergoing Percutaneous Coronary Interventions. ISAR-REACT-3[NCT00262054] | Phase 4 | 4,570 participants (Actual) | Interventional | 2005-11-30 | Completed | ||
| Non-randomized, Open-label, Historical Control, Single Group Assignment Trial of a Reduced Dose of Unfractionated Heparin in Patients Undergoing Percutaneous Coronary Interventions[NCT00735280] | Phase 4 | 2,505 participants (Actual) | Interventional | 2008-08-31 | Completed | ||
| Clopidogrel and Proton Pump Inhibitors: A Propensity Score Adjusted Cohort Study to Examine a Possible Interaction: A CALIBER Study[NCT01231867] | 24,471 participants (Actual) | Observational | 2010-12-31 | Completed | |||
| Efficacy of H2 Receptor Antagonist in Prevention of Thienopyridine-related Peptic Ulcer[NCT02418312] | 228 participants (Actual) | Interventional | 2012-01-31 | Completed | |||
| Pantoprazole Versus Famotidine for the Prevention of Recurrent Peptic Ulcers in Thienopyridine Users - a Double-blind Randomized Controlled Trial[NCT02551744] | 101 participants (Actual) | Interventional | 2012-07-31 | Completed | |||
| A Multicenter, Randomized, Controlled, Double-Blind Trial to Investigate the Clinical Efficacy and Tolerability of Early Treatment With Simvastatin 40 mg Daily for 30 Days, Followed by Simvastatin 80 mg Daily Thereafter in Tirofiban-Treated Acute Coronary[NCT00251576] | Phase 3 | 4,497 participants (Actual) | Interventional | 1999-11-01 | Completed | ||
| CHoosing Triple or Double therApy in the Era of nOac for patientS Undergoing PCI: the CHAOS a Multicenter Study.[NCT03558295] | 1,000 participants (Anticipated) | Observational [Patient Registry] | 2018-05-01 | Recruiting | |||
| Sclerotherapy With Polidocanol Foam In The Management Of First, Second And Third-Grade Hemorrhoidal Disease In Patients With Bleeding Disorders: A Prospective Cohort Study[NCT04188171] | Phase 2/Phase 3 | 150 participants (Anticipated) | Interventional | 2018-08-01 | Active, not recruiting | ||
| A Single-center, Randomized, Open-label, Controlled, Dose-escalating, Parallel-group Study to Assess the Anti-platelet Effect of Berberine in Patients Receiving Aspirin and Clopidogrel After Percutaneous Coronary Intervention[NCT03378934] | Phase 4 | 64 participants (Anticipated) | Interventional | 2018-09-26 | Recruiting | ||
| Efficacy of High Dose Atorvastatin Loading in ST Elevation Myocardial Infarction[NCT00808717] | Phase 4 | 170 participants (Anticipated) | Interventional | 2007-07-31 | Completed | ||
| Value of Abciximab in Patients With AMI Undergoing PCI After High Dose Clopidogrel Pretreatment (BRAVE 3)[NCT00133250] | Phase 4 | 800 participants (Actual) | Interventional | 2003-06-30 | Completed | ||
| Pharmacogenetics of Clopidogrel in Acute Coronary Syndromes[NCT03347435] | 889 participants (Actual) | Interventional | 2013-06-30 | Terminated (stopped due to Ethics Committe decision) | |||
| A Multi-center, Randomized, Double-blind and Placebo-controlled Clinical Research of 2200 Cases in Improving Curative Effect of Secondary Prevention for Patients With Ischemic Stroke Through Syndrome Differentiation of TCM[NCT02334969] | Phase 4 | 2,200 participants (Actual) | Interventional | 2016-04-30 | Completed | ||
| Antithrombotic Therapy After Left Atrial Appendage Occlusion: Double Antiplatelet Therapy vs Apixaban[NCT05632445] | Phase 4 | 160 participants (Actual) | Interventional | 2019-05-01 | Completed | ||
| PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes: A Double-blind, Active and Placebo Controlled Study of Aggrenox vs. Clopidogrel, With and Without Micardis[NCT00153062] | Phase 4 | 20,332 participants (Actual) | Interventional | 2003-08-31 | Completed | ||
| "PGDT With the Hypotension Prediction Index to Reduce the Number and Duration of Intraoperative Hypotension and the Incidence of Renal Failure in Patients Undergoing Lung Surgery"[NCT04149314] | 142 participants (Actual) | Interventional | 2019-11-20 | Completed | |||
| A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention[NCT00097591] | Phase 3 | 13,619 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
| WilL LOWer Dose Aspirin be More Effective Following ACS? (WILLOW-ACS)[NCT02741817] | Phase 4 | 20 participants (Actual) | Interventional | 2016-06-26 | Completed | ||
| Prospective Pilot Study- Does Mean Platelet Volume Change With Clopidogrel in Patients With Stable Angina Undergoing Percutaneous Coronary Intervention?[NCT02550301] | 100 participants (Anticipated) | Observational | 2015-09-30 | Not yet recruiting | |||
| Biological Efficacy of Clopidogrel 600 mg Loading Dose Followed by 75 mg Maintenance Dose After Implantation of Drug-eluting Stents in Patients With Diabetes Mellitus or Metabolic Syndrome (SPACE)[NCT00298428] | 159 participants (Actual) | Interventional | 2006-05-31 | Completed | |||
| Chewing Clopidogrel in Addition to Regular Oral Clopidogrel Treatment to Improve Platelets Aggregation in Patient With NON ST ELEVATION MI[NCT00889044] | Phase 3 | 30 participants (Anticipated) | Interventional | 2009-04-30 | Recruiting | ||
| [NCT00000614] | Phase 3 | 0 participants | Interventional | 1998-09-30 | Completed | ||
| Influence of the Compression Method After Transradial Catheterization in Radial Artery[NCT02697526] | 274 participants (Actual) | Interventional | 2007-01-31 | Completed | |||
| Antiplatelet Activity of Aspirin in Infants After Aortopulmonary and Cavopulmonary Shunts[NCT01656993] | 25 participants (Actual) | Observational | 2012-11-30 | Completed | |||
| Clopidogrel Hyper-Responsiveness: Incidence and Associated Outcomes in Patients With Cerebral Aneurysms[NCT05945563] | 208 participants (Anticipated) | Observational [Patient Registry] | 2023-01-17 | Recruiting | |||
| Improvements of Hand Function in Chronic Stroke Related to Upper Arm Anesthesia[NCT00006414] | 12 participants | Observational | 2000-10-31 | Completed | |||
| French Registry to Evaluate the Safety and Efficacy of the Diamondback 360TM Orbital Atherectomy System in the Preparation of Calcified Coronary Lesions Before Implantation of a Coronary Endoprothesis[NCT05417022] | 300 participants (Anticipated) | Observational [Patient Registry] | 2022-06-15 | Recruiting | |||
| Rotational Atherectomy Prior to Taxus Stent Treatment for Complex Native Coronary Artery Disease. A Multicenter, Prospective, Randomized Controlled Trial.[NCT00380809] | Phase 4 | 240 participants (Actual) | Interventional | 2006-08-31 | Completed | ||
| Induction of Mucosal Tolerance to E-Selectin for the Secondary Prevention of Stroke[NCT00012454] | Phase 2 | 60 participants | Interventional | 2001-03-31 | Terminated | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
This is a key secondary endpoint. The number of observed patients with all cause death and non-fatal stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 50 |
| Primary PCI (Group B) | 43 |
This is a key secondary endpoint. The number of observed patients with all cause death and shock within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 59 |
| Primary PCI (Group B) | 73 |
This is a key secondary endpoint. The number of observed patients with all cause death and shock and CHF within 30 days was reported. (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 100 |
| Primary PCI (Group B) | 123 |
This is a key secondary endpoint. The number of observed patients with all cause death and shock and CHF and reinfarction and disabling stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 117 |
| Primary PCI (Group B) | 135 |
This is a key secondary endpoint. The number of observed patients with all cause death and shock and reinfarction within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 77 |
| Primary PCI (Group B) | 85 |
This is a key secondary endpoint. The number of observed patients with all cause mortality within 30 days was reported. (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 43 |
| Primary PCI (Group B) | 42 |
The number of observed patients with all-cause mortality, cardiogenic shock, congestive heart failure (CHF) and recurrent myocardial infarction within 30 days was reported for full analysis set (FAS). (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 116 |
| Primary PCI (Group B) | 135 |
This is a key secondary endpoint. The number of observed patients with cardiac mortality within 30 days was reported. (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 31 |
| Primary PCI (Group B) | 32 |
This is a key secondary endpoint. The number of observed patients with cardiogenic shock within 30 days was reported. (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 41 |
| Primary PCI (Group B) | 56 |
This is a key secondary endpoint. The number of observed patients with congestive heart failure (CHF) within 30 days was reported. (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 57 |
| Primary PCI (Group B) | 72 |
This is a key secondary endpoint. The number of observed patients with intracranial haemorrhage within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 9 |
| Primary PCI (Group B) | 2 |
This is a key secondary endpoint. The number of observed patients with ischaemic stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 6 |
| Primary PCI (Group B) | 3 |
This is a key secondary endpoint. The number of observed patients with major non-intracranial bleeds including blood transfusions within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 61 |
| Primary PCI (Group B) | 45 |
This is a key secondary endpoint. The number of observed patients with minor non-intracranial bleeds within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 206 |
| Primary PCI (Group B) | 191 |
This is a key secondary endpoint. The number of observed patients with recurrent myocardial infarction (reinfarction) within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 23 |
| Primary PCI (Group B) | 21 |
This is a key secondary endpoint. The number of observed patients with rehospitalisation for cardiac reasons within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 45 |
| Primary PCI (Group B) | 41 |
This is a key secondary endpoint. The number of observed patients with rehospitalisation for non-cardiac reasons within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 19 |
| Primary PCI (Group B) | 11 |
This is a key secondary endpoint. The number of observed patients with serious repeat target vessel revascularization within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 1 |
| Primary PCI (Group B) | 2 |
This is a key secondary endpoint. The number of observed patients with serious resuscitated ventricular fibrillation within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 32 |
| Primary PCI (Group B) | 38 |
This is a key secondary endpoint. The number of observed patients with serious resuscitated ventricular fibrillation in association with invasive procedures (occurring at any time during catheterisation or urgent/elective PCI) within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 10 |
| Primary PCI (Group B) | 29 |
This is a key secondary endpoint. The number of observed patients with total disabling stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 2 |
| Primary PCI (Group B) | 0 |
This is a key secondary endpoint. The number of observed patients with total fatal stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 7 |
| Primary PCI (Group B) | 4 |
This is a key secondary endpoint. The number of observed patients with total non-disabling stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 8 |
| Primary PCI (Group B) | 1 |
This is a key secondary endpoint. The number of observed patients with total non-intracranial bleeds within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 267 |
| Primary PCI (Group B) | 236 |
This is a key secondary endpoint. The number of observed patients with total stroke (all types) within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 15 |
| Primary PCI (Group B) | 5 |
(NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) |
|---|---|
| Clopidogrel 300/75/75 mg + ASA Low Dose | 267 |
| Clopidogrel 300/75/75 mg + ASA High Dose | 290 |
| Clopidogrel 600/150/75 mg + ASA Low Dose | 282 |
| Clopidogrel 600/150/75 mg + ASA High Dose | 240 |
(NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| CV death/MI/Stroke | - CV death | - MI (fatal or not) | - Stroke (fatal or not) | |
| Clopidogrel + ASA High Dose | 527 | 211 | 251 | 65 |
| Clopidogrel + ASA Low Dose | 546 | 231 | 260 | 55 |
"The primary endpoint is the first occurrence of any of the following events:~Cardiovascular death (any death with a clear cardiovascular or unknown cause),~Myocardial Infarction (diagnosis of new Myocardial Infarction (MI) - nonfatal or fatal)~Stroke (presence of a new focal neurologic deficit thought to be vascular in origin, with signs or symptoms lasting more than 24 hours - nonfatal or fatal)~reported between the randomization and Day 30 (inclusive), and validated by the blinded Event Adjudication Committee (EAC)." (NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| CV death/MI/Stroke | - CV death | - MI (fatal or not) | - Stroke (fatal or not) | |
| Clopidogrel 300/75/75 mg + ASA | 557 | 222 | 274 | 61 |
| Clopidogrel 600/150/75 mg + ASA | 522 | 226 | 237 | 59 |
(NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| CV death/MI/Stroke | - CV death | - MI (fatal or not) | - Stroke (fatal or not) | |
| Clopidogrel 300/75/75 mg + ASA | 392 | 132 | 225 | 35 |
| Clopidogrel 600/150/75 mg + ASA | 330 | 130 | 172 | 28 |
(NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) | ||
|---|---|---|---|
| Major bleeding | - Severe bleeding | - Major but not severe bleeding | |
| Clopidogrel + ASA High Dose | 282 | 216 | 73 |
| Clopidogrel + ASA Low Dose | 285 | 215 | 74 |
Major bleeding is defined as any severe bleeding (associated with any of the following: death, leading to a drop in hemoglobin ≥ 5 g/dl, significant hypotension with the need for inotropic agents, symptomatic intracranial hemorrhage, requirement for surgery or for a transfusion ≥ 4 units of red blood cells or equivalent whole blood) and other major bleeding (significantly disabling bleeding, or intraocular bleeding leading to significant loss of vision or bleeding requiring transfusion of 2-3 units of red blood cells or equivalent whole blood) after validation by the independent EAC. (NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) | ||
|---|---|---|---|
| Major bleeding | - Severe bleeding | - Major but not severe bleeding | |
| Clopidogrel 300/75/75 mg + ASA | 255 | 195 | 65 |
| Clopidogrel 600/150/75 mg + ASA | 313 | 236 | 83 |
This includes definite stent thrombosis (confirmed by angiography or evidence of recent thrombus determined at autopsy or by examination of tissue retrieved following thrombectomy) and probable stent thrombosis (unexplained death having occurred after intracoronary stenting or, MI related to acute ischemia in the territory of the implanted stent without angiographic confirmation and in the absence of any obvious cause) after validation by the EAC. (NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) | ||
|---|---|---|---|
| Stent trombosis | - Definite | - Probable | |
| Clopidogrel 300/75/75 mg + ASA | 200 | 111 | 89 |
| Clopidogrel 600/150/75 mg + ASA | 135 | 58 | 77 |
Participants with death from any cause, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal of consent or date of scheduled withdrawal from therapy. ITT analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 901 |
| CLOPIDOGREL | 1065 |
Participants with death from vascular causes, MI, stroke, recurrent ischemia, or other thrombotic events. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT analysis of whole population. Events were adjudicated. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 1290 |
| CLOPIDOGREL | 1456 |
Participants with death from vascular causes, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT analysis of intent for invasive management population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 569 |
| CLOPIDOGREL | 668 |
Participants with death from vascular causes, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. Intention To Treat (ITT) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 864 |
| CLOPIDOGREL | 1014 |
Participants with major (fatal/life-threatening or other) bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 961 |
| CLOPIDOGREL | 929 |
Participants with a major CABG-related bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. All CABG surgeries were submitted for adjudication by an endpoint committee as potential bleeds. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 619 |
| CLOPIDOGREL | 654 |
Number of participants with a major fatal/life-threatening CABG-related bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. All CABG surgeries were submitted for adjudication by an endpoint committee as potential bleeds. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 329 |
| CLOPIDOGREL | 341 |
Participants with death from any cause. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 399 |
| CLOPIDOGREL | 506 |
Participants with death from vascular causes. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 353 |
| CLOPIDOGREL | 442 |
Participants with major (fatal/life-threatening or other) or minor bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 1339 |
| CLOPIDOGREL | 1215 |
Participants with MI event. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 504 |
| CLOPIDOGREL | 593 |
Participants with non CABG related major (fatal/life-threatening or other) bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 362 |
| CLOPIDOGREL | 306 |
Participants with non-procedural major bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 235 |
| CLOPIDOGREL | 180 |
Participants with stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 125 |
| CLOPIDOGREL | 106 |
Number of participants who were observed to have at least 1 ventricular pause of at least 3 seconds. Population is all patients who were observed over 2 week-long periods. Pauses were flagged algorithmically and confirmed by TIMI cardiologists. (NCT00391872)
Timeframe: 1-week period following randomization
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 21 |
| CLOPIDOGREL | 16 |
Number of participants who were observed to have at least 1 ventricular pause of at least 3 seconds. Population is all patients who were observed over 2 week-long periods. Pauses were flagged algorithmically and confirmed by Thrombolysis in Myocardial Infarction (TIMI) group cardiologists. (NCT00391872)
Timeframe: 1-week period following randomization
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 84 |
| CLOPIDOGREL | 51 |
The percentage of participants is the total number of participants experiencing an all-cause death, nonfatal MI, or nonfatal stroke divided by number of participants in the treatment arm. Endpoint events were adjudicated by the Clinical Endpoint Committee. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)
| Intervention | percentage of participants with an event (Number) |
|---|---|
| Prasugrel: <75 Years of Age | 10.61 |
| Prasugrel: 75 Years of Age or Older | 27.04 |
| Clopidogrel: <75 Years of Age | 11.12 |
| Clopidogrel: 75 Years of Age or Older | 26.83 |
The percentage of participants is the total number of participants experiencing a CV death, nonfatal MI, or nonfatal stroke divided by number of participants in the treatment arm multiplied by 100. Endpoint events were adjudicated by the Clinical Endpoint Committee. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)
| Intervention | percentage of participants with an event (Number) |
|---|---|
| Prasugrel: <75 Years of Age | 10.06 |
| Prasugrel: 75 Years of Age or Older | 24.64 |
| Clopidogrel: <75 Years of Age | 10.96 |
| Clopidogrel: 75 Years of Age or Older | 24.13 |
The percentage of participants is the total number of participants experiencing a CV death or nonfatal MI divided by number of participants in the treatment arm. Endpoint events were adjudicated by the Clinical Endpoint Committee. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)
| Intervention | percentage of participants with an event (Number) |
|---|---|
| Prasugrel: <75 Years of Age | 9.61 |
| Prasugrel: 75 Years of Age or Older | 22.53 |
| Clopidogrel: <75 Years of Age | 10.21 |
| Clopidogrel: 75 Years of Age or Older | 22.69 |
The percentage of participants is the total number of participants experiencing a CV death, nonfatal MI, nonfatal stroke or re-hospitalization for a recurrent UA divided by number of participants in the treatment arm. Endpoints events were adjudicated by the Clinical Endpoint Committee. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)
| Intervention | percentage of participants with an event (Number) |
|---|---|
| Prasugrel: <75 Years of Age | 12.13 |
| Prasugrel: 75 Years of Age or Older | 26.27 |
| Clopidogrel: <75 Years of Age | 12.83 |
| Clopidogrel: 75 Years of Age or Older | 25.67 |
Brain natriuretic peptide (BNP) is secreted by the ventricles of the heart in response to hemodynamic stress and is a biomarker associated with increased CV risk. Results are presented as geometric least squares means (Geometric LS means). Geometric LS means were adjusted for treatment + baseline value + clopidogrel status at randomization. (NCT00699998)
Timeframe: Day 30 and 6 Months
| Intervention | picograms per milliliter (pg/mL) (Geometric Mean) | |
|---|---|---|
| Day 30 | 6 Months (n=725, 125, 701, 174) | |
| Clopidogrel: <75 Years of Age | 319.345 | 250.982 |
| Clopidogrel: 75 Years of Age or Older | 951.359 | 722.750 |
| Prasugrel: <75 Years of Age | 313.494 | 253.434 |
| Prasugrel: 75 Years of Age or Older | 1082.396 | 770.132 |
C-Reactive Protein (CRP) is a biomarker associated with inflammation and increased CV risk. Results are presented as geometric least squares means (Geometric LS means). Geometric LS means were adjusted for treatment + baseline value + clopidogrel status at randomization. (NCT00699998)
Timeframe: Day 30 and Month 6
| Intervention | milligrams per liter (mg/L) (Geometric Mean) | |
|---|---|---|
| Day 30 | 6 Months (n=755, 143, 745, 178) | |
| Clopidogrel: <75 Years of Age | 2.287 | 2.149 |
| Clopidogrel: 75 Years of Age or Older | 2.226 | 1.543 |
| Prasugrel: <75 Years of Age | 2.330 | 2.272 |
| Prasugrel: 75 Years of Age or Older | 2.441 | 1.593 |
Seattle Angina Questionnaire (SAQ) is a validated, disease-specific questionnaire containing 11 questions (Q) yielding 5 summary scales related to angina: physical limitations, angina stability, angina frequency, treatment satisfaction and disease perception. In this study only angina frequency and the physical limitations scales were assessed. Anginal Frequency was assessed using Q3 and Q4 which consists of a Likert scale ranging from 1 to 6 (higher values equals better quality of life) to assess how often a patient is having symptoms now. Physical limitations was assessed using Q1 which contains 9 items each assessed via Likert scale ranging from 1 to 6 (higher values equals better quality of life) to assess how much a participant's condition is hampering their ability to do what they want to do. Scale scores are transformed to a 0-100 by subtracting the lowest possible score, dividing by the range of the scale, and multiplying by 100. Higher values equal better quality of life. (NCT00699998)
Timeframe: Baseline and follow-up (24 months)
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Baseline, physical limitations | Baseline, angina frequency | 24 Months, physical limitations (n=420, 412) | 24 Months, angina frequency (n=420, 412) | |
| Clopidogrel | 67.0 | 73.1 | 74.5 | 89.5 |
| Prasugrel | 67.8 | 73.6 | 75.1 | 89.7 |
Variation in the genes encoding the cytochrome P450 (CYP) enzymes (CYP2C19) can reduce the ability to metabolize clopidogrel and a reduced platelet response and have been associated with increased rates of CV events including CV death. Participants were classified as extensive metabolizers (EM); reduced metabolizers (RM); or unknown (UNK) metabolizers based on their CYP2C19 genotype. Possible extensive metabolizer (EM) phenotypes include EM=extensive metabolizer, UM=ultra-rapid metabolizer, and EM (non-UM) that are not UM. Possible reduced metabolizer (RM) phenotypes include IM=intermediate metabolizer and PM=poor metabolizer. Genotypes associated with each predicted phenotype are presented; predicted phenotype is presented first followed by the genotype. Percentage=(number of participants with the predicted phenotype and genotype divided by the total number of participants per arm) multiplied by 100. (NCT00699998)
Timeframe: Baseline
| Intervention | percentage participants with geneotype (Number) | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| UM, *1/*17 | UM, *17/*17 | EM (non-UM), *1/*1 | IM, *1/*2 | IM, *1/*3 | IM, *1/*4 | IM, *1/*6 | IM, *1/*8 | PM, *2/*2 | PM, *2/*3 | PM, *2/*4 | PM, *2/*6 | PM, *2/*8 | PM, *3/*3 | UNK, *1/*10 | UNK, *1/*13 | UNK, *1/*9 | UNK, *1/*9, *9/*17 | UNK, *13/*17 | UNK, *2/*13 | UNK, *2/*17 | UNK, *2/*9 | UNK, *3/*17 | UNK, *4/*17 | UNK, *4/*9 | UNK, *6/*17 | UNK, *8/*17 | UNK, *9/*17 | UNK, Undefined genotype | |
| Clopidogrel: <75 Years of Age | 25.1 | 5.4 | 35.7 | 19.8 | 0.5 | 0.1 | 0.0 | 0.4 | 4.3 | 0.3 | 0.2 | 0.0 | 0.0 | 0.2 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 6.8 | 0.1 | 0.0 | 0.2 | 0.0 | 0.0 | 0.1 | 0.0 | 0.5 |
| Clopidogrel: 75 Years of Age or Older | 21.8 | 4.3 | 41.2 | 19.7 | 0.6 | 0.3 | 0.2 | 0.3 | 3.8 | 0.3 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 6.2 | 0.0 | 0.3 | 0.0 | 0.0 | 0.2 | 0.0 | 0.0 | 0.6 |
| Prasugrel: <75 Years of Age | 24.0 | 5.1 | 38.8 | 18.6 | 0.8 | 0.4 | 0.0 | 0.1 | 3.9 | 0.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 6.3 | 0.0 | 0.1 | 0.2 | 0.0 | 0.0 | 0.2 | 0.0 | 0.7 |
| Prasugrel: 75 Years of Age or Older | 25.0 | 3.6 | 42.1 | 18.3 | 0.6 | 0.0 | 0.2 | 0.5 | 2.2 | 0.2 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | 0.2 | 0.0 | 0.0 | 0.0 | 6.1 | 0.0 | 0.0 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.6 |
Platelet aggregation was measured by as measured by Accumetrics Verify Now™ P2Y12. Results were reported in P2Y12 Reaction Units (PRU). PRU represents the rate and extent of adenosine (ADP)-stimulated platelet aggregation. Lower values indicate greater P2Y12 platelet inhibition and lower platelet activity and aggregation. ANCOVA Model was used and values were corrected for treatment + baseline value + clopidogrel status at randomization. (NCT00699998)
Timeframe: Day 30 and 12 Months
| Intervention | P2Y12 Reaction Units (PRU) (Least Squares Mean) | |
|---|---|---|
| Day 30 | Month 12 (n=386, 76, 400, 103) | |
| Clopidogrel: <75 Years of Age | 193.489 | 199.003 |
| Clopidogrel: 75 Years of Age or Older | 200.285 | 181.360 |
| Prasugrel: <75 Years of Age | 93.280 | 94.529 |
| Prasugrel: 75 Years of Age or Older | 151.872 | 135.096 |
All deaths, regardless of possible relatedness, with the exception of 1 event, were adjudicated by the Clinical Endpoint Committee (CEC) and are reported in this table. The 1 event which was not adjudicated was a result of the revocation of consent by the participant prior to their death. Deaths possibly related to study drug in the opinion of the investigator are also contained in the Serious Adverse Event (SAE) module. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)
| Intervention | participants (Number) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Congestive Heart Failure | Cardiogenic Shock | Cardiac Rupture | Myocardial Infarction | Dysrhythmia | Stent Thrombosis | Directly Related to Revascularization-CABG or PCI | Intracranial Hemorrhage | Non-Hemorrhagic Stroke | Sudden death due to cardiovascular event | Pulmonary Embolism | Stroke, unknown type | Other Cardiovascular Event | Cardiovascular event, unknown type | Accidental | Trauma | Hemorrhage, not intracranial | Infection | Malignancy | Suicide | Other Non-Cardiovascular event | Cause unknown (nonadjudicated event) | |
| Clopidogrel: <75 Years of Age | 13 | 10 | 0 | 24 | 6 | 0 | 1 | 4 | 4 | 70 | 2 | 0 | 0 | 45 | 1 | 0 | 0 | 16 | 14 | 0 | 8 | 0 |
| Clopidogrel: 75 Years of Age or Older | 23 | 9 | 0 | 21 | 3 | 0 | 1 | 1 | 3 | 43 | 1 | 0 | 1 | 45 | 1 | 1 | 4 | 17 | 11 | 0 | 6 | 0 |
| Prasugrel: <75 Years of Age | 10 | 8 | 0 | 16 | 5 | 0 | 1 | 2 | 4 | 75 | 0 | 0 | 6 | 40 | 1 | 2 | 1 | 14 | 14 | 1 | 8 | 0 |
| Prasugrel: 75 Years of Age or Older | 21 | 4 | 1 | 24 | 2 | 0 | 1 | 1 | 4 | 39 | 1 | 1 | 1 | 41 | 0 | 3 | 1 | 21 | 7 | 0 | 4 | 1 |
"Event-free survival is defined as freedom from the major adverse events of death, target lesion revascularization, target limb ischemia requiring surgical intervention (bypass or amputation of toe, foot or leg), surgical repair of the target vessel (e.g., dissection requiring surgery), and from worsening of the Rutherford classification by 2 classes or to class 5 or 6.~Participant flow is based on initial randomization of Zilver PTX or PTA (Percutaneous balloon angioplasty), and Event-free survival is based on Per-Protocol analysis where only patients who were treated according to their initial randomization are counted." (NCT00120406)
Timeframe: 12 months
| Intervention | Percentage of participants (Number) |
|---|---|
| Zilver PTX | 90.4 |
| PTA (Control) | 83.9 |
Primary patency is defined as a Peak systolic velocity (PSV) ratio < 2.0 or angiographic percent diameter stenosis < 50%. (NCT00120406)
Timeframe: 12 months
| Intervention | Percentage of participants (Number) |
|---|---|
| Zilver PTX | 82.7 |
| PTA (Control) | 32.7 |
The Duke CAD Index is a validated composite measure of angiographic burden, which assigns prognostic weights 1 through 100. Higher scores indicate greater angiographic burden and are associated with poorer prognosis. (NCT01088503)
Timeframe: Day 0 (study enrollment)
| Intervention | units on a scale (Mean) |
|---|---|
| Prasugrel | 40.36 |
| Other | 41.87 |
(NCT01088503)
Timeframe: Day 0 (study enrollment)
| Intervention | grams/deciliter (g/dL) (Mean) |
|---|---|
| Prasugrel | 14.59 |
| Other | 14 |
Academic Research Consortium (ARC) criteria were used to define ST. Definite ST is angiographic or pathologic confirmation of partial or total thrombotic occlusion within the peri-stent region, and at least 1 of the following additional criteria: acute ischemic symptoms; ischemic electrocardiogram changes; elevated cardiac biomarkers. Probable ST is any unexplained death within 30 days of stent implantation; any MI, which is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of ST and in the absence of any other obvious cause. Events that occurred more than 7 days after medication was switched or discontinued were excluded from the analysis. Observed (unadjusted) percentages of participants with ST events are presented. Kaplan-Meier analysis was used to estimate the percentage of participants with a definite or probable ST event. (NCT01088503)
Timeframe: Baseline through 15 months
| Intervention | percentage of participants (Number) |
|---|---|
| Prasugrel | 1.35 |
| Clopidogrel | 1.79 |
MACE is defined as a composite of all-cause death, MI, stroke, or unplanned coronary revascularization. Events that occurred more than 7 days after medication was switched or discontinued were excluded from the analysis. Observed (unadjusted) percentages of participants with MACE, as well as the statistical analyses adjusted for baseline cohort differences, are presented. Percentage of participant = (number of participants with events / number of participants treated) * 100. (NCT01088503)
Timeframe: Baseline through 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Prasugrel | 12.67 |
| Clopidogrel | 15.89 |
MACE is defined as a composite of all-cause death, myocardial infarction (MI), stroke, or unplanned coronary revascularization. Events that occurred more than 7 days after medication was switched or discontinued were excluded from the analysis. Observed (unadjusted) percentages of participants with MACE, as well as the statistical analyses adjusted for baseline cohort differences, are presented. Percentage of participants = (number of participants with events in 12 months/ number of participants treated) * 100. (NCT01088503)
Timeframe: Baseline through 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Prasugrel | 13.14 |
| Clopidogrel | 17.12 |
Factors are drug-eluting stent (DES) vs. bare metal stent (BMS) placement, other (no stent) vs. BMS, STEMI, other race, cardiogenic shock occurred within 24 hours, male, European Quality of Life Questionnaire-5 Dimension Health State Score (EQ-5D) - United States (US) Index =1 vs. <1, married, diabetes, and other vs. BMS placement. The EQ-5D US index is a participant-rated, health-related, quality-of-life instrument based on US population. Scores range from -0.11 to 1.0 with 1.0 = perfect health. (NCT01088503)
Timeframe: Day 0 (study enrollment)
| Intervention | participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Received DES | Received only BMS | STEMI | Other Race (Non-Caucasian) | Cardiogenic Shock on Presentation | Male Participants | EQ-5D US index = 1 vs. <1 | Married Participants | Participant has Diabetes | No BMS or DES | |
| Other | 6282 | 2491 | 4508 | 1049 | 176 | 6342 | 3873 | 5601 | 2472 | 331 |
| Prasugrel | 2365 | 672 | 1831 | 365 | 79 | 2451 | 1516 | 2044 | 767 | 86 |
Bleeding events were collected utilizing the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) definition of bleeding. Non-coronary artery bypass grafting (CABG)-related GUSTO severe or life-threatening bleeding is any intracranial hemorrhage (ICH) OR any bleeding event resulting in substantial hemodynamic compromise requiring treatment. Non-CABG-related GUSTO moderate bleeding is any bleeding event resulting in the need for transfusion that is not considered a GUSTO severe or life-threatening bleed. Additional bleeding events are fatal bleeding or ICH, or any non -fatal surgical-related bleeding events leading to ≥4 units of red cell transfusion. Observed (unadjusted) percentages of participants with bleeding events, as well as the statistical analyses adjusted for baseline cohort differences, are presented. Percentage of participants = (number of participants with events / number of participants treated) * 100. (NCT01088503)
Timeframe: Baseline, 1, 6, 12 and 15 months
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Baseline | 1 month | 6 months | 12 months | 15 months | |
| Clopidogrel | 0.45 | 1.62 | 2.77 | 3.86 | 4.21 |
| Prasugrel | 0.54 | 1.22 | 1.93 | 2.72 | 3.10 |
MACE is defined as a composite of all-cause death, MI, stroke, or unplanned coronary revascularization. Events that occurred more than 7 days after medication was switched or discontinued were excluded from the analysis. Observed (unadjusted) percentages of participants with MACE are presented. Kaplan-Meier analysis was used to estimate the percentage of participants with a MACE event. (NCT01088503)
Timeframe: Baseline through 1, 6 and 15 months
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| 1 month | 6 months | 15 months | |
| Clopidogrel | 5.40 | 12.04 | 19.13 |
| Prasugrel | 4.63 | 9.64 | 14.26 |
Follow-up endoscopy was performed at the end of the 6th month (NCT02418312)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Histamine-2 Receptor Antagonist Group | 106 |
| Placebo Group | 101 |
Follow-up endoscopy was performed at the end of the 6th month (NCT02551744)
Timeframe: six month
| Intervention | participants (Number) |
|---|---|
| Proton Pump Inhibitor Group | 1 |
| Histamine-2 Receptor Antagonist Group | 7 |
Number of patients with any of stroke, myocardial infarction, vascular death (NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years
| Intervention | Participants (Number) |
|---|---|
| Aspirin + Extended Release Dipyridamole | 1333 |
| Clopidogrel | 1333 |
Number of patients with any of stroke, myocardial infarction, vascular death, or new or worsening congestive heart failure (NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years
| Intervention | Participants (Number) |
|---|---|
| Telmisartan | 1367 |
| Placebo | 1463 |
(NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years
| Intervention | Participants (Number) |
|---|---|
| Aspirin + Extended Release Dipyridamole | 916 |
| Clopidogrel | 898 |
(NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years
| Intervention | Participants (Number) |
|---|---|
| Telmisartan | 880 |
| Placebo | 934 |
(NCT00153062)
Timeframe: Randomization to final patient contact
| Intervention | Participants (Number) |
|---|---|
| Telmisartan | 125 |
| Placebo | 151 |
The endpoint in this measure is a combination of all-cause death, nonfatal MI, or nonfatal stroke. Results are reported for the All ACS population. (NCT00097591)
Timeframe: Randomization up to 15 months
| Intervention | Participants (Number) |
|---|---|
| Prasugrel | 692 |
| Clopidogrel | 822 |
The endpoint in this measure is a combination of CV death, nonfatal MI, nonfatal stroke, or rehospitalization for cardiac ischemic events. Results are reported for the All ACS population. (NCT00097591)
Timeframe: Randomization up to 15 months
| Intervention | Participants (Number) |
|---|---|
| Prasugrel | 797 |
| Clopidogrel | 938 |
The endpoint in this measure is a combination of CV death, nonfatal MI, or nonfatal stroke. Results are reported for the All ACS population for the 30 and 90 day periods. (NCT00097591)
Timeframe: Randomization to 30 days; randomization to 90 days
| Intervention | Participants (Number) | |
|---|---|---|
| All ACS (Through 30 days) | All ACS (Through 90 days) | |
| Clopidogrel | 502 | 573 |
| Prasugrel | 389 | 462 |
The endpoint in this measure is a combination of CV death, nonfatal MI, or nonfatal stroke. The data is presented by the study population, which is represented as follows: 1) subjects who presented with unstable angina and non-ST-segment elevation myocardial infarction (UA/NSTEMI), 2) subjects who presented with ST segment elevation myocardial infarction (STEMI), and 3) all subjects with acute coronary syndromes (ACS) (i.e. all subjects with UA/NSTEMI or STEMI). (NCT00097591)
Timeframe: Randomization up to 15 months
| Intervention | Participants (Number) | ||
|---|---|---|---|
| UA/NSTEMI (n=5044, n=5030) | STEMI (n=1769, n=1765) | All ACS (n=6813, n=6795) | |
| Clopidogrel | 565 | 216 | 781 |
| Prasugrel | 469 | 174 | 643 |
The endpoint in this measure is a combination of CV death, nonfatal MI, or UTVR. Results are reported for the All ACS subject population for the 30 and 90 day periods. (NCT00097591)
Timeframe: Randomization to 30 days; randomization to 90 days
| Intervention | Participants (Number) | |
|---|---|---|
| All ACS (Through 30 days) | All ACS (Through 90 days) | |
| Clopidogrel | 504 | 588 |
| Prasugrel | 399 | 472 |
TIMI classification for major and minor bleeding in the subset of subjects who did not undergo a coronary artery bypass operation (CABG) were defined as follows: Major bleeding: any intracranial hemorrhage (ICH) OR any clinically overt bleeding (including bleeding evident on imaging studies) associated with a fall in hemoglobin (Hgb) of ≥5 grams/deciliter (gm/dL)from baseline. Minor Bleeding: any clinically overt bleeding associated with a fall in Hgb of ≥3 gm/dL but <5 gm/dL from baseline. Major bleeding events were further examined as events that were deemed life threatening and/or fatal. (NCT00097591)
Timeframe: First dose of study drug up to 15 months (while at risk)
| Intervention | Participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| TIMI Major or Minor Bleeding | TIMI Major Bleeding | TIMI Major Bleeding - Life-threatening (LT) | LT - Fatal | LT - Symptomatic intracranial hemorrage (ICH) | LT - Requiring inotropes | LT - Requiring surgical intervention | LT - Requiring transfusion (>=4 units) | TIMI Minor Bleeding | |
| Clopidogrel | 231 | 111 | 56 | 5 | 17 | 8 | 19 | 30 | 125 |
| Prasugrel | 303 | 146 | 85 | 21 | 19 | 21 | 19 | 45 | 164 |
50 reviews available for ticlopidine and Recrudescence
| Article | Year |
|---|---|
Antithrombotic strategies for preventing long-term major adverse cardiovascular events in patients with non-valvular atrial fibrillation who undergo percutaneous coronary intervention.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Drug Therapy, Co | 2017 |
Antiplatelet Regimen for Patients With Breakthrough Strokes While on Aspirin: A Systematic Review and Meta-Analysis.
Topics: Adenosine; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Plat | 2017 |
Recurrent Ischemic Stroke: Strategies for Prevention.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Humans; Ischemic Attack, Transient; Male; P | 2017 |
Front-loading with clopidogrel plus aspirin followed by dual antiplatelet therapy in the prevention of early stroke recurrence.
Topics: Animals; Aspirin; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Recurrence; Stroke; Ticlopid | 2014 |
Aspirin plus clopidogrel as secondary prevention after stroke or transient ischemic attack: a systematic review and meta-analysis.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attack, Transient; Pla | 2015 |
Recurrent acute coronary syndrome and restenosis after percutaneous coronary intervention in a patient with idiopathic thrombocytopenic purpura: a case report and literature review.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Aspirin; Clopidogrel; Coronary Angiography; Drug-Elut | 2015 |
[Meta-analysis on the efficacy and adverse events of aspirin plus clopidogrel versus aspirin-monotherapy in patients with ischemic stroke or transient ischemic attack].
Topics: Aspirin; Clopidogrel; Databases, Factual; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic At | 2015 |
Long-term antiplatelet therapy following myocardial infarction: implications of PEGASUS-TIMI 54.
Topics: Adenosine; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Hemorrhage | 2016 |
Dual antiplatelet therapy after stroke or transient ischaemic attack - how long to treat? The duration of aspirin plus clopidogrel in stroke or transient ischaemic attack: a systematic review and meta-analysis.
Topics: Aspirin; Clopidogrel; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Recurrenc | 2016 |
Antiplatelet drug response variability and the role of platelet function testing: a practical guide for interventional cardiologists.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Resistance; Drug | 2009 |
Aspirin and clopidogrel hyporesponsiveness and nonresponsiveness in patients with coronary artery stenting.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Resistance; Huma | 2009 |
Current standings of the proton pump inhibitor and clopidogrel co-therapy: review on an evolving field with the eyes of the gastroenterologist.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Interactions; Dr | 2010 |
Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated meta-analysis.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; | 2010 |
Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis.
Topics: Adolescent; Adult; Aged; Aryl Hydrocarbon Hydroxylases; Cardiovascular Diseases; Clopidogrel; Corona | 2011 |
[Dilemma between gastroprotection and cardiovascular prevention].
Topics: Alleles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; | 2010 |
Review and management of side effects associated with antiplatelet therapy for prevention of recurrent cerebrovascular events.
Topics: Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Headache; Hemorrhage; Humans; Ischemi | 2011 |
[Decreasing incidence of stent thrombosis].
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Drug Therap | 2011 |
Dual or mono antiplatelet therapy for patients with acute ischemic stroke or transient ischemic attack: systematic review and meta-analysis of randomized controlled trials.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Clopidogrel; Datab | 2012 |
Influence of the paraoxonase-1 Q192R genetic variant on clopidogrel responsiveness and recurrent cardiovascular events: a systematic review and meta-analysis.
Topics: Aryldialkylphosphatase; Cardiovascular Diseases; Clopidogrel; Humans; Platelet Aggregation Inhibitor | 2012 |
Reducing adverse effects of proton pump inhibitors.
Topics: Anemia, Iron-Deficiency; Clopidogrel; Clostridioides difficile; Critical Care; Diarrhea; Drug Intera | 2012 |
State of the art--a journey through the world of antithrombotic therapy.
Topics: Ambulatory Care; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Coronary Disease; Fibrinolytic A | 2002 |
[Secondary and primary prevention of coronary heart disease: platelet aggregation inhibitors and anticoagulants].
Topics: Anticoagulants; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Dose-Respon | 2002 |
Preventing thrombosis: update of first-line therapy in the management of non-ST segment elevation acute coronary syndromes.
Topics: Acute Disease; Algorithms; Clopidogrel; Coronary Disease; Coronary Thrombosis; Enoxaparin; Fibrinoly | 2002 |
[Carotid stenosis: diagnosis, patient selection, therapy].
Topics: Aged; Aged, 80 and over; Angiography, Digital Subtraction; Angioplasty, Balloon; Aspirin; Carotid St | 2003 |
Clopidogrel: how good is it and how does it work?
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; | 2004 |
Comparison of bilateral thoracic artery grafting with percutaneous coronary interventions in diabetic patients.
Topics: Abciximab; Aged; Angioplasty, Balloon; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspir | 2004 |
Comparative benefits of clopidogrel and aspirin in high-risk patient populations: lessons from the CAPRIE and CURE studies.
Topics: Angina, Unstable; Aspirin; Clopidogrel; Comorbidity; Diabetes Mellitus; Humans; Hypercholesterolemia | 2004 |
Stroke prevention. MATCHing therapy to the patient with TIA.
Topics: Aspirin; Clopidogrel; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Recurrenc | 2005 |
Review of antiplatelet therapy in secondary prevention of cerebrovascular events: a need for direct comparisons between antiplatelet agents.
Topics: Aspirin; Clopidogrel; Dipyridamole; Humans; Platelet Aggregation Inhibitors; Recurrence; Salicylates | 2005 |
[Preventing cerebrovascular accidents during atrial fibrillation].
Topics: Administration, Oral; Age Factors; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Conver | 2005 |
[Current concepts of the antiplatelet and anticoagulant treatment in the prevention of stroke].
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clinical Trials as Topic; Clopidogrel; | 2005 |
[Atheromatosis of the thoracic aorta and risk of stroke].
Topics: Anticoagulants; Aorta, Thoracic; Aortic Diseases; Aspirin; Atherosclerosis; Clopidogrel; Controlled | 2006 |
Secondary prevention of stroke and transient ischemic attack: is more platelet inhibition the answer?
Topics: Aspirin; Atherosclerosis; Cilostazol; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Dipyr | 2007 |
[Ticlopidine].
Topics: Cerebral Infarction; Clinical Trials as Topic; Platelet Aggregation Inhibitors; Recurrence; Ticlopid | 2006 |
Antiplatelet therapy for atherothrombotic disease: an update for the primary care physician.
Topics: Anticoagulants; Aspirin; Atherosclerosis; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial | 2007 |
Chronic antithrombotic therapy in post-myocardial infarction patients.
Topics: Anticoagulants; Aspirin; Azetidines; Benzylamines; Clopidogrel; Humans; Myocardial Infarction; Perip | 2008 |
Medical treatment for stroke prevention.
Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Ischemic Attack, Transient; Myocard | 1994 |
[Ticlopidine. Secondary prevention of ischemic cerebral infarct].
Topics: Adult; Aged; Cerebral Infarction; Clinical Trials as Topic; Dose-Response Relationship, Drug; Female | 1993 |
Stents for intracoronary placement: current status and future directions.
Topics: Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Artery Bypass; Coronary Disease; Coro | 1996 |
Stent thrombosis. Closing in on the best preventive treatment.
Topics: Aspirin; Atherectomy; Coronary Disease; Humans; Platelet Aggregation Inhibitors; Recurrence; Stents; | 1997 |
[Antiplatelet therapy during coronary endoprosthesis placement].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Disease; Coronary Thrombosis; Drug Therapy, Combin | 1996 |
[Secondary prevention following cerebral ischemia: is monotherapy with acetylsalicylic acid still first choice?].
Topics: Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Cerebrovascular Disorders; Clopidogrel | 1998 |
The results of CAPRIE, IST and CAST. Clopidogrel vs. Aspirin in Patients at Risk of Ischaemic Events. International Stroke Trial. Chinese Acute Stroke Trial.
Topics: Aspirin; Cerebrovascular Disorders; Clopidogrel; Double-Blind Method; Humans; Ischemia; Myocardial I | 1998 |
Bleeding complications in secondary stroke prevention by antiplatelet therapy: a benefit-risk analysis.
Topics: Aspirin; Cerebrovascular Disorders; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors | 1999 |
Antiplatelet and anticoagulant therapy in the secondary prevention of ischemic heart disease.
Topics: Anticoagulants; Aspirin; Clopidogrel; Coronary Disease; Humans; Myocardial Infarction; Platelet Aggr | 2000 |
[Aspirin and cerebral ischemic accidents].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Cerebral Infarction; Clinica | 2000 |
Stroke prevention: antiplatelet and antithrombolytic therapy.
Topics: Anticoagulants; Aspirin; Brain Damage, Chronic; Carotid Stenosis; Clinical Trials as Topic; Clopidog | 2000 |
From CURE to MATCH: ADP receptor antagonists as the treatment of choice for high-risk atherothrombotic patients.
Topics: Angina, Unstable; Aspirin; Clopidogrel; Drug Therapy, Combination; Heparin; Humans; Intracranial Art | 2002 |
Stroke prevention in women: role of aspirin versus ticlopidine.
Topics: Aspirin; Cerebrovascular Disorders; Female; Humans; Meta-Analysis as Topic; Recurrence; Sex Factors; | 1991 |
Review of antiplatelet drug use in preventing restenosis following percutaneous transluminal coronary angioplasty.
Topics: Angioplasty, Balloon; Aspirin; Calcium Channel Blockers; Coronary Disease; Cyclooxygenase Inhibitors | 1988 |
93 trials available for ticlopidine and Recrudescence
| Article | Year |
|---|---|
Microbleeds in the Secondary Prevention of Small Subcortical Strokes Trial: Stroke, mortality, and treatment interactions.
Topics: Aspirin; Cerebral Hemorrhage; Clopidogrel; Double-Blind Method; Female; Humans; Magnetic Resonance I | 2017 |
SAFE (Sarpogrelate Anplone in Femoro-popliteal artery intervention Efficacy) study: study protocol for a randomized controlled trial.
Topics: Amputation, Surgical; Aspirin; Clinical Protocols; Clopidogrel; Computed Tomography Angiography; Con | 2017 |
Double-Dose Versus Standard-Dose Clopidogrel According to Smoking Status Among Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Aged; Chi-Square Distribution; Clopidogrel; Coronary Thrombosis; Female; He | 2017 |
Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial.
Topics: Acute Disease; Aged; Aspirin; Brain Ischemia; Clopidogrel; Denmark; Dipyridamole; Drug Therapy, Comb | 2018 |
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; | 2013 |
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; | 2013 |
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; | 2013 |
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; | 2013 |
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; | 2013 |
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; | 2013 |
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; | 2013 |
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; | 2013 |
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; | 2013 |
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; | 2013 |
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; | 2013 |
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; | 2013 |
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; | 2013 |
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; | 2013 |
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; | 2013 |
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; | 2013 |
A prospective randomized controlled clinical trial on clopidogrel combined with warfarin versus clopidogrel alone in the prevention of restenosis after endovascular treatment of the femoropopliteal artery.
Topics: Aged; Anticoagulants; Clopidogrel; Constriction, Pathologic; Drug Therapy, Combination; Endovascular | 2013 |
Twelve-month results of a randomized trial comparing mono with dual antiplatelet therapy in endovascularly treated patients with peripheral artery disease.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Aspirin; Clopidogrel; Double-Blind Method; Drug Thera | 2013 |
C-reactive protein as a prognostic marker after lacunar stroke: levels of inflammatory markers in the treatment of stroke study.
Topics: Aged; Antihypertensive Agents; Aspirin; Biomarkers; Blood Pressure; C-Reactive Protein; Clopidogrel; | 2014 |
The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Dose-Response Relationship, Drug; Double-Blin | 2014 |
A comparative study of dual versus monoantiplatelet therapy in patients with acute large-artery atherosclerosis stroke.
Topics: Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Endpoint Determination; Female; Humans; Intra | 2014 |
Prospective validation of the Bleeding Academic Research Consortium classification in the all-comer PRODIGY trial.
Topics: Administration, Oral; Aged; Aspirin; Clopidogrel; Epidemiologic Methods; Female; Hemorrhage; Humans; | 2014 |
Applying novel methods to assess clinical outcomes: insights from the TRILOGY ACS trial.
Topics: Aged; Angina, Unstable; Clopidogrel; Endpoint Determination; Humans; Middle Aged; Myocardial Infarct | 2015 |
Is clopidogrel better than aspirin following breakthrough strokes while on aspirin? A retrospective cohort study.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Dose-Response Relationship, Drug; Female; Follow-Up Stud | 2014 |
Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial.
Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Phosphodi | 2015 |
Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial.
Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Phosphodi | 2015 |
Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial.
Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Phosphodi | 2015 |
Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial.
Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Phosphodi | 2015 |
Glycated albumin predicts the effect of dual and single antiplatelet therapy on recurrent stroke.
Topics: Aged; Aspirin; Biomarkers; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Glyc | 2015 |
Safety profile of prasugrel and clopidogrel in patients with acute coronary syndromes in Switzerland.
Topics: Adolescent; Adult; Aged; Cerebrovascular Disorders; Clopidogrel; Drug-Eluting Stents; Female; Guidel | 2015 |
Safety profile of prasugrel and clopidogrel in patients with acute coronary syndromes in Switzerland.
Topics: Adolescent; Adult; Aged; Cerebrovascular Disorders; Clopidogrel; Drug-Eluting Stents; Female; Guidel | 2015 |
Safety profile of prasugrel and clopidogrel in patients with acute coronary syndromes in Switzerland.
Topics: Adolescent; Adult; Aged; Cerebrovascular Disorders; Clopidogrel; Drug-Eluting Stents; Female; Guidel | 2015 |
Safety profile of prasugrel and clopidogrel in patients with acute coronary syndromes in Switzerland.
Topics: Adolescent; Adult; Aged; Cerebrovascular Disorders; Clopidogrel; Drug-Eluting Stents; Female; Guidel | 2015 |
Left Ventricular Geometry on Transthoracic Echocardiogram and Prognosis after Lacunar Stroke: The SPS3 Trial.
Topics: Aged; Aspirin; Clopidogrel; Echocardiography; Female; Heart Ventricles; Humans; Magnetic Resonance I | 2015 |
CYP2C19 metabolizer status and clopidogrel efficacy in the Secondary Prevention of Small Subcortical Strokes (SPS3) study.
Topics: Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genotype; Humans; Male; Middle Aged; Platelet Aggrega | 2015 |
Dual antiplatelet therapy in stroke and ICAS: Subgroup analysis of CHANCE.
Topics: Aged; Aspirin; Clopidogrel; Constriction, Pathologic; Double-Blind Method; Drug Therapy, Combination | 2015 |
Achieved Blood Pressure and Outcomes in the Secondary Prevention of Small Subcortical Strokes Trial.
Topics: Aspirin; Blood Pressure; Blood Pressure Determination; Clopidogrel; Drug Therapy, Combination; Femal | 2016 |
Protocol for the comparison of triflusal and clopidogrel in secondary prevention of stroke based on cytochrome P450 2C19 genotyping (MASETRO study): A multicenter, randomized, open-label, parallel-group trial.
Topics: Brain Ischemia; Cerebral Hemorrhage; Chemoprevention; Clopidogrel; Cytochrome P-450 CYP2C19; Follow- | 2016 |
Morphological classification of penetrating artery pontine infarcts and association with risk factors and prognosis: The SPS3 trial.
Topics: Antihypertensive Agents; Aspirin; Cerebral Infarction; Clopidogrel; Constriction, Pathologic; Double | 2016 |
Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial.
Topics: Adult; Aged; Angioplasty; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Combine | 2016 |
Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial.
Topics: Adult; Aged; Angioplasty; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Combine | 2016 |
Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial.
Topics: Adult; Aged; Angioplasty; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Combine | 2016 |
Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial.
Topics: Adult; Aged; Angioplasty; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Combine | 2016 |
Treatment Effect of Clopidogrel Plus Aspirin Within 12 Hours of Acute Minor Stroke or Transient Ischemic Attack.
Topics: Aged; Aspirin; Chi-Square Distribution; China; Clopidogrel; Disease Progression; Double-Blind Method | 2016 |
Assessment of Ticagrelor Versus Clopidogrel Treatment in Patients With ST-elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
Topics: Adenosine; Aged; Chi-Square Distribution; China; Clopidogrel; Coronary Thrombosis; Drug Therapy, Com | 2016 |
Rationale and design of the Affordability and Real-world Antiplatelet Treatment Effectiveness after Myocardial Infarction Study (ARTEMIS): A multicenter, cluster-randomized trial of P2Y12 receptor inhibitor copayment reduction after myocardial infarction.
Topics: Adenosine; Clopidogrel; Cost Sharing; Drug Costs; Financial Support; Health Care Costs; Health Expen | 2016 |
The curative effect comparison of two kinds of therapeutic regimens on decreasing the relative intensity of microembolic signal in CLAIR trial.
Topics: Aspirin; Brain Ischemia; Carotid Stenosis; Cerebral Arterial Diseases; Clopidogrel; Drug Therapy, Co | 2016 |
Abnormal glucose regulation increases stroke risk in minor ischemic stroke or TIA.
Topics: Aged; Aspirin; Blood Glucose; Brain Ischemia; Clopidogrel; Diabetes Complications; Double-Blind Meth | 2016 |
A comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization: Design and rationale of the randomized Elderly-ACS 2 study.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Drug Therapy | 2016 |
Histamine-2 Receptor Antagonist Cannot Prevent Recurrent Peptic Ulcers in Patients With Atherosclerotic Diseases Who Receive Platelet ADP Receptor Antagonist Monotherapy: A Randomized-Controlled, Double-Blind, and Double-Dummy Trial.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Atherosclerosis; Clopidogrel; Double-Blind Method; F | 2017 |
Impact of Glycemic Control on Efficacy of Clopidogrel in Transient Ischemic Attack or Minor Stroke Patients With
Topics: Aged; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Double-Blind Method; Female; Glycated Serum Al | 2017 |
Bivalirudin versus unfractionated heparin during percutaneous coronary intervention.
Topics: Aged; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Clopidogrel | 2008 |
Bivalirudin versus unfractionated heparin during percutaneous coronary intervention.
Topics: Aged; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Clopidogrel | 2008 |
Bivalirudin versus unfractionated heparin during percutaneous coronary intervention.
Topics: Aged; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Clopidogrel | 2008 |
Bivalirudin versus unfractionated heparin during percutaneous coronary intervention.
Topics: Aged; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Clopidogrel | 2008 |
Safety and tolerability of 600 mg clopidogrel bolus in patients with acute ischemic stroke: preliminary experience.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Clopidogrel; Female; Humans; Male; Middle A | 2008 |
Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy.
Topics: Acute Coronary Syndrome; Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Clopi | 2008 |
Frequency of CYP3A4, CYP3A5, CYP2C9, and CYP2C19 variant alleles in patients receiving clopidogrel that experience repeat acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytoch | 2009 |
Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardi
Topics: Acute Coronary Syndrome; Angina, Unstable; Angioplasty, Balloon, Coronary; Biomarkers; Clopidogrel; | 2009 |
Marked reduction of early stent thrombosis with pre-hospital initiation of high-dose Tirofiban in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Thrombosis; Dis | 2009 |
Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Angiography; C | 2009 |
Primary percutaneous coronary angioplasty with and without eptifibatide in ST-segment elevation myocardial infarction: a safety and efficacy study of integrilin-facilitated versus primary percutaneous coronary intervention in ST-segment elevation myocardi
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiograp | 2009 |
Warfarin after anterior myocardial infarction in current era of dual antiplatelet therapy: a randomized feasibility trial.
Topics: Aged; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Embolism; Feasibility Studies | 2010 |
Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the STATIN STEMI trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Chi-Square Distribution; Clopidogrel; Coronary A | 2010 |
One-year clinical outcomes with abciximab in acute myocardial infarction: results of the BRAVE-3 randomized trial.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Double-Blind M | 2010 |
Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Dose- | 2011 |
Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Loss, Surgical; Cause | 2012 |
Effects of clopidogrel added to aspirin in patients with recent lacunar stroke.
Topics: Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Hem | 2012 |
Benefit of long-term dual anti-platelet therapy in patients treated with drug-eluting stents: from the NHLBI dynamic registry.
Topics: Antineoplastic Agents, Phytogenic; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Rela | 2013 |
Thrombotic thrombocytopenic purpura (TTP): initial treatment with plasma exchange plus steroids and immunosuppressive agents for relapsing cases.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Hemolytic; Bilirubin; Biomarkers; Combined Modal | 2003 |
The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study: to what extent should the results be generalizable?
Topics: Angina, Unstable; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; Female; Heart Failure | 2003 |
Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial.
Topics: Aged; Aspirin; Black or African American; Double-Blind Method; Female; Humans; Male; Middle Aged; Pl | 2003 |
Ticlopidine alone versus ticlopidine plus aspirin for preventing recurrent stroke.
Topics: Adult; Aged; Aspirin; Cerebral Infarction; Drug Therapy, Combination; Female; Humans; Ischemic Attac | 2003 |
Serial urinary 11-dehydrothromboxane B2, aspirin dose, and vascular events in blacks after recent cerebral infarction.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Black People; Cerebral Infarction; Dose-Response R | 2004 |
Leukocyte count as an independent predictor of recurrent ischemic events.
Topics: Aspirin; Biomarkers; Brain Ischemia; Cause of Death; Clopidogrel; Female; Humans; Inflammation; Leuk | 2004 |
Does pre-treatment with aspirin and loading dose clopidogrel obviate the need for glycoprotein IIb/IIIa antagonists during elective coronary stenting? A focus on peri-procedural myonecrosis.
Topics: Abciximab; Aged; Antibodies, Monoclonal; Aspirin; Clopidogrel; Coronary Angiography; Coronary Diseas | 2005 |
Prospective randomized comparison of early and late results of a carbonized stent versus a high-grade stainless steel stent of identical design: the PREVENT Trial [corrected].
Topics: Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Biocompatibl | 2005 |
A randomized trial comparing clopidogrel versus ticlopidine therapy in patients undergoing infarct artery stenting for acute myocardial infarction with abciximab as adjunctive therapy.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Anti-Inflammatory Agents, Non-Steroidal; Antibodies | 2005 |
Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Bypass; Coronary Dise | 2005 |
Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Electrocardiography; F | 2006 |
Comparison of three-year clinical outcome of sirolimus- and paclitaxel-eluting stents versus bare metal stents in patients with ST-segment elevation myocardial infarction (from the RESEARCH and T-SEARCH Registries).
Topics: Angioplasty, Balloon, Coronary; Cause of Death; Clopidogrel; Cohort Studies; Coronary Restenosis; El | 2007 |
Prevalence of platelet nonresponsiveness to aspirin in patients treated for secondary stroke prophylaxis and in patients with recurrent ischemic events.
Topics: Age Factors; Aged; Anti-Inflammatory Agents; Arachidonic Acid; Aspirin; Blood Platelets; Clopidogrel | 2008 |
Residual prothrombotic status in low responder patients to clopidogrel identified by Vasodilator-Stimulated Phosphoprotein Phosphorylation (VASP) analysis?
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Aged, 80 and over; Biomarkers; Blood Platelets | 2008 |
[Aftercare of heart infarct patients to reduce the risk of a subsequent infarction].
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Clinical Trials as Top | 1983 |
Comparison of symptomatic and asymptomatic reinfarctions after small subcortical stroke.
Topics: Aged; Aspirin; Cerebral Angiography; Cerebral Infarction; Cholesterol, HDL; Female; Fibrinogen; Foll | 1994 |
[Ticlopidine may prevent subtotal or total occlusion of dilated lesions after percutaneous coronary angioplasty].
Topics: Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Disease; Drug Therapy, Combination; F | 1993 |
Coronary stent placement in patients with acute myocardial infarction: comparison of clinical and angiographic outcome after randomization to antiplatelet or anticoagulant therapy.
Topics: Anticoagulants; Aspirin; Coronary Angiography; Coronary Disease; Female; Follow-Up Studies; Heparin; | 1997 |
Aspirin plus either dipyridamole or ticlopidine is effective in preventing recurrent myocardial infarction. Secondary Prevention Group.
Topics: Aged; Aspirin; Dipyridamole; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Mid | 1997 |
Major benefit from antiplatelet therapy for patients at high risk for adverse cardiac events after coronary Palmaz-Schatz stent placement: analysis of a prospective risk stratification protocol in the Intracoronary Stenting and Antithrombotic Regimen (ISA
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Cardiovascular Diseases; Combined Modality | 1997 |
Coronary stenting after rotational atherectomy in calcified and complex lesions. Angiographic and clinical follow-up results.
Topics: Aged; Aspirin; Atherectomy, Coronary; Calcinosis; Coronary Angiography; Coronary Disease; Coronary T | 1997 |
Coronary stenting after rotational atherectomy in calcified and complex lesions. Angiographic and clinical follow-up results.
Topics: Aged; Aspirin; Atherectomy, Coronary; Calcinosis; Coronary Angiography; Coronary Disease; Coronary T | 1997 |
Coronary stenting after rotational atherectomy in calcified and complex lesions. Angiographic and clinical follow-up results.
Topics: Aged; Aspirin; Atherectomy, Coronary; Calcinosis; Coronary Angiography; Coronary Disease; Coronary T | 1997 |
Coronary stenting after rotational atherectomy in calcified and complex lesions. Angiographic and clinical follow-up results.
Topics: Aged; Aspirin; Atherectomy, Coronary; Calcinosis; Coronary Angiography; Coronary Disease; Coronary T | 1997 |
Restenosis after coronary stent placement and randomization to a 4-week combined antiplatelet or anticoagulant therapy: six-month angiographic follow-up of the Intracoronary Stenting and Antithrombotic Regimen (ISAR) Trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon; Anticoagulants; Coronary Angiography; Coronary Dis | 1997 |
[Immediate and long-term clinical and angiographic results of the Wiktor stent in the treatment of chronic coronary occlusions].
Topics: Analysis of Variance; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Chronic Disease; Coro | 1997 |
Wiktor stent for treatment of chronic total coronary artery occlusions: short- and long-term clinical and angiographic results from a large multicenter experience.
Topics: Analysis of Variance; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Catheterization, Peri | 1998 |
PAMI (Primary Angioplasty in Myocardial Infarction) Stent Pilot Trial.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Drug Therapy, Combination; Follow-Up Studies; Humans; Myoca | 1998 |
Clinical outcome at six months of coronary stenting followed by ticlopidine monotherapy.
Topics: Adult; Aged; Aged, 80 and over; Coronary Angiography; Coronary Thrombosis; Coronary Vessels; Electro | 1998 |
The results of CAPRIE, IST and CAST. Clopidogrel vs. Aspirin in Patients at Risk of Ischaemic Events. International Stroke Trial. Chinese Acute Stroke Trial.
Topics: Aspirin; Cerebrovascular Disorders; Clopidogrel; Double-Blind Method; Humans; Ischemia; Myocardial I | 1998 |
Advances in post stenting medication protocol.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Disease; Drug Therapy, Combination | 1995 |
Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Combined Modality Therapy; Corona | 1999 |
Clopidogrel-rt-PA-heparin combination in the treatment of acute myocardial infarction.
Topics: Administration, Oral; Adult; Aged; Clopidogrel; Drug Therapy, Combination; Female; Fibrinolytic Agen | 1999 |
Comparison of cilostazol versus ticlopidine therapy after stent implantation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Coronary Disease; Coronary Thrombo | 1999 |
Changes in levels of factor VII and protein S after acute myocardial infarction: effects of low-dose warfarin.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antigens; Aspirin; Brain Ischemia; Death, Sudden, Ca | 1999 |
Usefulness of cilostazol versus ticlopidine in coronary artery stenting.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Cilostazol; Coronary Angiograp | 1999 |
Chest pain--a strong predictor of adverse cardiac events following precutaneous intervention (from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Trial [EPISENT])].
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Chest Pain; Corona | 1999 |
A randomized comparison of elective high-pressure stenting with balloon angioplasty: six-month angiographic and two-year clinical follow-up. On behalf of AS (Angioplasty or Stent) trial investigators.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Coronary Angiography; Coronary D | 2000 |
Effects of cilostazol on angiographic restenosis after coronary stent placement.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Coronary Angiography; Coronary Disease; Disease | 2000 |
Effects of cilostazol on late lumen loss and repeat revascularization after Palmaz-Schatz coronary stent implantation.
Topics: Cilostazol; Coronary Disease; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multivariate Ana | 2001 |
Comparison of effects of clopidogrel versus ticlopidine on platelet function in patients undergoing coronary stent placement.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Dose- | 2001 |
Sustained benefit over four years from an initial combined antiplatelet regimen after coronary stent placement in the ISAR trial. Intracoronary Stenting and Antithrombotic Regimen.
Topics: Angioplasty, Balloon; Anticoagulants; Aspirin; Coronary Angiography; Coronary Disease; Drug Therapy, | 2001 |
Ticlopidine versus aspirin after myocardial infarction (STAMI) trial.
Topics: Adult; Aged; Aspirin; Cause of Death; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; | 2001 |
Insights from CURE: using clopidogrel on top of standard therapy.
Topics: Aged; Angina, Unstable; Aspirin; Clopidogrel; Double-Blind Method; Female; Follow-Up Studies; Hepari | 2002 |
Cessation of embolic signals after antithrombotic prevention is related to reduced risk of recurrent arterioembolic transient ischaemic attack and stroke.
Topics: Aged; Aspirin; Clopidogrel; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Intracranial Emb | 2002 |
Late vascular response to repeat stenting for in-stent restenosis with and without radiation: an intravascular ultrasound volumetric analysis.
Topics: Blood Vessel Prosthesis Implantation; Brachytherapy; Cohort Studies; Coronary Restenosis; Disease Pr | 2002 |
Ticlopidine versus aspirin for the prevention of recurrent stroke. Analysis of patients with minor stroke from the Ticlopidine Aspirin Stroke Study.
Topics: Adult; Aspirin; Cerebrovascular Disorders; Diarrhea; Double-Blind Method; Female; Humans; Male; Midd | 1992 |
Ticlopidine, a new anti-thrombotic drug.
Topics: Aspirin; Dipyridamole; Humans; Intracranial Embolism and Thrombosis; Long-Term Care; Recurrence; Tic | 1991 |
The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke.
Topics: Aged; Canada; Cause of Death; Cerebrovascular Disorders; Cohort Studies; Drug Administration Schedul | 1989 |
[Ticlopidine in the prevention of cerebral ischemia. Experience with a geriatric case load].
Topics: Aged; Aged, 80 and over; Brain Ischemia; Clinical Trials as Topic; Double-Blind Method; Drug Evaluat | 1988 |
205 other studies available for ticlopidine and Recrudescence
| Article | Year |
|---|---|
Clinical and Pharmacological Parameters Determine Relapse During Clopidogrel Treatment of Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Calcium Channel Blockers; Clopidogrel; Coronary Artery Disease; Cy | 2022 |
CSPS.com Trial of Adding Cilostazol to Antiplatelet Therapy to Reduce Recurrent Stroke.
Topics: Aspirin; Cerebral Infarction; Cilostazol; Drug Therapy, Combination; Female; Humans; Male; Middle Ag | 2020 |
Efficacy of aspirin, clopidogrel, and ticlopidine in stroke prevention: A population-based case-cohort study in Taiwan.
Topics: Adult; Aged; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Female; Humans; Male; Middle Aged | 2020 |
Balancing Benefits and Risks of Long-Term Antiplatelet Therapy in Noncardioembolic Transient Ischemic Attack or Stroke.
Topics: Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Humans; Intracranial Hemorrhages; Isc | 2021 |
The association between high on-treatment platelet reactivity and early recurrence of ischemic events after minor stroke or TIA.
Topics: Adult; Aged; Aspirin; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Humans; Ischem | 2017 |
Relationship Between Arterial Access and Outcomes in ST-Elevation Myocardial Infarction With a Pharmacoinvasive Versus Primary Percutaneous Coronary Intervention Strategy: Insights From the STrategic Reperfusion Early After Myocardial Infarction (STREAM)
Topics: Aged; Aspirin; Catheterization, Peripheral; Clopidogrel; Coronary Angiography; Enoxaparin; Female; F | 2016 |
Platelet distribution width as the prognostic marker in coronary bifurcation treatment.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Female; H | 2017 |
Repetitive stent thrombosis in a patient with suspected allergy to aspirin and multiple switch between clopidogrel, prasugrel, and ticagrelor.
Topics: Adenosine; Aspirin; Clopidogrel; Coronary Vessels; Drug Hypersensitivity; Humans; Male; Middle Aged; | 2017 |
Safety and Efficacy of a 600-mg Loading Dose of Clopidogrel 24 Hours Before Pipeline Embolization Device Treatment.
Topics: Clopidogrel; Embolization, Therapeutic; Female; Follow-Up Studies; Humans; Intracranial Aneurysm; Ma | 2017 |
High On-Treatment Platelet Reactivity to Adenosine Diphosphate Predicts Ischemic Events of Minor Stroke and Transient Ischemic Attack.
Topics: Adenosine Diphosphate; Adult; Aged; Aspirin; Blood Platelets; Brain Ischemia; Clopidogrel; Drug Resi | 2017 |
Aspirin Versus Clopidogrel for Type 2 Diabetic Patients with First-Ever Noncardioembolic Acute Ischemic Stroke: Ten-Year Survival Data from the Athens Stroke Outcome Project.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Chi-Square Distribution; Clopidogrel; Diabetes Mel | 2017 |
Association between platelet function and recurrent ischemic vascular events after TIA and minor stroke
.
Topics: Alleles; Aspirin; Blood Coagulation Tests; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; F | 2017 |
Isolated left ventricular non-compaction (LVNC) and recurrent strokes: to anticoagulate or not to anticoagulate, that is the question.
Topics: Aged; Anticoagulants; Aspirin; Clopidogrel; Diagnosis, Differential; Humans; Isolated Noncompaction | 2017 |
Clinical characteristics and outcomes of patients with coronary artery spasm who initially presented with acute myocardial infarction.
Topics: Adult; Aged; Angina Pectoris; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Dise | 2018 |
CYP2C19 and ABCB1 genetic polymorphisms correlate with the recurrence of ischemic cardiovascular adverse events after clopidogrel treatment.
Topics: Aged; Analysis of Variance; ATP Binding Cassette Transporter, Subfamily B; Clopidogrel; Coronary Dis | 2018 |
Prevention of recurrent venous thrombosis and post-thrombotic syndrome.
Topics: Aspirin; Drug Therapy, Combination; Female; Fibrinolytic Agents; Flavonoids; Glycosaminoglycans; Hum | 2018 |
Secondary Stroke Prophylaxis with Clopidogrel Produces Sufficient Antiplatelet Response.
Topics: Aged; Clopidogrel; Denmark; Drug Resistance; Female; Humans; Ischemic Attack, Transient; Male; Medic | 2018 |
Recurrent retinal vein thrombosis: prevention with Aspirin, Pycnogenol®, ticlopidine, or sulodexide.
Topics: Adult; Aspirin; Female; Fibrinolytic Agents; Flavonoids; Glycosaminoglycans; Humans; Incidence; Male | 2019 |
[3-year follow-up after endovascular aneurysm treatment with Silk® flow diverter].
Topics: Adult; Aged; Aspirin; Cerebral Angiography; Clopidogrel; Embolization, Therapeutic; Equipment Design | 2013 |
Abciximab bolus with optional infusion in intervention for ST-elevation myocardial infarction.
Topics: Abciximab; Aged; Aged, 80 and over; Antibodies, Monoclonal; Clopidogrel; Coronary Thrombosis; Cost S | 2013 |
Reduced clopidogrel metabolism in a multiethnic population: prevalence and rates of recurrent cerebrovascular events.
Topics: Aryl Hydrocarbon Hydroxylases; Cerebrovascular Disorders; Clopidogrel; Cytochrome P-450 CYP2C19; Dru | 2014 |
Duration of dual antiplatelet treatment with clopidogrel and aspirin in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; | 2014 |
Simultaneous intrahepatic and subgaleal hemorrhage in antiphospholipid syndrome following anticoagulation therapy.
Topics: Adolescent; Anticoagulants; Antiphospholipid Syndrome; Chemical and Drug Induced Liver Injury; Clopi | 2013 |
Thrombotic aortic restenosis after transapical SAPIEN valve implantation.
Topics: Aged, 80 and over; Anticoagulants; Aortic Valve Stenosis; Aspirin; Bioprosthesis; Clopidogrel; Echoc | 2014 |
Residual thrombin generation potential is inversely linked to the occurrence of atherothrombotic events in patients with peripheral arterial disease.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Blood Platelets; Cardiovascular Diseases; Clopidogrel | 2014 |
[Rescue treatment in acute thrombosis of intracranial stents].
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Basilar Artery; Capillary Permeability; Cerebral Angiogr | 2014 |
Secondary prevention of atherothrombotic or cryptogenic stroke.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Clopidogrel; Drug Th | 2014 |
Positive clinical response to clopidogrel is independent of paraoxonase 1 Q192R and CYP2C19 genetic variants.
Topics: Aged; Alleles; Angina Pectoris; Aryldialkylphosphatase; Aspirin; Clopidogrel; Cohort Studies; Corona | 2014 |
[Effect of drug interaction between clopidogrel and omeprazole in hospital readmision of patients by a recurrent acute coronary syndrome: a case-control study].
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Case-Control Studies; Clopidogrel; Drug Interactio | 2014 |
Effectiveness and safety of antiplatelet in stroke patients with end-stage renal disease undergoing dialysis.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate | 2014 |
Pharmacologic strategy for one repeated stent thrombosis patient with hyporesponsiveness to standard dual antiplatelet therapy.
Topics: Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Electrocardiography; Huma | 2015 |
Early ambulance initiation versus in-hospital initiation of high dose clopidogrel in ST-segment elevation myocardial infarction.
Topics: Aged; Clopidogrel; Cohort Studies; Electrocardiography; Emergency Medical Services; Emergency Servic | 2014 |
In-hospital switching between clopidogrel and prasugrel among patients with acute myocardial infarction treated with percutaneous coronary intervention: insights into contemporary practice from the national cardiovascular data registry.
Topics: Acute Disease; Age Factors; Aged; Clopidogrel; Drug Substitution; Female; Humans; Male; Middle Aged; | 2014 |
Benefit of clopidogrel therapy in patients with myocardial infarction and chronic kidney disease-a Danish nation-wide cohort study.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Case-Control Studies; Clopidogrel; Cohort Studies; | 2014 |
Prasugrel vs clopidogrel in cardiogenic shock patients undergoing primary PCI for acute myocardial infarction. Results of the ISAR-SHOCK registry.
Topics: Aged; Aged, 80 and over; Blood Platelets; Clopidogrel; Coronary Thrombosis; Female; Germany; Hemorrh | 2014 |
Variant recurrent risk among stroke patients with different CYP2C19 phenotypes and treated with clopidogrel.
Topics: Aged; Alleles; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Gene Frequency; Genotype; Humans; Male | 2015 |
Endovascular treatment of internal carotid artery pseudo-aneurysm presenting with epistaxis. A case report.
Topics: Angiography, Digital Subtraction; Aspirin; Carotid Artery Injuries; Carotid Artery, Internal; Clopid | 2014 |
CYP2C19 genotype and early ischemic lesion recurrence in stroke patients treated with clopidogrel.
Topics: Aged; Asian People; Brain; Brain Ischemia; Clopidogrel; Cytochrome P-450 CYP2C19; Diffusion Magnetic | 2015 |
Diversity of platelet function and genetic polymorphism in clopidogrel-treated Chinese patients.
Topics: Adenosine Diphosphate; Adult; Aged; Alleles; Blood Coagulation; Blood Platelets; China; Clopidogrel; | 2015 |
A case of repetitive and simultaneous stent thromboses.
Topics: Coronary Angiography; Coronary Thrombosis; Diagnosis, Differential; Electrocardiography; Graft Occlu | 2015 |
CYP2C19 LOF alleles confer no risk for HTPR but higher risk for recurrent ischemic events in clopidogrel treated elderly ACS patients.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Aged, 80 and over; Alleles; Blood Platelets; Clopidogrel | 2015 |
A population-based study of the drug interaction between clopidogrel and angiotensin converting enzyme inhibitors.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Case-Control Studies; Clopidogrel; Databases, Factua | 2015 |
Cytochrome P450 CYP 2C19*2 Associated with Adverse 1-Year Cardiovascular Events in Patients with Acute Coronary Syndrome.
Topics: Activation, Metabolic; Acute Coronary Syndrome; Aged; Alleles; Angina Pectoris; Aspirin; Clopidogrel | 2015 |
Dual Antiplatelet Therapy Prior to Expedited Carotid Surgery Reduces Recurrent Events Prior to Surgery without Significantly Increasing Peri-operative Bleeding Complications.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Loss, Surgical; Carotid Stenosis; Clopidogrel; Drug A | 2015 |
Successful Prasugrel Therapy for Recurrent Left Main Stent Thrombosis in a Clopidogrel Hyporesponder.
Topics: Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Thrombosis; Drug Resis | 2015 |
Comparison of antiplatelet regimens in secondary stroke prevention: a nationwide cohort study.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Clopidogrel; Cohort Studies; | 2015 |
[Association of CYP2C19 gene polymorphisms with long-term recurrent risk of ischemic stroke among ethnic Han Chinese from Fujian].
Topics: Aged; Alleles; Asian People; Brain Ischemia; China; Clopidogrel; Cytochrome P-450 CYP2C19; Female; G | 2015 |
Successful Management of Recurrent Colon Ulcer in Hemodialysis Patient after Conversion to Peritoneal Dialysis.
Topics: Aspirin; Colon; Colonic Diseases; Colonoscopy; Drug Therapy, Combination; Gastrointestinal Hemorrhag | 2015 |
Clopidogrel Versus Aspirin as an Antiplatelet Monotherapy After 12-Month Dual-Antiplatelet Therapy in the Era of Drug-Eluting Stents.
Topics: Aged; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug-Eluting Stents; Female; Humans; I | 2016 |
Risk of early recurrent stroke in symptomatic carotid stenosis after best medical therapy and before endarterectomy.
Topics: Aged; Aged, 80 and over; Aspirin; Carotid Arteries; Carotid Stenosis; Clopidogrel; Endarterectomy, C | 2016 |
Continuation and adherence rates on initially-prescribed intensive secondary prevention therapy after Rapid Access Stroke Prevention (RASP) service assessment.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Brain Ischemia; Clopidogrel; Dipyr | 2016 |
Clopidogrel Resistance Increases Rate of Recurrent Stroke and Other Vascular Events in Chinese Population.
Topics: Aged; Aged, 80 and over; Asian People; Chi-Square Distribution; China; Clopidogrel; Disability Evalu | 2016 |
TRAF3 Epigenetic Regulation Is Associated With Vascular Recurrence in Patients With Ischemic Stroke.
Topics: Aged; Aged, 80 and over; Brain Ischemia; Clopidogrel; CpG Islands; DNA Methylation; Epigenesis, Gene | 2016 |
Proton pump inhibitors and other disease-based factors in the recurrence of adverse cardiovascular events following percutaneous coronary angiography: A long-term cohort.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Cohort Studies; Drug Combinations; Female; Foll | 2016 |
High on-treatment platelet reactivity and outcomes after percutaneous endovascular procedures in patients with peripheral artery disease.
Topics: Aged; Aspirin; Blood Platelets; Chi-Square Distribution; Clopidogrel; Drug Resistance; Drug Therapy, | 2016 |
[After the first stroke, acetylsalicylic acid is no longer enough].
Topics: Aged; Aspirin; Clopidogrel; Drug Substitution; Drug Therapy, Combination; Humans; Recurrence; Stroke | 2016 |
Complication of Stenting in Intracranial Arterial Stenosis.
Topics: Age Factors; Aged; Angioplasty; Aspirin; China; Clopidogrel; Computed Tomography Angiography; Constr | 2016 |
Interaction of CYP2C19, P2Y12, and GPIIIa Variants Associates With Efficacy of Clopidogrel and Adverse Events on Patients With Ischemic Stroke.
Topics: Aged; Aged, 80 and over; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genetic Variation; Humans; I | 2017 |
[Retrospective cohort study for the impact on readmission of patients with ischemic stroke after treatment of aspirin plus clopidogrel or aspirin mono-therapy].
Topics: Aspirin; Beijing; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; | 2016 |
High-Sensitive C-Reactive Protein Predicts Recurrent Stroke and Poor Functional Outcome: Subanalysis of the Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events Trial.
Topics: Aged; Aspirin; C-Reactive Protein; Clopidogrel; Drug Therapy, Combination; Female; Humans; Incidence | 2016 |
Concomitant Use of Proton Pump Inhibitors and Clopidogrel Is Not Associated with Adverse Outcomes after Ischemic Stroke in Chinese Population.
Topics: Aged; Aged, 80 and over; Brain Ischemia; China; Clopidogrel; Cytochrome P-450 CYP2C19; Cytochrome P- | 2016 |
Early Cessation of Adenosine Diphosphate Receptor Inhibitors Among Acute Myocardial Infarction Patients Treated With Percutaneous Coronary Intervention: Insights From the TRANSLATE-ACS Study (Treatment With Adenosine Diphosphate Receptor Inhibitors: Longi
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Drug Administration Schedule; Drug Costs; Female; Health | 2016 |
Impact of Proton Pump Inhibitor Use on the Comparative Effectiveness and Safety of Prasugrel Versus Clopidogrel: Insights From the Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acu
Topics: Acute Coronary Syndrome; Aftercare; Aged; Cardiovascular Diseases; Clopidogrel; Comparative Effectiv | 2016 |
Platelet reactivity in human immunodeficiency virus infected patients on dual antiplatelet therapy for an acute coronary syndrome: the EVERE2ST-HIV study.
Topics: Acute Coronary Syndrome; Adenosine; Anti-HIV Agents; Aspirin; Blood Platelets; Clopidogrel; Cross-Se | 2017 |
Clopidogrel and ischemic stroke outcomes by smoking status: Smoker's paradox?
Topics: Aspirin; Brain Ischemia; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Plat | 2017 |
Poor adherence to P2Y12 antagonists increased cardiovascular risks in Chinese PCI-treated patients.
Topics: Acute Coronary Syndrome; Adenosine; Aged; China; Clopidogrel; Coronary Artery Bypass; Female; Follow | 2017 |
Clopidogrel, prasugrel, or ticagrelor use and clinical outcome in patients with acute coronary syndrome: A nationwide long-term registry analysis from 2009 to 2014.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Austria; Clopidogrel; Drug Therapy, Combination; | 2017 |
Association of genetic variant and platelet function in patients undergoing neuroendovascular stenting.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Aspirin; Brain Ischemia; Clopidogrel; Female; Genetic Varia | 2017 |
[Secondary stroke prevention according to the PRoFESS Study. What are the sequelae for practical therapy?].
Topics: Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Germany; Humans; Multicenter Studies | 2008 |
Reversible clopidogrel resistance due to right ventricular myocardial infarction: risk factor of recurrent stent thrombosis?
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug R | 2008 |
Secondary stroke prevention with antiplatelet drugs: have we reached the ceiling?
Topics: Age Factors; Aged; Aspirin; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Drug Therapy, Combi | 2006 |
Recurrent myocardial infarction in a young football player with antithrombin III deficiency.
Topics: Angioplasty, Balloon, Coronary; Antithrombin III Deficiency; Clopidogrel; Coronary Angiography; Drug | 2008 |
ExTRACT-TIMI 25 in perspective: key lessons regarding enoxaparin as an adjunct to fibrinolytic therapy.
Topics: Aged; Anticoagulants; Clopidogrel; Combined Modality Therapy; Comorbidity; Disease-Free Survival; Dr | 2009 |
Cardiovascular outcomes after a change in prescription policy for clopidogrel.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Co | 2008 |
[Recurrent idiopathic cerebral infarction in a 5-year-old boy, with emphasis on the importance of platelet aggregation analysis for appropriate selection of anti-platelet drugs].
Topics: Adenosine Diphosphate; Aspirin; Blood Coagulation Tests; Cerebral Infarction; Child, Preschool; Cilo | 2009 |
A population-based study of the drug interaction between proton pump inhibitors and clopidogrel.
Topics: Age Distribution; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Case-Control Studies; Clo | 2009 |
A population-based study of the drug interaction between proton pump inhibitors and clopidogrel.
Topics: Age Distribution; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Case-Control Studies; Clo | 2009 |
A population-based study of the drug interaction between proton pump inhibitors and clopidogrel.
Topics: Age Distribution; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Case-Control Studies; Clo | 2009 |
A population-based study of the drug interaction between proton pump inhibitors and clopidogrel.
Topics: Age Distribution; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Case-Control Studies; Clo | 2009 |
A population-based study of the drug interaction between proton pump inhibitors and clopidogrel.
Topics: Age Distribution; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Case-Control Studies; Clo | 2009 |
A population-based study of the drug interaction between proton pump inhibitors and clopidogrel.
Topics: Age Distribution; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Case-Control Studies; Clo | 2009 |
A population-based study of the drug interaction between proton pump inhibitors and clopidogrel.
Topics: Age Distribution; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Case-Control Studies; Clo | 2009 |
A population-based study of the drug interaction between proton pump inhibitors and clopidogrel.
Topics: Age Distribution; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Case-Control Studies; Clo | 2009 |
A population-based study of the drug interaction between proton pump inhibitors and clopidogrel.
Topics: Age Distribution; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Case-Control Studies; Clo | 2009 |
Prognosis of patients suffering an acute coronary syndrome while already under chronic clopidogrel therapy.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2009 |
Headache and visual symptoms in two patients with MRI alterations in posterior cerebral artery territory.
Topics: Acute Disease; Adult; Aged; Anticoagulants; Clopidogrel; Diagnosis, Differential; Diffusion Magnetic | 2009 |
Acknowledging a failed strategy.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogr | 2009 |
Clopidogrel. More on proton pump inhibitors.
Topics: Clopidogrel; Drug Combinations; Humans; Myocardial Infarction; Proton Pump Inhibitors; Recurrence; R | 2009 |
Clopidogrel. Patients with peptic ulcers.
Topics: Aspirin; Clopidogrel; Histamine H2 Antagonists; Humans; Peptic Ulcer Hemorrhage; Platelet Aggregatio | 2009 |
Retinal artery embolization during carotid angioplasty and carotid artery stenting: case report.
Topics: Aged; Angioplasty, Balloon; Anticoagulants; Antipyrine; Aspirin; Carotid Artery, External; Carotid S | 2009 |
Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogr | 2009 |
Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data.
Topics: Adult; Aged; Aspirin; Clopidogrel; Denmark; Drug Therapy, Combination; Female; Follow-Up Studies; He | 2009 |
Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data.
Topics: Adult; Aged; Aspirin; Clopidogrel; Denmark; Drug Therapy, Combination; Female; Follow-Up Studies; He | 2009 |
Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data.
Topics: Adult; Aged; Aspirin; Clopidogrel; Denmark; Drug Therapy, Combination; Female; Follow-Up Studies; He | 2009 |
Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data.
Topics: Adult; Aged; Aspirin; Clopidogrel; Denmark; Drug Therapy, Combination; Female; Follow-Up Studies; He | 2009 |
Long-term results of carotid artery stents to manage symptomatic carotid artery stenosis and factors that affect outcome.
Topics: Adult; Aged; Aged, 80 and over; Blood Vessel Prosthesis Implantation; Carotid Stenosis; Chemotherapy | 2010 |
Impact of persistence with antiplatelet therapy on recurrent ischemic stroke and predictors of nonpersistence among ischemic stroke survivors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Fema | 2010 |
Cost-effectiveness analysis of short-term clopidogrel therapy for ST elevation myocardial infarction.
Topics: Adolescent; Adult; Aged; Clopidogrel; Cost-Benefit Analysis; Diagnosis-Related Groups; Female; Hospi | 2010 |
Recurrence of acute myocardial infarction in patients discharged on clopidogrel and a proton pump inhibitor after stent placement for acute myocardial infarction.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Angioplasty, Balloon, Coronary; Anti-Ulcer Agents; Clopidog | 2010 |
[Recurrent stent thrombosis in a patient with non-ST-segment elevation acute coronary syndrome].
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Drug Resistance; El | 2010 |
Low risk of rebound events after a short course of clopidogrel in acute TIA or minor stroke.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Humans; Ischemic A | 2010 |
Recurrent acute stent thrombosis due to allergic reaction secondary to clopidogrel therapy.
Topics: Acute Disease; Adult; Clopidogrel; Coronary Thrombosis; Drug Hypersensitivity; Humans; Male; Platele | 2011 |
Adjunctive treatment with ticagrelor, but not clopidogrel, added to tPA enables sustained coronary artery recanalisation with recovery of myocardium perfusion in a canine coronary thrombosis model.
Topics: Adenosine; Animals; Bleeding Time; Blood Coagulation; Clopidogrel; Coronary Circulation; Coronary Th | 2010 |
Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events.
Topics: Aged; Alleles; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Biotransformation; Car | 2010 |
Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study.
Topics: Adult; Cardiovascular Diseases; Clopidogrel; Cohort Studies; Drug Interactions; Drug Therapy, Combin | 2010 |
Risk of recurrent myocardial infarction with the concomitant use of clopidogrel and proton pump inhibitors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Case-Control Studies; Clopidogrel; Combined Modality The | 2011 |
Ischaemic stroke--prevention is better than cure.
Topics: Adult; Age Factors; Aged; Anticoagulants; Antihypertensive Agents; Aspirin; Atrial Fibrillation; Blo | 2010 |
What is the optimal duration of triple anti-platelet therapy in patients with acute myocardial infarction undergoing drug-eluting stent implantation?
Topics: Aspirin; Cilostazol; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Female; Follow-Up Studie | 2011 |
Recurrent episodes of very late stent thrombosis in a patient with aspirin hypersensitivity, stent fracture and malapposition.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Occlusion; Coronary Thrombosis; Drug | 2011 |
Relapsed spontaneous spinal epidural hematoma associated with aspirin and clopidogrel.
Topics: Aspirin; Clopidogrel; Hematoma, Epidural, Spinal; Humans; Magnetic Resonance Imaging; Male; Middle A | 2011 |
[Beyond coronary artery disease: interventional approach to carotid occlusive disease].
Topics: Aged; Aged, 80 and over; Angioplasty; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carotid Arte | 2010 |
[Intracerebral hemorrhage in anticoagulated patients: what do we do afterwards?].
Topics: Aged; Anticoagulants; Aspirin; Cerebral Hemorrhage; Clopidogrel; Female; Follow-Up Studies; Humans; | 2012 |
Massive thrombus burden with recurrence of intracoronary thrombosis early after stenting and delayed onset of prasugrel action in a patient with ST-elevation myocardial infarction and cardiac shock.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiopulmonary Resuscitation; Catecholamines; Clopidogrel; Co | 2011 |
Patent foramen ovale may be causal for the first stroke but unrelated to subsequent ischemic events.
Topics: Adult; Aged; Aspirin; Brain Ischemia; Clopidogrel; Female; Follow-Up Studies; Foramen Ovale, Patent; | 2011 |
Relationship between cardiovascular outcomes and proton pump inhibitor use in patients receiving dual antiplatelet therapy after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aryl Hydrocarbon Hydroxylases; Aspirin; Cardiovascular Diseases; Clop | 2011 |
Comparison of platelet reactivity and clopidogrel response in patients ≤ 75 Years Versus > 75 years undergoing percutaneous coronary intervention for non-ST-segment elevation acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Age Factors; Aged; Aged, 80 and over; Angioplasty, B | 2011 |
Safety and efficacy of a pharmaco-invasive reperfusion strategy in rural ST-elevation myocardial infarction patients with expected delays due to long-distance transfers.
Topics: Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Emergency T | 2012 |
The HEART study: a real-world experience using the CID Chrono Carbostent in primary and rescue PCI.
Topics: Aged; Aspirin; Chi-Square Distribution; Chromium Alloys; Clopidogrel; Coated Materials, Biocompatibl | 2012 |
Level of systolic blood pressure within the normal range and risk of recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Blood Pressure; | 2011 |
Level of systolic blood pressure within the normal range and risk of recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Blood Pressure; | 2011 |
Level of systolic blood pressure within the normal range and risk of recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Blood Pressure; | 2011 |
Level of systolic blood pressure within the normal range and risk of recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Blood Pressure; | 2011 |
Clopidogrel discontinuation after myocardial infarction and risk of thrombosis: a nationwide cohort study.
Topics: Adult; Aged; Clopidogrel; Denmark; Drug Administration Schedule; Epidemiologic Methods; Female; Graf | 2012 |
Side effects of proton pump inhibitors.
Topics: Clopidogrel; Diarrhea; Drug Interactions; Gastroesophageal Reflux; Hip Fractures; Humans; Platelet A | 2012 |
Treatment of blood blister-like aneurysms of the internal carotid artery with stent-assisted coil embolization.
Topics: Aspirin; Carotid Artery Diseases; Carotid Artery, Internal; Cerebral Angiography; Clopidogrel; Embol | 2013 |
Antidepressant use, serotonin transporter affinity, and reinfarction among patients receiving clopidogrel: a population-based study.
Topics: Acute Disease; Aged; Aged, 80 and over; Antidepressive Agents; Case-Control Studies; Clopidogrel; Fe | 2012 |
Effects of pre-hospital clopidogrel administration on early and late residual platelet reactivity in ST-segment elevation myocardial infarction patients undergoing primary intervention.
Topics: Aged; Belgium; Blood Platelets; Clopidogrel; Coronary Thrombosis; Drug Administration Schedule; Emer | 2013 |
Treatment of a pediatric recurrent fusiform middle cerebral artery (MCA) aneurysm with a flow diverter.
Topics: Adolescent; Aspirin; Cerebral Angiography; Clopidogrel; Embolization, Therapeutic; Humans; Intracran | 2012 |
Long-term results of plaque excision combined with aggressive pharmacotherapy in high-risk patients with advanced peripheral artery disease (SAVE a LEG registry).
Topics: Adult; Aged; Aged, 80 and over; Amputation, Surgical; Aspirin; Atherectomy; Atorvastatin; Cardiovasc | 2013 |
[Correlation between antiplatelet resistance and recurrent cardiac ischemic events of patients with acute myocardial infarction].
Topics: Aged; Aspirin; Clopidogrel; Drug Resistance; Electric Impedance; Female; Humans; Male; Middle Aged; | 2012 |
Ambulatory use of ticlopidine and clopidogrel in association with percutaneous coronary revascularization procedures in a national managed care organization.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Female; | 2002 |
[Long-term anticoagulation after bypass operation].
Topics: Arterial Occlusive Diseases; Aspirin; Clopidogrel; Humans; Long-Term Care; Platelet Aggregation Inhi | 2002 |
Ischaemic stroke in young people: a prospective and long-term follow-up study.
Topics: Acenocoumarol; Adolescent; Adult; Anticoagulants; Aspirin; Brain Ischemia; Disability Evaluation; Ec | 2003 |
Brachytherapy for renal artery in-stent restenosis.
Topics: Aged; Angioplasty, Balloon; Brachytherapy; Clopidogrel; Female; Humans; Platelet Aggregation Inhibit | 2003 |
[Anticoagulation and antiaggregation in neurological patients].
Topics: Acute Disease; Administration, Oral; Aged; Anticoagulants; Aspirin; Clinical Trials as Topic; Clopid | 2003 |
Use of restenting should be minimized with intracoronary radiation therapy for in-stent restenosis.
Topics: Brachytherapy; Chi-Square Distribution; Clopidogrel; Coronary Restenosis; Female; Humans; Male; Midd | 2003 |
Brachytherapy for in-stent restenosis: the problem is one of commitment.
Topics: Brachytherapy; Clopidogrel; Coronary Restenosis; Humans; Platelet Aggregation Inhibitors; Recurrence | 2003 |
High incidence of clopidogrel-associated gastrointestinal bleeding in patients with previous peptic ulcer disease.
Topics: Aged; Aspirin; Clopidogrel; Cohort Studies; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; | 2003 |
High incidence of clopidogrel-associated gastrointestinal bleeding in patients with previous peptic ulcer disease.
Topics: Aged; Aspirin; Clopidogrel; Cohort Studies; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; | 2003 |
High incidence of clopidogrel-associated gastrointestinal bleeding in patients with previous peptic ulcer disease.
Topics: Aged; Aspirin; Clopidogrel; Cohort Studies; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; | 2003 |
High incidence of clopidogrel-associated gastrointestinal bleeding in patients with previous peptic ulcer disease.
Topics: Aged; Aspirin; Clopidogrel; Cohort Studies; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; | 2003 |
[PRoFESS study presented. Change in secondary prevention].
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Aspirin, Dipyridamole Drug Combination; Benzimida | 2003 |
Regression of collateral function after recanalization of chronic total coronary occlusions: a serial assessment by intracoronary pressure and Doppler recordings.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Collateral Circulation; | 2003 |
Clopidogrel-associated TTP: an update of pharmacovigilance efforts conducted by independent researchers, pharmaceutical suppliers, and the Food and Drug Administration.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Causality; Clopidogrel; Fem | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Different treatments and outcomes of consecutive patients with non-ST-elevation myocardial infarction depending on initial electrocardiographic changes (results of the Acute Coronary Syndromes [ACOS] Registry).
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converti | 2004 |
Clopidogrel resistance marks recurrent risks.
Topics: Aged; Bibliometrics; Cardiology; Clopidogrel; Cohort Studies; Coronary Restenosis; Drug Resistance; | 2004 |
[Clopidogrel protection is not increased further by ASS!].
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ische | 2004 |
Subacute coronary stent thrombosis in a patient developing clopidogrel associated thrombotic thrombocytopenic purpura.
Topics: Aged; Angina, Unstable; Blood Vessel Prosthesis; Clopidogrel; Coronary Restenosis; Coronary Stenosis | 2005 |
Long-term combination therapy with aspirin and clopidogrel.
Topics: Angina, Unstable; Arteriosclerosis; Aspirin; Clopidogrel; Cyclooxygenase Inhibitors; Double-Blind Me | 2004 |
A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone.
Topics: Angina, Unstable; Aspirin; Cardiovascular Diseases; Clopidogrel; Computer Simulation; Cost-Benefit A | 2005 |
Intralamellar haemorrhage 44 years following lamellar keratoplasty.
Topics: Blindness; Clopidogrel; Corneal Neovascularization; Corneal Transplantation; Eye Hemorrhage; Humans; | 2006 |
Treatment disparities in the care of patients with and without diabetes presenting with non-ST-segment elevation acute coronary syndromes.
Topics: Acute Disease; Adrenergic beta-Antagonists; Adult; Aspirin; Cardiac Catheterization; Clopidogrel; Co | 2006 |
Clinical, biochemical and genetical resistance to clopidogrel in a patient with the recurrent coronary stent thrombosis--a case report and review of the literature.
Topics: Aged; Clopidogrel; Coronary Angiography; Coronary Disease; Drug Resistance; Female; Humans; Platelet | 2006 |
Postoperative clopidogrel improves mid-term outcome after off-pump coronary artery bypass graft surgery: a prospective study.
Topics: Aged; Anticoagulants; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Bypass, Off-Pum | 2006 |
Recurrent arterial thromboses in a woman with heparin induced thrombocytopenia, successfully managed with iloprost followed by clopidogrel. An alternative therapeutic option for heparin induced thrombocytopenia type II syndrome.
Topics: Aged; Arterial Occlusive Diseases; Clopidogrel; Drug Therapy, Combination; Female; Fibrinolytic Agen | 2006 |
Suspected clopidogrel resistance in a patient with acute stent thrombosis.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Coronary Stenosis; Coronary | 2006 |
Combined aspirin and clopidogrel resistance associated with recurrent coronary stent thrombosis.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Rest | 2006 |
Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance.
Topics: Adenosine Diphosphate; Arachidonic Acid; Aspirin; Clopidogrel; Coronary Artery Disease; Cyclooxygena | 2006 |
[Recurrent hemoptysis following thienopyridines and amiodarone administration. therapeutic dilemma].
Topics: Aged; Amiodarone; Cardiovascular Agents; Clopidogrel; Coronary Disease; Drug Interactions; Drug Ther | 2005 |
[Gastroenterology in family practice. Updates for your "stomach patient"].
Topics: Anti-Ulcer Agents; Aspirin; Clopidogrel; Dyspepsia; Esophagitis, Peptic; Family Practice; Heartburn; | 2006 |
Clinical, biochemical and genetical resistance to clopidogrel in a patient with recurrent stent thrombosis.
Topics: Clopidogrel; Coronary Thrombosis; Dose-Response Relationship, Drug; Drug Monitoring; Drug Resistance | 2007 |
The significance of incomplete stent apposition in patients undergoing stenting of internal carotid artery stenosis.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Aspirin; Brain Ischemia; Carotid Arteries; Carotid St | 2006 |
Saddle embolism after corrective femoral osteotomy: a case report.
Topics: Arterial Occlusive Diseases; Atrial Fibrillation; Echocardiography, Transesophageal; Embolectomy; Em | 2006 |
Usefulness of clopidogrel in abolishing the increased risk of reinfarction associated with higher platelet counts in patients with ST-elevation myocardial infarction (results from CLARITY-TIMI 28).
Topics: Aged; Clopidogrel; Electrocardiography; Female; Humans; Male; Middle Aged; Myocardial Infarction; Pl | 2006 |
[Prevention of vascular events after transient ischemic attack or cerebral infarct].
Topics: Angioplasty, Balloon; Anticoagulants; Aspirin; Cerebral Infarction; Clopidogrel; Dipyridamole; Drug | 2006 |
Platelet function in patients with acute coronary syndrome (ACS) predicts recurrent ACS.
Topics: Acute Disease; Adrenergic beta-Antagonists; Aspirin; Clopidogrel; Coronary Disease; Diabetes Complic | 2006 |
Effectiveness and safety of glycoprotein IIb/IIIa inhibitors and clopidogrel alone and in combination in non-ST-segment elevation myocardial infarction (from the National Registry of Myocardial Infarction-4).
Topics: Aged; Aged, 80 and over; Analysis of Variance; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary | 2006 |
[Antiplatelet therapy after aspirin-induced upper gastrointestinal bleeding].
Topics: Anti-Ulcer Agents; Aspirin; Clopidogrel; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combinatio | 2006 |
A current problem in cardiology: very late thrombosis after implantation of sirolimus eluting stent.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Huma | 2007 |
Clopidogrel response variability and future therapies: clopidogrel: does one size fit all?
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Chest Pain; Clopidogrel; Coronary Angiography; Electr | 2006 |
Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Isc | 2007 |
Persistent platelet activation is related to very early cardiovascular events in patients with acute coronary syndromes.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; | 2007 |
Endpoints in studies on myocardial infarction.
Topics: Clopidogrel; Coronary Disease; Endpoint Determination; Humans; Myocardial Infarction; Platelet Aggre | 2007 |
Carotid artery in-stent restenosis in a patient with contralateral total occlusion, resolved with drug-eluting stenting.
Topics: Aged; Angioplasty, Balloon; Carotid Arteries; Carotid Artery Thrombosis; Carotid Stenosis; Catheteri | 2007 |
Factitious anticoagulant-resistance as a cause of recurrent arterial bypass graft occlusions.
Topics: Anticoagulants; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Drug Resistance; Drug Therapy, Co | 2007 |
Dual antiplatelet agent failure: a new syndrome or clinical nonentity?
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Drug Resistance; Drug Therapy, Combination; Female; Hum | 2007 |
[Antithrombotic therapy in ischemic stroke and transient ischemic attack].
Topics: Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Fibrinolytic Agents; | 2007 |
[The effect of carotid stenting on rheological parameters, free radical production and platelet aggregation].
Topics: Aged; Carotid Stenosis; Clopidogrel; Female; Fibrinogen; Follow-Up Studies; Free Radicals; Hematocri | 2007 |
2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
Topics: Acute Coronary Syndrome; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; | 2008 |
The success of clopidogrel treatment for recurrent coronary thrombosis in a patient with aortic and mitral valve replacement.
Topics: Aortic Valve; Clopidogrel; Coronary Thrombosis; Female; Heart Valve Prosthesis; Humans; Middle Aged; | 2008 |
Prediction and prevention of stroke in patients with symptomatic carotid stenosis: the high-risk period and the high-risk patient.
Topics: Aspirin; Carotid Stenosis; Clopidogrel; Endarterectomy, Carotid; Humans; Ischemic Attack, Transient; | 2008 |
Effect of clopidogrel pretreatment on angiographic and clinical outcomes in patients undergoing primary percutaneous coronary intervention for ST-elevation acute myocardial infarction.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Coronary Circulation; Coronary St | 2008 |
Single antiplatelet therapy for patients with previous gastrointestinal bleeds.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Female; Gastrointest | 2008 |
Drug interaction with anti-mycobacterial treatment as a cause of clopidogrel resistance.
Topics: Abciximab; Aged; Antibiotics, Antitubercular; Antibodies, Monoclonal; Clopidogrel; Drug Interactions | 2008 |
[Ticlopidine in the prevention of recurrent cerebral ischemic accidents].
Topics: Anticoagulants; Brain Ischemia; Humans; Recurrence; Thiophenes; Ticlopidine | 1984 |
[Effect of ticlopidine in the prevention of recurrences of cerebral ischemic accidents: comparative study with dipyridamol].
Topics: Brain Ischemia; Dipyridamole; Drug Evaluation; Female; Gastrointestinal Hemorrhage; Humans; Male; Re | 1984 |
Clopidogrel is more effective than aspirin in preventing coronary artery reocclusion after thrombolysis.
Topics: Animals; Aspirin; Blood Coagulation; Clopidogrel; Coronary Thrombosis; Disease Models, Animal; Dogs; | 1993 |
Clopidogrel is more effective than aspirin as adjuvant treatment to prevent reocclusion after thrombolysis.
Topics: Animals; Aspirin; Clopidogrel; Coronary Thrombosis; Dogs; Drug Therapy, Combination; Fibrinolytic Ag | 1994 |
Guidelines for medical treatment for stroke prevention. American College of Physicians.
Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Ischemic Attack, Transient; Myocard | 1994 |
Ischemic stroke, Part 2: Optimal treatment and prevention.
Topics: Aged; Aspirin; Brain Edema; Brain Ischemia; Cerebral Infarction; Heparin; Humans; Recurrence; Risk F | 1993 |
Percutaneous transluminal angioplasty for transplant renal artery stenosis.
Topics: Adolescent; Adult; Angioplasty, Balloon; Female; Heparin; Humans; Kidney Transplantation; Male; Midd | 1996 |
Primary stent implantation without coumadin in acute myocardial infarction.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Case-Control Studies; Coronary Angiography; | 1996 |
[The use of Ticlid in treating cerebrovascular diseases].
Topics: Aged; Blood Coagulation; Cerebrovascular Disorders; Drug Evaluation; Female; Follow-Up Studies; Hemo | 1996 |
Ticlopidine and aspirin interactions.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Coronary Disease; Drug Therapy, C | 1997 |
Revascularization after CABG: atherectomy and stenting.
Topics: Aftercare; Aged; Algorithms; Atherectomy, Coronary; Coronary Angiography; Coronary Artery Bypass; Co | 1998 |
[Coronary stents].
Topics: Aspirin; Belgium; Coronary Disease; Humans; Myocardial Revascularization; Platelet Aggregation Inhib | 1998 |
Clinical and angiographic outcome of Micro Stent II implantation in native coronary arteries.
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Aspirin; Blood Vessel Prosthesis Implantation; Coro | 1998 |
[Secondary prevention of recurrent transient ischemic attacks].
Topics: Anticoagulants; Aspirin; Cerebral Infarction; Drug Therapy, Combination; Female; Humans; Ischemic At | 1998 |
Micro stent implantation in patients with acute myocardial infarction without anticoagulation: clinical experience with two different antithrombotic protocols.
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Blood Vessel Prosthesis Implantation; Coronary Angiograp | 1998 |
[Wiktor coronary stent for elective placement with an antiaggregation regimen. WINE study. WINE Group Study].
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Catheterization; Coronary Disease; Female; | 1998 |
Aspirin and newer orally active antiplatelet agents in the treatment of the post-myocardial infarction patient.
Topics: Administration, Oral; Aspirin; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhi | 1998 |
Procedural results and long-term clinical outcomes following coronary stenting in perimyocardial infarction syndromes.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Disease-Free Survival; Female; Follow | 1998 |
Effectiveness of aspirin and clopidogrel combination therapy in coronary stenting.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Dise | 1999 |
Ticlopidine induced prolonged leucopenia in a patient with immunocytoma and chronic hepatitis C.
Topics: Aged; Arterial Occlusive Diseases; Bone Marrow; Female; Hepatitis C, Chronic; Humans; Leukemia, Lymp | 1999 |
Generalizing the results of clinical trials to actual practice: the example of clopidogrel therapy for the prevention of vascular events. CAPRA (CAPRIE Actual Practice Rates Analysis) Study Group. Clopidogrel versus Aspirin in Patients at Risk of Ischaemi
Topics: Aged; Arterial Occlusive Diseases; Aspirin; Brain Ischemia; Clinical Trials as Topic; Clopidogrel; C | 1999 |
Saphenous vein graft disease treated with the Wiktor Hepamed stent: procedural outcome, in-hospital complications and six-month angiographic follow-up.
Topics: Aged; Aspirin; Coronary Angiography; Coronary Artery Bypass; Female; Fibrinolytic Agents; Follow-Up | 2000 |
Thrombotic thrombocytopenic purpura associated with clopidogrel.
Topics: Adult; Aged; Clopidogrel; Fatal Outcome; Female; Humans; Male; Middle Aged; Plasma Exchange; Platele | 2000 |
Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: a cost-effectiveness analysis.
Topics: Aspirin; Clopidogrel; Cost-Benefit Analysis; Dipyridamole; Drug Therapy, Combination; Humans; Platel | 2000 |
Cost-effectiveness of new antiplatelet regimens used as secondary prevention of stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Cost-Benefit Analysis; Decision Trees; Dipyridamole; Drug Therapy, Combi | 2000 |
[Late stent thrombosis after intracoronary brachytherapy. A case report and review of the literature].
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Brachytherapy; Clinical Trials as Topic; C | 2001 |
Short-term outcome of stent implantation in saphenous vein grafts: predictors of distal embolization and restenosis.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Combined Modality Therapy; Comorbidity; Coronary Ang | 2001 |
Edge stenosis after intracoronary radiotherapy: angiographic, intravascular, and histological findings.
Topics: Aged; Angioplasty, Balloon, Laser-Assisted; Anticoagulants; Aspirin; Brachytherapy; Clopidogrel; Com | 2001 |
Effect of cilostazol on restenosis after coronary angioplasty and stenting in comparison to conventional coronary artery stenting with ticlopidine.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Angioplasty, Balloon, Coronary; Aspirin; Cilos | 2001 |
Clinical application of procedural platelet monitoring during percutaneous coronary intervention among patients at increased bleeding risk.
Topics: Abciximab; Adult; Aged; Aged, 80 and over; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibod | 2001 |
Late acute thrombosis after paclitaxel eluting stent implantation.
Topics: Acute Disease; Angiogenesis Inhibitors; Aspirin; Coronary Disease; Coronary Thrombosis; Drug Implant | 2001 |
Clopidogrel and recurrent severe haematuria in a patient with paraplegia.
Topics: Clopidogrel; Hematuria; Humans; Male; Middle Aged; Paraplegia; Platelet Aggregation Inhibitors; Recu | 2002 |
[Strategies for antiplatelet therapy-drug-fixed method and suppression-fixed method].
Topics: Aspirin; Cerebral Infarction; Dipyridamole; Drug Therapy, Combination; Humans; Myocardial Infarction | 1992 |
A critical appraisal of ticlopidine, a new antiplatelet agent. Effectiveness and clinical indications for prophylaxis of atherosclerotic events.
Topics: Arteriosclerosis; Cerebrovascular Disorders; Diarrhea; Female; Humans; Male; Neutropenia; Randomized | 1992 |
[Recurrent thromboembolism due to increased acetylsalicylic acid-resistant platelet aggregation].
Topics: Aspirin; Fibrin; Humans; Male; Middle Aged; Platelet Aggregation; Recurrence; Thromboembolism; Ticlo | 1991 |
[A case of hemoptysis due to administration of an anti-thrombotic drug].
Topics: Cerebral Infarction; Female; Hemoptysis; Humans; Middle Aged; Platelet Aggregation Inhibitors; Recur | 1990 |
[Ticlopidine and pentoxifylline in acute cerebral infarct. Clinical study on 151 patients].
Topics: Acute Disease; Aged; Cerebral Infarction; Drug Therapy, Combination; Female; Follow-Up Studies; Huma | 1987 |